var title_f28_55_29552="Fibroblast reticulum";
var content_f28_55_29552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroblast reticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computer generated reconstruction of the complex reticulum that is highly interconnected and extends from the pleura (yellow) into the underlying parenchyma (Left: the blood vessels are represented in red). The green zone added (right) represents the fibroblast reticulum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cool, CD, Groshong, SD, Rai, PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 2006; 174:654. Official Journal of the American Thoracic Society. Copyright &copy;2006 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29552=[""].join("\n");
var outline_f28_55_29552=null;
var title_f28_55_29553="CT scan Marfan aorta";
var content_f28_55_29553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomographic (CT) image of the ascending aorta in a patient with Marfan syndrome.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this coronal CT view, the aortic root is dilated at the level of the sinuses of Valsalva.",
"    <div class=\"footnotes\">",
"     Ao: ascending aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heidi Connolly, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29553=[""].join("\n");
var outline_f28_55_29553=null;
var title_f28_55_29554="Patient information: Crohn’s disease in children (The Basics)";
var content_f28_55_29554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86454\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"           Upper endoscopy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/31/13810\">",
"         Patient information: Late puberty (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/17/42258\">",
"         Patient information: Ulcerative colitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/40/29315\">",
"         Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/40/24196\">",
"         Patient information: Crohn's disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Crohn&rsquo;s disease in children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H93733732\">",
"      <span class=\"h1\">",
"       What is Crohn&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Crohn&rsquo;s disease is a condition that can cause diarrhea, belly pain, and other symptoms. It mainly affects the digestive system. The digestive system includes all the parts of the body that take in food and break it down into nutrients and waste. It includes the mouth, stomach, and intestines (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Crohn&rsquo;s disease happens when the body&rsquo;s infection-fighting system attacks and damages the lining of the digestive system. The infection-fighting system is called the &ldquo;immune system.&rdquo; When it attacks the body&rsquo;s healthy cells, this is called an &ldquo;autoimmune response.&rdquo; This is what happens in Crohn&rsquo;s disease. The autoimmune response causes inflammation that can lead to sores (ulcers) and bleeding in the intestines and other parts of the digestive system.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93733766\">",
"      <span class=\"h1\">",
"       What are the symptoms of Crohn&rsquo;s disease in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Diarrhea, blood in bowel movements, or both",
"       </li>",
"       <li>",
"        Being shorter or growing more slowly than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some children with Crohn&rsquo;s disease also get mouth sores, skin rashes, joint pain, and eye redness.",
"     </p>",
"     <p>",
"      The symptoms of Crohn&rsquo;s disease can get better or worse at different times. So far, doctors do not have a cure for Crohn&rsquo;s disease. But medicines and other treatments can help with symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93733783\">",
"      <span class=\"h1\">",
"       Is there a test for Crohn&rsquo;s disease in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Imaging tests &ndash; Such as X-rays, CT scans or MRI scans. Imaging tests show pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A test called a &ldquo;colonoscopy&rdquo; &ndash; This test looks at the lining of the large intestine (",
"        <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"         figure 1",
"        </a>",
"        ). During this test, a doctor puts a thin tube into the rectum and moves it up into the last part of the digestive system, called the &ldquo;colon.&rdquo; The tube has a camera on the end so the doctor can look inside the colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A test called an &ldquo;upper endoscopy&rdquo; &ndash; This test looks at the lining of the stomach and upper part of the small intestine, called the &ldquo;duodenum.&rdquo; During this test, a doctor puts a thin tube with a camera on the end into a person&rsquo;s mouth and moves it down into the stomach and duodenum (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors usually need to do all these tests to know for sure if your child has Crohn&rsquo;s disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93733899\">",
"      <span class=\"h1\">",
"       How is Crohn&rsquo;s disease in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many different medicines that can help with symptoms of Crohn&rsquo;s disease. Some medicines are used when symptoms are very bad. Other medicines help keep symptoms from starting or coming back. Your child might have to try a few different medicines and take several medicines to control symptoms.",
"     </p>",
"     <p>",
"      Some children with Crohn&rsquo;s disease need a liquid diet for a while. This can help the lining of the digestive system heal. It might also help your child get the nutrients he or she needs to grow. The doctor will also check your child&rsquo;s height and weight to make sure he or she is growing as normally as possible.",
"     </p>",
"     <p>",
"      Crohn&rsquo;s disease can make it hard a child to get enough nutrients from food. Your child might need vitamin supplements to get extra nutrients. Supplements are pills, capsules, or liquids that have nutrients in them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93733916\">",
"      <span class=\"h1\">",
"       Will my child need surgery for Crohn&rsquo;s disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child might have surgery if medicines do not help with symptoms. Or doctors can do surgery if Crohn&rsquo;s disease causes certain problems. Doctors can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Remove diseased tissue",
"       </li>",
"       <li>",
"        Reopen a part of the digestive system that is blocked",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93733933\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with Crohn&rsquo;s disease often need treatment for life. But with treatment, many people can live fairly normal lives.",
"     </p>",
"     <p>",
"      Children with Crohn&rsquo;s disease might be shorter than other children their age or go through puberty later. Puberty is a term for the body changes that happen when a child becomes an adult. Your child might feel embarrassed or anxious about being different. He or she might have other worries, and you might, too. Getting counseling or joining a support group can help you and your child cope.",
"     </p>",
"     <p>",
"      Crohn&rsquo;s disease can increase the risk of colon cancer. Experts suggest that people with Crohn's disease that affects the colon get screened early and often. This might mean having a colonoscopy a few years after Crohn&rsquo;s disease is found and once a year after that. Doctors can look for signs of colon cancer and treat it if they find it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93733950\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=see_link\">",
"       Patient information: Late puberty (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       Patient information: Ulcerative colitis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/40/29315?source=see_link\">",
"       Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       Patient information: Crohn's disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/55/29554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86454 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29554=[""].join("\n");
var outline_f28_55_29554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733732\">",
"      What is Crohn&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733766\">",
"      What are the symptoms of Crohn&rsquo;s disease in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733783\">",
"      Is there a test for Crohn&rsquo;s disease in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733899\">",
"      How is Crohn&rsquo;s disease in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733916\">",
"      Will my child need surgery for Crohn&rsquo;s disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733933\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93733950\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"        Upper endoscopy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/40/29315?source=related_link\">",
"      Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=related_link\">",
"      Patient information: Late puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29555="MPM 55yr man";
var content_f28_55_29555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epithelial diffuse peritoneal malignant mesothelioma in a 55-year-old man who formerly worked in a shipyard and complained of abdominal discomfort",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Panel A, Panel B) Intravenous contrast-enhanced CT scans show complex ascites, serosal implants on the liver margin (black arrows in Panel A), extension of the tumor across the diaphragm (white arrow in Panel A), and extensive tumor encasement of the small bowel (arrows in Panel B). The tumor also extends throughout the small bowel mesentery. (Panel C) Photograph of the small bowel and mesentery at autopsy shows thick, nodular tumor on the serosal surface of the bowel and throughout the mesentery. The opened segment of the small bowel (arrow) shows tumor thickening the bowel wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. RadioGraphics 2008; 28:583. Copyright &copy;2008 Radiological Society of North America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29555=[""].join("\n");
var outline_f28_55_29555=null;
var title_f28_55_29556="Cefuroxime: Patient drug information";
var content_f28_55_29556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefuroxime: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     see \"Cefuroxime: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"     see \"Cefuroxime: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ceftin&reg;;",
"     </li>",
"     <li>",
"      Zinacef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefuroxime&reg;;",
"     </li>",
"     <li>",
"      Auro-Cefuroxime;",
"     </li>",
"     <li>",
"      Ceftin&reg;;",
"     </li>",
"     <li>",
"      Cefuroxime For Injection;",
"     </li>",
"     <li>",
"      Cefuroxime For Injection, USP;",
"     </li>",
"     <li>",
"      PRO-Cefuroxime;",
"     </li>",
"     <li>",
"      ratio-Cefuroxime",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefuroxime or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Do not freeze. Throw away any part not used after 10 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11920 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29556=[""].join("\n");
var outline_f28_55_29556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148305\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015363\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015362\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015367\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015368\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015370\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015365\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015366\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015371\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015372\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=related_link\">",
"      Cefuroxime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=related_link\">",
"      Cefuroxime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29557="Entecavir: Drug information";
var content_f28_55_29557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Entecavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/49/11029?source=see_link\">",
"    see \"Entecavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baraclude&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4297830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Baraclude&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatitis B virus (HBV) infection, treatment",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nucleoside treatment naive: 0.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lamivudine-refractory or -resistant viremia (or known lamivudine- or telbivudine-resistant mutations): 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decompensated liver disease: 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HBV reinfection prophylaxis, post liver transplant (with or without HBIG) (unlabeled use):",
"     </b>",
"     Oral: 0.5 mg once daily (Fung, 2011) or 1 mg once daily (Perrillo, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV/HBV coinfection (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nucleoside treatment naive: 0.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lamivudine refractory or resistant: 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Only recommended in patients who cannot take tenofovir; must be used in addition to a fully suppressive antiretroviral therapy regimen (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Treatment duration (AASLD Practice Guidelines, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decompensated liver disease: Lifelong treatment is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving a primary response (&lt;2 log decrease in serum HBV DNA) after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F165239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hepatitis B virus (HBV) infection, treatment (nucleoside treatment na&iuml;ve or lamivudine-refractory or -resistant viremia [or known lamivudine- or telbivudine-resistance mutations]):",
"     </b>",
"     Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daily-dosage regimen preferred:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Administer 50% of usual dose daily or administer the normal dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Administer 30% of usual dose daily or administer the normal dose every 72 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute (including hemodialysis and CAPD): Administer 10% of usual dose daily or administer the normal dose every 7 days; administer after hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4472037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baraclude&reg;: 0.05 mg/mL (210 mL) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baraclude&reg;: 0.5 mg, 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach (2 hours before or after a meal). Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe. Oral solution and tablet are bioequivalent on a mg-to-mg basis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis B virus (HBV) infection, with compensated or decompensated liver disease, in patients with evidence of active viral replication and either evidence of persistent transaminase elevations or histologically-active disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15591850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HBV reinfection prophylaxis, post liver transplant; HIV/HBV coinfection",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (16% with decompensated liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pyrexia (14% with decompensated liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Ascites (15% with decompensated liver disease), ALT increased (&gt;5 x ULN: 11% to 12%; post-treatment flare [lamivudine refractory]: &gt;10 x ULN and &gt;2 x baseline: 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 4%), fatigue (1% to 3%), dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (2% to 3%), blood bicarbonate decreased (2% with decompensated liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Lipase increased (7%), amylase increased (2% to 3%), diarrhea (&le;1%), dyspepsia (&le;1%), nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic encephalopathy (10% with decompensated liver disease), bilirubin increased (2% to 3%), ALT increased (&gt;10 x ULN and &gt;2 x baseline: 2%; post-treatment flare [nucleoside-naive]: &gt;10 x ULN and &gt;2 x baseline: 2% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (9%), glycosuria (4%), creatinine increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (10% with decompensated liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, anaphylactoid reaction, hepatomegaly, hypoalbuminemia, insomnia, lactic acidosis,  rash, renal failure, somnolence, thrombocytopenia, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's U.S. labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to entecavir or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with nucleoside analogues;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, decompensated liver disease, obesity, or prolonged nucleoside exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation of antihepatitis B therapy, including entecavir. Monitor liver function for at least several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV:",
"     <b>",
"      [U.S. Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection.",
"     </b>",
"     Determine HIV status prior to initiating treatment with entecavir.",
"     <b>",
"      Not recommended for HIV/HBV coinfected patients unless also receiving highly active antiretroviral therapy (HAART).",
"     </b>",
"     The manufacturer's labeling states that entecavir does not exhibit any clinically-relevant activity against human immunodeficiency virus (HIV type 1). However, a small number of case reports have indicated declines in virus levels during entecavir therapy. HIV resistance to a common HIV drug has been reported in an HIV/HBV-infected patient receiving entecavir as monotherapy for HBV.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Dose adjustment not required. Limited data supporting treatment of chronic hepatitis B in patients with decompensated liver disease; observe for increased adverse reactions, including hepatorenal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment or patients receiving concomitant therapy which may reduce renal function; dose adjustment recommended for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Resistance: Cross-resistance may develop in patients failing previous therapy with lamivudine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3053493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F165229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food: Food delays absorption and reduces AUC by 18% to 20%. Management: Administer on an empty stomach 2 hours before or after a meal.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk. Pregnant women taking entecavir should enroll in the pregnancy registry by calling 1-800-258-4263.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F165222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach (2 hours before or after a meal).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Baraclude Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/mL (210 mL): $839.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Baraclude Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (30): $1199.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $1199.63",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV status (prior to initiation of therapy); liver function tests, renal function; in HBV/HIV-coinfected patients, monitor HIV viral load and CD4 count; HBeAg, HBV DNA; in patients with lamivudine-refractory or -resistant viremia (or known lamivudine- or telbivudine-resistance mutations) entecavir resistance can develop rapidly.  Monitor HBV DNA every 3 months (DHHS, 2013)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Baraclude (AR, AT, AU, BE, BG, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Entecavir is intracellularly phosphorylated to guanosine triphosphate which competes with natural substrates to effectively inhibit hepatitis B viral polymerase; enzyme inhibition blocks reverse transcriptase activity thereby reducing viral DNA synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Delayed with food; C",
"     <sub>",
"      max",
"     </sub>",
"     decreased 44% to 46%, AUC decreased 18% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive (V",
"     <sub>",
"      d",
"     </sub>",
"     in excess of body water)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minor hepatic glucuronide/sulfate conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~5-6 days; accumulation: ~24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 73% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fung J, Cheung C, Chan SC, et al, \"Entecavir Monotherapy is Effective in Suppressing Hepatitis B Virus After Liver Transplantation,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2011, 141(4):1212-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/55/29557/abstract-text/21762659/pubmed\" id=\"21762659\" target=\"_blank\">",
"        21762659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;AASLD Practice Guidelines, Chronic Hepatitis B: Update 2009,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009. Available at  file://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrillo R, Ferret MB, Durand F, et al, \"Safety and Efficacy of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B,\"  47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain; 2012, Poster 535.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8816 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-3A022BFF98-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29557=[""].join("\n");
var outline_f28_55_29557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708732\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165232\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4297830\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165244\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165233\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165239\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165234\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165235\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4472037\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165216\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165206\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165218\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165217\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15591850\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165242\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165220\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165208\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299265\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3053493\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165229\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165213\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165221\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165237\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165222\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422226\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165214\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301433\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165207\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165219\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8816\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8816|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/49/11029?source=related_link\">",
"      Entecavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29558="Overview of massive hemoptysis";
var content_f28_55_29558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of massive hemoptysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29558/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29558/contributors\">",
"     David H Ingbar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29558/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29558/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/55/29558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with massive hemoptysis, the initial steps are to correctly position the patient, establish a patent airway, insure adequate gas exchange and cardiovascular function, and control the bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/1\">",
"     1",
"    </a>",
"    ]. The source of massive hemoptysis may be identified either during the initial efforts to control the bleeding or later during a diagnostic evaluation once the patient has been stabilized. It is important to identify the cause of the massive hemoptysis even if the bleeding has ceased, since the cause determines the appropriate definitive treatment.",
"   </p>",
"   <p>",
"    The definition, diagnostic evaluation, and definitive treatment of massive hemoptysis are reviewed here. The initial management of massive hemoptysis (ie, positioning, airway control, controlling the bleeding) and the causes of massive hemoptysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26838?source=see_link\">",
"     \"Massive hemoptysis: Causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11002558\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive hemoptysis is generally used to describe the expectoration of a large amount of blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a rapid rate of bleeding, although the precise thresholds that constitute massive hemoptysis are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/2\">",
"     2",
"    </a>",
"    ]. Thresholds of 100 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/3\">",
"     3",
"    </a>",
"    ], 200 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/4\">",
"     4",
"    </a>",
"    ], 240 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/5\">",
"     5",
"    </a>",
"    ], 500 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/6\">",
"     6",
"    </a>",
"    ], 600 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/7\">",
"     7",
"    </a>",
"    ], and 1000 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/8\">",
"     8",
"    </a>",
"    ] over 24 hours have been proposed, but none has been universally accepted. Some clinicians argue that a large volume of expectorated blood alone should not define massive hemoptysis, but rather, that abnormal gas exchange and hemodynamic instability should also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/2\">",
"     2",
"    </a>",
"    ]. In our clinical practice, we define massive hemoptysis as either &ge;500 mL of expectorated blood over a 24 hour period or bleeding at a rate &ge;100",
"    <span class=\"nowrap\">",
"     mL/hour,",
"    </span>",
"    regardless of whether abnormal gas exchange or hemodynamic instability exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5686367\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of blood expectorated has traditionally been used by clinicians to determine the severity of the hemoptysis. However, the identification of other risk factors may also be helpful in characterizing the severity of the hemoptysis. A retrospective cohort study of 1087 consecutive patients admitted to an ICU over a 14-year period found that independent risk factors for in-hospital mortality included mechanical ventilation, infiltrates involving two or more quadrants on an admission chest radiograph, bleeding from the pulmonary artery, cancer, aspergillosis, and alcoholism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24619289\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous causes of bleeding from the lower respiratory tract, as listed in the table (",
"    <a class=\"graphic graphic_table graphicRef62661 \" href=\"UTD.htm?36/43/37565\">",
"     table 1",
"    </a>",
"    ). These etiologies are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26838?source=see_link\">",
"     \"Massive hemoptysis: Causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2767161\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with massive hemoptysis, the initial steps are to identify which lung is bleeding, appropriately position the patient, establish a patent airway, insure adequate gas exchange and cardiovascular function, and control the bleeding. Each of these steps are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    ). The goal of this initial management is to render the patient clinically stable with either intermittent or slowing hemoptysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2767170\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The source of massive hemoptysis may be identified during the initial efforts to control the bleeding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    ). If it is not, then a dedicated diagnostic evaluation is necessary. The timing of the diagnostic evaluation depends upon the course of the hemoptysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the hemoptysis is brisk despite initial measures to control the bleeding, then initial diagnostic efforts must begin in concert with ongoing efforts to stabilize the patient and control the bleeding.",
"     </li>",
"     <li>",
"      If the hemoptysis is intermittent or slowing following initial measures to control the bleeding, then the diagnostic evaluation begins after the patient has stabilized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchoscopy is an important early test because it can provide useful diagnostic and management information. For patients in whom bronchoscopy is non-diagnostic and who continue to bleed, we suggest arteriography as the next diagnostic test because it may be useful for therapy as well as diagnosis. In contrast, for patients in whom bronchoscopy is non-diagnostic, but in whom the bleeding has ceased, we favor CT of the chest with high-resolution cuts as the next diagnostic test.",
"   </p>",
"   <p>",
"    Some diagnostic procedures may have already been performed in an effort to control the acute bleeding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link&amp;anchor=H4655186#H4655186\">",
"     \"Massive hemoptysis: Initial management\", section on 'Control the bleeding'",
"    </a>",
"    ). It is reasonable to repeat such tests later, during a more careful diagnostic evaluation, since visualization and diagnostic sensitivity are generally poor during acute pulmonary hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7373565\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC MODALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination may be helpful in determining the cause of hemoptysis, as well as in assessing pulmonary function and the severity of any chronic lung disease. The latter is important for deciding whether surgery is an option. The history and physical examination are rarely helpful for localizing the bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link&amp;anchor=H4655275#H4655275\">",
"     \"Massive hemoptysis: Initial management\", section on 'Identify which side is bleeding'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The following issues are important to address when obtaining the history:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does the patient have known or suspected pulmonary, cardiac, or renal disease?",
"     </li>",
"     <li>",
"      Does the patient currently smoke?",
"     </li>",
"     <li>",
"      Has the patient previously smoked?",
"     </li>",
"     <li>",
"      Has the patient had prior hemoptysis, other pulmonary symptoms, or infectious symptoms?",
"     </li>",
"     <li>",
"      Is there a family history of hemoptysis, brain aneurysms, epistaxis, or gastrointestinal bleeding (suggesting possible hereditary hemorrhagic telangiectasia)?",
"     </li>",
"     <li>",
"      Has the patient had a skin rash?",
"     </li>",
"     <li>",
"      Has the patient been exposed to trimellitic anhydride or other organic chemicals?",
"     </li>",
"     <li>",
"      Where has the patient travelled, either recently or in the past?",
"     </li>",
"     <li>",
"      Has the patient been exposed to asbestos?",
"     </li>",
"     <li>",
"      Does the patient have a known or suspected bleeding disorder?",
"     </li>",
"     <li>",
"      Does the patient take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , nonsteroidal anti-inflammatory drugs, anti-platelet drugs, or an anticoagulant?",
"     </li>",
"     <li>",
"      Does the patient have a history of upper airway or upper gastrointestinal disease or symptoms?",
"     </li>",
"     <li>",
"      Has the patient had tuberculosis (TB) or been exposed to TB?",
"     </li>",
"     <li>",
"      Is the patient at high risk for TB or unusual parasitic disorders based upon travel history?",
"     </li>",
"     <li>",
"      Is there a history of blood clots in either the patient or his or her family? Are there any recent risk factors for deep vein thrombosis (DVT)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination may also provide diagnostic clues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Telangiectasias suggest that the patient may have hereditary hemorrhagic telangiectasia.",
"     </li>",
"     <li>",
"      A skin rash may indicate vasculitis, systemic lupus erythematosus (SLE), fat embolism, or infective endocarditis.",
"     </li>",
"     <li>",
"      Splinter hemorrhages suggest endocarditis or vasculitis.",
"     </li>",
"     <li>",
"      Needle tracks suggest endocarditis.",
"     </li>",
"     <li>",
"      An audible chest bruit or murmur that increases with inspiration may indicate a large pulmonary arteriovenous malformation.",
"     </li>",
"     <li>",
"      An augmented P2, a murmur of tricuspid regurgitation or pulmonic insufficiency, or a right ventricular lift suggests pulmonary hypertension.",
"     </li>",
"     <li>",
"      Heart murmurs may be due to congenital heart disease, endocarditis with septic emboli, or mitral stenosis (characterized by a diastolic rumble or opening snap).",
"     </li>",
"     <li>",
"      Asymmetric peripheral edema or a palpable cord indicates possible deep venous thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4404158\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests that should be performed in all patients with massive hemoptysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type and cross-matching of a blood specimen",
"     </li>",
"     <li>",
"      A complete blood count (white blood cell count, hemoglobin level, hematocrit, and platelet count) and white blood cell differential",
"     </li>",
"     <li>",
"      Prothrombin time (or International Normalized Ratio) and partial thromboplastin time",
"     </li>",
"     <li>",
"      Electrolytes, blood urea nitrogen, and creatinine",
"     </li>",
"     <li>",
"      Arterial blood gas",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The purpose of the complete blood count is to determine whether the patient may benefit from a platelet or red blood cell transfusion, while the purpose of the prothrombin time (or International Normalized Ratio) and partial thromboplastin time is to determine whether the patient is coagulopathic and may benefit from fresh frozen plasma. Patients whose electrolytes, blood urea nitrogen, and creatinine suggest renal dysfunction may benefit from a platelet transfusion even in the context of a normal platelet count due to potential platelet dysfunction. Arterial blood gases assess the impact of the massive hemoptysis on oxygenation and ventilation, which may guide therapeutic decisions. The purpose of the liver function tests and urinalysis is to provide clues about the underlying cause of the hemoptysis. Abnormal liver function tests may be a consequence of hepatic congestion due to heart disease, metastatic disease, or drugs or other toxins, while hematuria or red blood cell casts detected by urinalysis may indicate a pulmonary-renal syndrome (eg, granulomatosis with polyangiitis [formerly called Wegener&rsquo;s Granulomatosis], Goodpasture&rsquo;s Syndrome).",
"   </p>",
"   <p>",
"    Additional laboratory testing may be helpful in selected patients. As examples, appropriate drug levels should be obtained (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) if there is a question of specific drugs playing a role and a bleeding time can be measured to confirm qualitative platelet dysfunction, such as that due to renal failure or nonsteroidal antiinflammatory medications. Cytology should be obtained if cancer is suspected and sputum may be sent for stains and culture for Mycobacterium tuberculosis, fungi, and bacteria. Serologic tests including anti-neutrophil cytoplasmic antibodies (ANCA), anti-nuclear antibodies (ANA), double-stranded DNA, and anti-glomerular basement membrane antibodies (anti-GBM antibodies) may be very helpful if positive. A transthoracic echocardiogram may detect endocarditis, mitral stenosis, congenital heart disease, or pulmonary hypertension, while a transesophageal echocardiogram may identify a thoracic aortic aneurysm as the cause of hemoptysis.",
"   </p>",
"   <p>",
"    Finally, patients who are capable of doing so should undergo pulmonary function testing at the bedside. This provides an assessment of the patient&rsquo;s pulmonary reserve and, therefore, is an indicator of whether the patient is a candidate for surgical intervention if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic interventions used to control acute bleeding (eg, balloon tamponade, iced saline lavage, topical medication) are discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link&amp;anchor=H13#H13\">",
"     \"Massive hemoptysis: Initial management\", section on 'Bronchoscopy'",
"    </a>",
"    ). This section addresses the diagnostic aspects of bronchoscopy in the setting of massive hemoptysis.",
"   </p>",
"   <p>",
"    Flexible bronchoscopy is the initial diagnostic procedure of choice in most patients with massive hemoptysis because it can be performed at the bedside, it is readily available, and it is highly successful at localizing the bleeding site if it is performed while the patient is bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/10\">",
"     10",
"    </a>",
"    ]. In one study of 28 patients with massive hemoptysis, flexible bronchoscopy successfully localized the bleeding site in 26 patients (93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We perform bronchoscopy early in a patient&rsquo;s course, even though bronchoscopy has not been shown to improve clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/12\">",
"     12",
"    </a>",
"    ]. We believe that this approach provides clinicians with the maximal amount of information upon which to base future decisions, particularly in patients who develop sudden recurrence or acceleration of their bleeding. In addition, this strategy may lead to earlier treatment or earlier initiation of additional diagnostic testing. Practically speaking, we aim to perform bronchoscopy within the first 12 to 18 hours if the patient is clinically stable and their bleeding has become quiescent. Alternatively, we perform bronchoscopy as early as feasible if the patient is unstable.",
"   </p>",
"   <p>",
"    Intubation for the bronchoscopy should be considered when massive hemoptysis is the indication. This improves patient safety, as illustrated by the following examples. First, if the bleeding accelerates or recurs during the procedure, the bronchoscope often needs to be removed due to worsening oxygenation. Intubation maintains control of the airway and allows endotracheal suctioning to continue after the bronchoscope has removed. Second, if visualization becomes obscured by a clot on the tip of the bronchoscope, intubation facilitates the safe and efficient removal of the bronchoscope for cleaning, as well as its reinsertion to continue the examination.",
"   </p>",
"   <p>",
"    Localizing the bleeding site requires visualization of active bleeding. Finding blood clots within bronchi is insufficient. When active bleeding cannot be directly visualized, small volume lavage of multiple bronchial segments can sometimes help localize the bleeding site by identifying bronchi that contain fresh blood. Once the bleeding site is localized, the area should be carefully inspected for a culprit lesion, such as a bronchogenic carcinoma or a telangiectasia. Even if the bleeding lesion cannot be identified, there may be other clues regarding the cause of the bleeding. As an example, erythematous and edematous airways in the area of bleeding may indicate an infection. Specimens should be taken for microbiological and cytological testing.",
"   </p>",
"   <p>",
"    Rigid bronchoscopy is used less often than flexible bronchoscopy in the initial diagnostic evaluation of massive hemoptysis because it is performed in the operating room under general anesthesia rather than at the bedside and it cannot visualize the airways as far distally as flexible bronchoscopy. However, rigid bronchoscopy may be helpful if flexible bronchoscopy is inadequate because rigid bronchoscopy has greater suctioning capacity, which may provide superior visualization. In addition, there are a wider variety of interventions available via rigid bronchoscopy, which is beneficial if a lesion is amenable to immediate treatment. Another option is to insert a flexible bronchoscope through the lumen of a rigid bronchoscopy, thereby combining the more distal visualization of the airways offered by flexible bronchoscopy with the superior suction capabilities and the wider range of therapeutic options offered by rigid bronchoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriography is generally performed if there is persistent bleeding following bronchoscopy. The preceding bronchoscopy may be helpful in identifying the area of bleeding, thereby assisting the radiologist in locating the precise bleeding site. Therapeutic embolization is possible during the diagnostic arteriography procedure. Arteriography for massive hemoptysis is discussed in the context of initial management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link&amp;anchor=H14#H14\">",
"     \"Massive hemoptysis: Initial management\", section on 'Arteriography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past ten years, early computed tomography (CT) of the chest has been increasingly advocated to help localize the bleeding site and to diagnose the cause of the hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. It is generally performed in patients whose bronchoscopy was non-diagnostic and in whom arteriography is not necessary because the bleeding has ceased.",
"   </p>",
"   <p>",
"    The major advantage of CT is that it may identify abnormalities that are difficult to detect by bronchoscopy and arteriography, such as bronchiectasis, lung abscess, pulmonary artery (Rasmussen's) aneurysm, and mass lesions (eg, cancer, aspergilloma, arteriovenous malformations). In addition, CT scans may identify a systemic arterial supply to a lesion. Features suggestive of a systemic blood supply include increased pleural thickness (&gt;3 mm) adjacent to a parenchymal lesion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enhanced vascular structures in a nearby extrapleural fat layer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/17\">",
"     17",
"    </a>",
"    ]. The primary disadvantages of chest CT are that it requires movement of the patient away from the intensive care unit and occasionally it may provide misleading results. As an example, a clot in an airway or bleeding into a cavity may be mistaken as a tumor mass.",
"   </p>",
"   <p>",
"    A prospective cohort study of 57 patients with hemoptysis compared bronchoscopy to chest CT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/16\">",
"     16",
"    </a>",
"    ]. High resolution CT was particularly useful for detecting bronchiectasis and aspergillomas (ie, a fungus ball), while bronchoscopy was most useful for detecting bronchitis and endobronchial carcinoma. High resolution CT was diagnostic more often than bronchoscopy, although the study was criticized for having an unusually high percentage of patients with lesions amenable to diagnosis by CT: bronchiectasis (25 percent), tuberculosis (16 percent), aspergilloma (12 percent), and cancer (12 percent). Despite this study, most clinicians favor bronchoscopy prior to chest CT, largely due to the preference to not move a patient with massive hemoptysis from the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2546651\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;With its increased availability in the ICU, echocardiography can be performed at the bedside to look for evidence of mitral stenosis, shunting through AVMs (bubble study), or endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3282312\">",
"    <span class=\"h2\">",
"     Radionuclide scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have described using radionuclide scanning with tagged red blood cells to localize the bleeding site in patients with hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this requires a rapid rate of bleeding and can give false localization if blood pools in dependent regions. From a practical standpoint, tagged red blood cell scanning is probably not very useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Combined modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using both bronchoscopy and chest CT to evaluate hemoptysis appears to improve the diagnostic yield. The former examines inside of the airways, while the latter examines structures outside of the airways. This was illustrated by a study in patients with hemoptysis that found that lung cancer was diagnosed by chest CT alone with a sensitivity of 67 percent, bronchoscopy alone with a sensitivity of 42 percent, and chest CT plus bronchoscopy with a sensitivity of 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29558/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2767250\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive therapy for massive hemoptysis is treatment of the underlying cause. Bronchiectasis, tuberculosis, bronchogenic carcinoma, and various lung infections appear to be the most common modern causes of hemoptysis and their treatment is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massive hemoptysis is generally used to describe the expectoration of a large amount of blood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a rapid rate of bleeding, although the precise thresholds that constitute massive hemoptysis are controversial. In our clinical practice, we define massive hemoptysis as &ge;500 mL of expectorated blood over a 24 hour period or bleeding at a rate &ge; 100",
"      <span class=\"nowrap\">",
"       mL/hour.(See",
"      </span>",
"      <a class=\"local\" href=\"#H11002558\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient presents with massive hemoptysis, the initial steps are to correctly position the patient, establish a patent airway, insure adequate gas exchange and cardiovascular function, and control the bleeding. These steps are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"       \"Massive hemoptysis: Initial management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Timing of the diagnostic evaluation depends upon the course of the massive hemoptysis. If the hemoptysis is brisk despite initial measures to control the bleeding, then initial diagnostic efforts must begin in concert with ongoing efforts to stabilize the patient and control the bleeding. If the hemoptysis is intermittent or slowing following initial measures to control the bleeding, then the diagnostic evaluation begins after the patient has stabilized. (See",
"      <a class=\"local\" href=\"#H2767170\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flexible bronchoscopy is our preferred initial diagnostic study because it can be performed in the intensive care unit, is readily available, and provides a distal view of the airways. Rigid bronchoscopy is an acceptable alternative if flexible bronchoscopy is either inadequate or seems likely to be insufficient in light of the amount of bleeding. Rigid bronchoscopy has greater suctioning capacity that may provide superior visualization. (See",
"      <a class=\"local\" href=\"#H2767170\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Bronchoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If bronchoscopy fails to identify the cause of the massive hemoptysis and the patient continues to bleed, arteriography should next be performed because it may be useful for therapy as well as diagnosis. (See",
"      <a class=\"local\" href=\"#H2767170\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Arteriography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If bronchoscopy fails to identify the cause of the massive hemoptysis, but the bleeding has ceased, computed tomography (CT) of the chest with high-resolution cuts should be performed. (See",
"      <a class=\"local\" href=\"#H2767170\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Computed tomography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Combined modalities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive therapy for massive hemoptysis is treatment of the underlying cause (",
"      <a class=\"graphic graphic_table graphicRef62661 \" href=\"UTD.htm?36/43/37565\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2767250\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/1\">",
"      Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med 2000; 28:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/2\">",
"      Ibrahim WH. Massive haemoptysis: the definition should be revised. Eur Respir J 2008; 32:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/3\">",
"      Amirana M, Frater R, Tirschwell P, et al. An aggressive surgical approach to significant hemoptysis in patients with pulmonary tuberculosis. Am Rev Respir Dis 1968; 97:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/4\">",
"      Knott-Craig CJ, Oostuizen JG, Rossouw G, et al. Management and prognosis of massive hemoptysis. Recent experience with 120 patients. J Thorac Cardiovasc Surg 1993; 105:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/5\">",
"      Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998; 157:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/6\">",
"      Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/7\">",
"      Crocco JA, Rooney JJ, Fankushen DS, et al. Massive hemoptysis. Arch Intern Med 1968; 121:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/8\">",
"      Corey R, Hla KM. Major and massive hemoptysis: reassessment of conservative management. Am J Med Sci 1987; 294:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/9\">",
"      Fartoukh M, Khoshnood B, Parrot A, et al. Early prediction of in-hospital mortality of patients with hemoptysis: an approach to defining severe hemoptysis. Respiration 2012; 83:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/10\">",
"      Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management. Clin Chest Med 1994; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/11\">",
"      Hsiao EI, Kirsch CM, Kagawa FT, et al. Utility of fiberoptic bronchoscopy before bronchial artery embolization for massive hemoptysis. AJR Am J Roentgenol 2001; 177:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/12\">",
"      Haponik EF, Chin R. Hemoptysis: clinicians' perspectives. Chest 1990; 97:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/13\">",
"      Revel MP, Fournier LS, Hennebicque AS, et al. Can CT replace bronchoscopy in the detection of the site and cause of bleeding in patients with large or massive hemoptysis? AJR Am J Roentgenol 2002; 179:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/14\">",
"      Haponik EF, Britt EJ, Smith PL, Bleecker ER. Computed chest tomography in the evaluation of hemoptysis. Impact on diagnosis and treatment. Chest 1987; 91:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/15\">",
"      Naidich DP, Funt S, Ettenger NA, Arranda C. Hemoptysis: CT-bronchoscopic correlations in 58 cases. Radiology 1990; 177:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/16\">",
"      McGuinness G, Beacher JR, Harkin TJ, et al. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest 1994; 105:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/17\">",
"      Yoon W, Kim YH, Kim JK, et al. Massive hemoptysis: prediction of nonbronchial systemic arterial supply with chest CT. Radiology 2003; 227:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29558/abstract/18\">",
"      M&uuml;ller NL. Hemoptysis: high-resolution CT vs bronchoscopy. Chest 1994; 105:982.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4394 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29558=[""].join("\n");
var outline_f28_55_29558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11002558\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5686367\">",
"      RISK FACTORS FOR MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24619289\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2767161\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2767170\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7373565\">",
"      DIAGNOSTIC MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4404158\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2546651\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3282312\">",
"      Radionuclide scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combined modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2767250\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4394\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4394|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/43/37565\" title=\"table 1\">",
"      Causes of massive hemoptysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26838?source=related_link\">",
"      Massive hemoptysis: Causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29559="Adalimumab for treatment of Crohn's disease in adults";
var content_f28_55_29559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adalimumab for treatment of Crohn's disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Robert M Penner, BSc, MD, FRCPC, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Richard N Fedorak, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29559/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/55/29559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    (Humira&reg;) is a recombinant human IgG1 monoclonal antibody directed against tumor necrosis factor (TNF) that has been approved for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , which requires an intravenous infusion, adalimumab is administered by subcutaneous injection.",
"   </p>",
"   <p>",
"    This topic review will focus on the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in Crohn's disease, while its role in other disorders is presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY FOR INDUCTION AND MAINTENANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulatory approval for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was based upon three pivotal studies (CLASSIC-I, CHARM, and GAIN) that focused on its role as induction therapy, maintenance therapy, and therapy in patients who had lost response to or were intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , respectively. A fourth study (CLASSIC-II) provided follow-up of CLASSIC-I, by assessing maintenance therapy in patients who were in remission following induction. EXTEND is an additional trial that examined adalimumab for induction and maintenance therapy. EXTEND differed from previous trials with adalimumab in that its primary objective was mucosal healing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CLASSIC-I trial included 299 patients with moderate to severely active Crohn's disease despite concomitant therapies (including one or more of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      , glucocorticoid, immunosuppressive agents and antibiotics) who had no previous exposure to TNF antagonists. They were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      at three different doses, or placebo, at zero and two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/1\">",
"       1",
"      </a>",
"      ]. The primary endpoint was induction of clinical remission after four weeks. A linear dose-response curve was demonstrated, with the most effective dose being the highest studied: a loading dose of 160 mg at week zero followed by 80 mg at week two. Remission (Crohn&rsquo;s disease activity index [CDAI] &lt;150 points) at four weeks was achieved significantly more often in patients receiving the 160",
"      <span class=\"nowrap\">",
"       mg/80",
"      </span>",
"      mg dose compared with placebo (36 versus 12 percent). Similarly, a response (CDAI decrease of 100 points) at four weeks was achieved significantly more often in patients who received the 160",
"      <span class=\"nowrap\">",
"       mg/80",
"      </span>",
"      mg dose compared with placebo (50 versus 25 percent).",
"     </li>",
"     <li>",
"      The CLASSIC-II trial included a total of 276 patients from CLASSIC-I who received open label",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (40 mg) at weeks zero and two [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/2\">",
"       2",
"      </a>",
"      ]. Fifty-five patients who were in remission at both weeks zero (week four of the CLASSIC-I trial) and four were re-randomized to three treatment groups: placebo or adalimumab 40 mg every other week or 40 mg weekly for 56 weeks. Patients who were not in remission at both weeks zero and four received open label adalimumab 40 mg every other week. In those who did not respond or who had a flare, the dose could be increased to 40 mg weekly. The primary endpoint was clinical remission after 56 weeks.",
"      <br/>",
"      <br/>",
"      Of the 55 patients randomized at week four, remission at week 56 was seen in 79 percent of adalimumab 40 mg every other week, 83 percent of 40 mg weekly, and 44 percent of those treated with placebo. Response at week 56 was seen in 89 percent, 79 percent and 56 percent, respectively. These data suggest that the maintenance of remission can be achieved in the majority of patients who achieved remission with induction therapy.",
"      <br/>",
"      <br/>",
"      Of the 204 who entered the open label arm, 46 percent were in clinical remission and 65 percent were considered responders at week 56. That the open label arm had a lower percentage of patients in remission compared to the randomized arm implies that patients in full remission after their induction of adalimumab have a greater chance of staying in remission after one year. Approximately one-half of the patients in the open label arm had increased the dose of adalimumab from every other week to weekly by week 56.",
"      <br/>",
"      <br/>",
"      Patients generally respond within the first week. However, in some patients, the response to adalimumab was not fully achieved until week 12 after induction. This observation suggests a timeframe that may be required for assessing the clinical response and need for maintenance therapy.",
"     </li>",
"     <li>",
"      The \"CHARM\" trial (\"Crohn's Trial of the Fully Human Antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      for Remission Maintenance\") examined the efficacy of adalimumab for long-term maintenance [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/3\">",
"       3",
"      </a>",
"      ]. It included a total of 854 patients with active disease despite concomitant therapies that included one or more of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      , glucocorticoid, immunosuppressive agents, and antibiotics. Previous responders to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      were also included. All patients received open label adalimumab (80 mg at week zero and 40 mg at week two). It is noteworthy that this dose is lower than that in CLASSIC and that approved for clinical use. At week four, patients were randomly assigned to adalimumab (40 mg every other week or 40 mg weekly) or placebo for a total of 56 weeks.",
"      <br/>",
"      <br/>",
"      Of the 854 enrolled, 76 withdrew before randomization. At week four, 499 of the remaining 778 patients (64 percent) had achieved a clinical response, a response rate similar to that seen in CLASSIC-I. At week 56, remission rates in the 40 mg every other week and 40 mg weekly groups were significantly higher than with placebo (36 and 41 versus 12 percent, respectively). A clinical response was seen in 52 percent, 53 percent, and 26 percent, respectively. There was no statistical difference between the two adalimumab doses. In two follow-up reports, patients in the adalimumab group had significantly lower risk of hospitalization and surgery at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/4\">",
"       4",
"      </a>",
"      ] and had sustained improvements in health-related quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Subgroup analysis of the CHARM data demonstrates that among the 260 patients randomized to adalimumab 40 mg every other week maintenance dosing, 71 patients (27 percent) required dose-escalation to 40 mg every week dosing. Among those who required dose-escalation, 54 (76 percent) subsequently achieved a response.",
"      <br/>",
"      <br/>",
"      A follow-up report described outcomes in patients who received continuous adalimumab versus those who received induction followed by reinitiation when clinical deterioration occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/6\">",
"       6",
"      </a>",
"      ]. At week 56, significantly more patients who received continuous therapy were in clinical remission (50 versus 38 percent). Furthermore, patients receiving continuous adalimumab had significantly lower rates of Crohn's disease-related and all-cause hospitalization.",
"      <br/>",
"      <br/>",
"      An open label extension of CHARM was conducted in which patients from all groups were given adalimumab 40 mg every other week up to two years of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients who had already been moved to open label weekly adalimumab continued their regimen. At the conclusion of this time period, patients were analyzed depending on their original treatment randomization. Clinical remission rates were 37.6, 41.9, and 49.8 percent in patients who had originally been randomized to placebo, adalimumab every other week, and adalimumab weekly, respectively.",
"     </li>",
"     <li>",
"      The EXTEND trial looked at",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      for induction and maintenance of mucosal healing in 135 adults with moderate to severe Crohn&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/8\">",
"       8",
"      </a>",
"      ]. All patients received induction with adalimumab (160 mg at week 0 and 80 mg at week 2). At week 4, patients were randomly assigned to receive adalimumab 40 mg or placebo every other week through week 52. Starting at week 8, patients who did not respond to treatment or developed flares were allowed to receive open-label adalimumab after first undergoing ileocolonoscopy. For continued",
"      <span class=\"nowrap\">",
"       flares/nonresponse,",
"      </span>",
"      the dosing interval was decreased to 40 mg weekly.",
"      <br/>",
"      <br/>",
"      The primary endpoint was mucosal healing at week 12 (for patients who switched to adalimumab between weeks 8 and 12, ileocolonoscopy results prior to switching, were used). There was a trend toward more patients in the adalimumab group than in the placebo group achieving the primary endpoint (27 versus 13 percent, p = 0.056). A statistically significant difference in mucosal healing rates was seen between the groups at week 52 (24 and 0 percent, respectively; patients who switched to open-label adalimumab were considered treatment failures for the secondary endpoints). Patients treated with adalimumab also had higher clinical remission rates at weeks 12 (47 versus 28 percent) and 52 (33 versus 9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis found that patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    were more likely to achieve remission than patients treated with placebo (RR of no remission 0.85) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY IN SECONDARY INFLIXIMAB FAILURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GAIN trial included 325 patients who had lost response to or were intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    who were randomly assigned to either 160 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    at week zero and 80 mg at week two or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/10\">",
"     10",
"    </a>",
"    ]. Results were assessed at week four. Clinical remission (21 versus 7 percent) and response (38 versus 25 percent) were observed significantly more often in the adalimumab group.",
"   </p>",
"   <p>",
"    The remission and response rates were slightly lower (by approximately 15 percent) compared with studies of TNF-alpha na&iuml;ve patients. This pattern was also reported in the subgroup analysis of the CHARM study.",
"   </p>",
"   <p>",
"    A retrospective review of a single center experience examined 118 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    for Crohn&rsquo;s disease, with a median length of follow-up of 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/11\">",
"     11",
"    </a>",
"    ]. Ninety-six percent of the patients had previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . Various loading regimens were used, but the initial maintenance dose in most patients (92 percent) was 40 mg every other week. At one year, a complete response was seen in 46 percent of patients and a partial response was seen in 35 percent. Dose escalation was required in 54 percent of patients. At one year, 29 percent of patients had discontinued adalimumab (12 percent had a primary nonresponse, 3 percent had a loss of response, and 14 percent had an adverse event). Serious adverse events (including bacteremia and death) occurred in 11 percent of patients.",
"   </p>",
"   <p>",
"    In another cohort study, a total of 168 patients with Crohn's disease treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    who had previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in a tertiary center were included in a prospective follow-up program [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/12\">",
"     12",
"    </a>",
"    ]. Trough serum concentration and antibodies against adalimumab had been measured at predefined time points using enzyme-linked immunosorbent assays. A short-term response was obtained in 67 percent of the patients, and a sustained clinical benefit was observed in two-thirds of the primary responders during a median follow-up period of almost two years. Discontinuation was directly related to low adalimumab trough serum concentration, which was observed more frequently in patients who developed antibodies against adalimumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY IN PERIANAL FISTULAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One clinical trial and two observational studies have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in perianal fistula closure.",
"   </p>",
"   <p>",
"    Subgroup analysis of the CHARM study (open label induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    followed by placebo-controlled maintenance therapy) demonstrated complete fistula closure at week 56 in 33 percent of patients on adalimumab as compared to 13 percent on placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/3\">",
"     3",
"    </a>",
"    ]. Of those who achieved fistula healing, 90 percent maintained healing after one year in an open label extension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Canadian study (ACCESS) evaluated fistula closure rates in 67 patients with moderate to severe Crohn&rsquo;s disease and at least one draining fistula at baseline. Patients received open-label",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    as induction (160 and 80 mg) at weeks 0 and 2, respectively, and maintenance (40 mg every other week) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/14\">",
"     14",
"    </a>",
"    ]. By week 24, 40 percent had no draining fistula. Anti-tumor necrosis factor (TNF) na&iuml;ve patients had significantly higher healing rates than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    -experienced patients (60 versus 28 percent).",
"   </p>",
"   <p>",
"    The CARE (Crohn&rsquo;s Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    : Patient Response to a Safety and Efficacy) study, a large pan-European multicenter cohort study of 945 patients with moderate to severe Crohn&rsquo;s disease also evaluated fistula closure rates in patients who received open-label adalimumab [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/15\">",
"     15",
"    </a>",
"    ]. Of the 171 patients with fistulae present at baseline (35 percent with multiple fistulae), complete fistula closure was observed in 26 percent at week 20. In this study, there were no significant differences in fistula closure rates between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    -na&iuml;ve and infliximab-experienced patients at week 4 and week 20.",
"   </p>",
"   <p>",
"    It should be noted that both the CHARM and CARE studies used an",
"    <span class=\"nowrap\">",
"     80/40",
"    </span>",
"    mg induction regimen, which is lower than the",
"    <span class=\"nowrap\">",
"     160/80",
"    </span>",
"    mg regimen used in the Canadian study. The Canadian study had numerically higher rates of fistula healing than the other two studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1906505\">",
"    <span class=\"h1\">",
"     EFFICACY IN EXTRAINTESTINAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CARE study demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in the resolution of extraintestinal manifestations (EIM). In this open-label adalimumab study, of the 497 patients with at least one EIM at baseline, 51 percent had no signs or symptoms of an EIM at week 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/15\">",
"     15",
"    </a>",
"    ]. The rates of resolution of at least one EIM were significantly higher in patients in remission at week 20 than those who were not in remission (88 versus 71 percent). There was no significant difference in the rate of EIM resolution based on prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY FOR GLUCOCORTICOID DISCONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subgroup analysis of the CHARM study demonstrated that glucocorticoids remained tapered and discontinued at week 56 in 6 percent, 29 percent, and 23 percent of patients treated with placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    40 mg every other week, and 40 mg weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/3\">",
"     3",
"    </a>",
"    ]. In the CLASSIC-II study, 58 percent of open label adalimumab patients were able to discontinue their glucocorticoids at week 56 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/2\">",
"     2",
"    </a>",
"    ]. The reason for the difference between CHARM and CLASSIC-II may be the higher induction dose of adalimumab used in the CLASSIC-II trial.",
"   </p>",
"   <p>",
"    In the ADHERE study, a follow-up two-year, open-label extension of the CHARM study, the rates of steroid-free remission in 206 individuals randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and on glucocorticoids at baseline were 26 and 23 percent at one and three years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/16\">",
"     16",
"    </a>",
"    ]. The rates of steroid sparing remission (CDAI &lt;150 and reduction of steroid dose by at least 50 percent) at one and three years were 29 and 25 percent, respectively. These data suggest a modest, but clinically significant, sustained effect of adalimumab in achieving steroid free remission, sustained over three years of treatment, in a pretreated cohort of patients with Crohn&rsquo;s disease receiving steroids at the start of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932216\">",
"    <span class=\"h1\">",
"     EFFICACY IN POSTOPERATIVE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no randomized controlled trial data demonstrate efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in the prevention of postoperative Crohn&rsquo;s recurrence. A single case series of six patients has demonstrated clinical and endoscopic remission in all patients for three years following ileocecal resection for stricturing disease with subsequent",
"    <span class=\"nowrap\">",
"     160/80/40",
"    </span>",
"    induction and 40 mg every other week maintenance with adalimumab [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTI-ADALIMUMAB ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human antibody development to monoclonal anti-TNF-alpha agents is well described and reduces efficacy and increases injection reactions. Unfortunately, anti-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    antibodies were only measured in the CLASSIC and not in subsequent trials with adalimumab. Antibodies to adalimumab were identified in approximately 3 percent of patients at week 56. This is substantially lower than antibody development in studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    over the same time interval. In a study of patients with rheumatoid arthritis, antibodies were seen in 28 percent of patients after three years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/18\">",
"     18",
"    </a>",
"    ]. The presence of antibodies was associated with lower serum adalimumab concentrations and a lower likelihood of having minimal disease or being in remission.",
"   </p>",
"   <p>",
"    There are no data on the effect of concomitant immunosuppressive therapy on antibodies to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in Crohn's disease. However, in rheumatoid arthritis the formation of anti-adalimumab antibodies is lower in patients receiving concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (1 versus 12 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of adverse events have been described following treatment with anti-TNF-alpha agents. These are summarized separately along with recommendations for screening patients prior to starting these medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approved induction dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in Crohn's disease is 160 mg given subcutaneously initially at week zero, 80 mg at week two, followed by a maintenance dose of 40 mg every other week beginning at week four. We suggest the same induction regimen also be used in patients who are being switched to adalimumab from another anti-tumor necrosis factor (TNF) agent. Adalimumab is available in a single-use prefilled pen (Humira&reg; Pen) or in a single-use, prefilled glass syringe.",
"   </p>",
"   <p>",
"    Patients generally respond within the first week. However, as described above, the response appears to be delayed for up to 12 weeks in a subset of patients. Patients who do not respond within this interval should not continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients who lose their response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    should have their dosing interval shortened to every week [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/19\">",
"     19",
"    </a>",
"    ]. A meta-analysis of 39 studies showed that the mean percentage of loss of response to adalimumab among primary responders was 18 percent and the annual risk was 20 percent per patient-year; the mean percentage of patients who required dose intensification among primary responders to adalimumab was 37 percent and the annual risk was 25 percent per patient-year.",
"   </p>",
"   <p>",
"    A large number of factors predict loss of response or dose escalation in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (male gender, high body mass index,",
"    <span class=\"nowrap\">",
"     current/former",
"    </span>",
"    smoking, family history of inflammatory bowel disease, isolated colonic disease, extraintestinal manifestations,",
"    <span class=\"nowrap\">",
"     80/40",
"    </span>",
"    mg induction therapy, longer disease duration, greater baseline Crohn's Disease Activity Index, concomitant glucocorticoid use, absence of deep remission at week 12, low serum trough concentrations of adalimumab, previous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    non-response and prior treatment with an anti-TNF-alpha agent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, there are no data to support the use of a higher initial dose of adalimumab in any patient subgroup, as pooled analysis demonstrated that dose escalation permitted response to be regained in 71 percent and remission in 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CONCOMITANT IMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In subgroup analysis of the CLASSIC-II study, concomitant immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 6-mercatopurine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    did not enhance remission or response rates. Additional studies will be needed to clarify the role of concomitant immunosuppressive agents with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    since a synergistic effect has been seen in rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADALIMUMAB VERSUS INFLIXIMAB VERSUS CERTOLIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and certolizumab have generally shown similar results but no studies have directly compared them. The decision whether to use adalimumab, infliximab, or certolizumab in patients with Crohn's disease requiring anti-TNF therapy will mostly be influenced by the convenience (and availability in individual countries) of subcutaneous administration of adalimumab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    contrasted against the requirement for intravenous infusion and the larger body of safety and efficacy data on infliximab. We recommend against switching patients in remission electively from infliximab to adalimumab for reasons of convenience, as doing so has been demonstrated to worsen outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188279#H11188279\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Anti-TNF therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    for treatment of Crohn's disease is evolving, and its use is becoming more widespread based on the efficacy data above and evidence that its use is cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29559/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Our general approach is to advance to anti-tumor necrosis factor (TNF)-alpha therapy (including adalimumab or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) in patients who have demonstrated failure or intolerance to a course of glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunosuppressive agents, who are steroid dependent despite immunosuppressants, or who have failed glucocorticoids and are too sick to wait for the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with moderate to severely active Crohn's disease despite concomitant immunosuppressive therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      induction therapy (160 mg at week zero and 80 mg at week two) is more effective than placebo at achieving clinical remission (CDAI &lt;150 points) at four weeks (36 versus 12 percent). Similarly, a clinical response (CDAI decrease of 100 points) at four weeks occurs significantly more often with adalimumab compared with placebo (50 versus 25 percent). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy for induction and maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who achieved clinical remission, maintenance treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (40 mg subcutaneously every two weeks) is more effective than placebo in maintaining remission (79 versus 56 percent) for up to one year. However, between 30 and 50 percent may require escalation of the dose from every two weeks to weekly over the course of one year to sustain a remission or response. Data from an open label study suggest that remission can frequently be maintained for over two years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy for induction and maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      results in mucosal healing at rates similar to other anti-TNF agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy for induction and maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who had lost response to or were intolerant of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      is more effective than placebo at achieving clinical remission (21 versus 7 percent). Our experience is to switch to adalimumab when patients are intolerant or lose response to infliximab. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy in secondary infliximab failures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      in patients with fistulizing disease appears to be similar to other anti-TNF therapies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Efficacy in perianal fistulas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      for Crohn's disease is similar to that observed in its role for other indications (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Safety'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision whether to use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      in patients with Crohn's disease requiring anti-TNF therapy will be influenced mostly by the convenience and availability of subcutaneous administration of adalimumab and certolizumab pegol contrasted against the requirements for intravenous infusions and the larger body of safety and efficacy data on infliximab. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188279#H11188279\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Anti-TNF therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/1\">",
"      Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/2\">",
"      Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/3\">",
"      Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/4\">",
"      Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/5\">",
"      Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/6\">",
"      Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009; 104:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/7\">",
"      Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/8\">",
"      Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial. Gastroenterology 2012; 142:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/9\">",
"      Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/10\">",
"      Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/11\">",
"      Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010; 16:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/12\">",
"      Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/13\">",
"      Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/14\">",
"      Panaccione R, Loftus EV Jr, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011; 25:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/15\">",
"      L&ouml;fberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/16\">",
"      Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2011; 34:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/17\">",
"      Savarino E, Dulbecco P, Bodini G, et al. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. Eur J Gastroenterol Hepatol 2012; 24:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/18\">",
"      Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/19\">",
"      D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/20\">",
"      Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/21\">",
"      Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012; 35:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/22\">",
"      Van Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/23\">",
"      Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-&alpha;) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29559/abstract/24\">",
"      Binion DG, Louis E, Oldenburg B, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol 2011; 25:492.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4049 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29559=[""].join("\n");
var outline_f28_55_29559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY FOR INDUCTION AND MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY IN SECONDARY INFLIXIMAB FAILURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY IN PERIANAL FISTULAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1906505\">",
"      EFFICACY IN EXTRAINTESTINAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY FOR GLUCOCORTICOID DISCONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H932216\">",
"      EFFICACY IN POSTOPERATIVE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTI-ADALIMUMAB ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CONCOMITANT IMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADALIMUMAB VERSUS INFLIXIMAB VERSUS CERTOLIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29560="Treatment of nocardiosis";
var content_f28_55_29560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of nocardiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29560/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29560/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29560/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29560/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29560/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/55/29560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardiosis is an uncommon gram-positive bacterial infection caused by aerobic actinomycetes in the genus Nocardia. Nocardia spp have the ability to cause localized or systemic suppurative disease in humans and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Nocardiosis is typically regarded as an opportunistic infection, but approximately one-third of infected patients are immunocompetent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two characteristics of nocardiosis are its ability to disseminate to virtually any organ, particularly the central nervous system, and its tendency to relapse or progress despite appropriate therapy.",
"   </p>",
"   <p>",
"    The treatment of nocardiosis will be reviewed here. The microbiology, epidemiology, pathogenesis, clinical manifestations, and diagnosis of nocardiosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported antimicrobial susceptibility patterns have varied among different studies, countries, and Nocardia species. In a retrospective review of 765 isolates submitted voluntarily to the United States Centers for Disease Control and Prevention (CDC) between 1995 and 2004, 42 percent were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) and 61 percent were resistant to sulfamethoxazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6\">",
"     6",
"    </a>",
"    ]. This incidence of resistance is significantly higher than in other reports. There are limitations to this study, with the authors concluding that the presented data are probably not representative of all United States cases. As an example, patients who were not responding to treatment due to resistance may have been more likely to have had their isolates sent to the CDC than patients with susceptible isolates who were responding to treatment.",
"   </p>",
"   <p>",
"    In contrast, in a study of 552 clinical isolates collected from six major medical referral centers in the United States between 2005 and 2011, which was prompted by the unexpected results of the CDC study, only 2 percent of isolates were resistant to TMP-SMX",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sulfamethoxazole [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/7\">",
"     7",
"    </a>",
"    ]. Possible reasons for the discrepancy between these results and the results of the CDC study are that there might have been differences in the preparation of samples",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the interpretation of results of in vitro susceptibility testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have shown similar results to the study of 552 clinical isolates described above. Among 138 Nocardia isolates collected in Taiwan between 1998 and 2009, only 2 percent were resistant to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/9\">",
"     9",
"    </a>",
"    ]. A study of 28 cases from Switzerland reported that 16 percent of Nocardia isolates were resistant to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/10\">",
"     10",
"    </a>",
"    ]. Given that some isolates are resistant to TMP-SMX, formal antimicrobial susceptibility testing is",
"    <strong>",
"     always",
"    </strong>",
"    necessary to ensure optimal antibiotic therapy.",
"   </p>",
"   <p>",
"    The most common Nocardia species have the following antibiotic susceptibility patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N. asteroides sensu stricto is typically susceptible to TMP-SMX, third-generation cephalosporins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      . Resistance to third-generation cephalosporins has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2\">",
"       2",
"      </a>",
"      ]. It is variably resistant to imipenem (64 to 98 percent of isolates are susceptible) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2,11\">",
"       2,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      N. farcinica is uniformly susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , but is resistant to other aminoglycosides, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/12\">",
"       12",
"      </a>",
"      ]. Many, but not all, isolates have been reported as susceptible to TMP-SMX and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2\">",
"       2",
"      </a>",
"      ]. In contrast, in the 10-year review described above, 80 percent of N. farcinica isolates were resistant to TMP-SMX and 79 percent to minocycline [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6\">",
"       6",
"      </a>",
"      ]. N. farcinica is generally resistant to third-generation cephalosporins [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6,12,13\">",
"       6,12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most isolates of N. nova were susceptible to TMP-SMX and third-generation cephalosporins in reports from the early 1990s [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/14\">",
"       14",
"      </a>",
"      ]. However, a later review reported 53 percent resistance to both antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6\">",
"       6",
"      </a>",
"      ]. Most isolates remain susceptible to imipenem, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6,14\">",
"       6,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      N. brasiliensis is typically susceptible to TMP-SMX and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      . In previous reports, most isolates (88 to 100 percent) were susceptible to third-generation cephalosporins [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/11\">",
"       11",
"      </a>",
"      ]. However, much higher levels of resistance (81 percent) to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      have since been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6\">",
"       6",
"      </a>",
"      ]. Only 20 to 30 percent of isolates are susceptible to imipenem [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/11,15\">",
"       11,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many N. transvalensis isolates are susceptible to TMP-SMX (88 percent), imipenem (90 percent), and third-generation cephalosporins (50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/11\">",
"       11",
"      </a>",
"      ]. N. transvalensis is usually resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      and other aminoglycosides [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      N. otitidiscaviarum is generally resistant to TMP-SMX, but is usually susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nocardia susceptibility varies among the carbapenems. A study of the in vitro activity of various antibiotics against 51 Nocardia isolates from more than 10 Nocardia species found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    was fourfold less active than imipenem and that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    was 16-fold less active than imipenem [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/19\">",
"     19",
"    </a>",
"    ]. However, other data suggest that meropenem has better activity than imipenem against some Nocardia species but confirm decreased activity against N. farcinica and N. nova [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the Nocardia species described above are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/6,19,20\">",
"     6,19,20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     Amoxicillin-clavulanate",
"    </a>",
"    has efficacy against some isolates, but use of oral agents is limited to cutaneous disease in immunocompetent hosts and to suppressive therapy following induction therapy of severe infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prospective randomized trials have determined the most effective therapy for nocardiosis. In addition, it is unlikely that such trials will ever be performed, since a large number of patients with similar clinical manifestations would be required. Two hallmarks of nocardiosis are its relative rarity and the diversity of the clinical presentation in different patients. Thus, the choice of antimicrobials is based upon cumulative retrospective experience, investigations in animal models, and in vitro antimicrobial activity profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antimicrobial agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical isolates of Nocardia spp are variably resistant to antibiotics. As a result, we recommend empiric coverage with two or three agents in patients with severe infection, as defined below. Cutaneous infection in an immunocompetent host can be treated with monotherapy.",
"   </p>",
"   <p>",
"    Most authorities recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    as part of first-line therapy for nocardiosis. If the patient is allergic to sulfonamides, desensitization should be performed when possible. If this is not appropriate, or if the patient is intolerant of sulfonamides, then alternative agents should be chosen based upon susceptibility studies of the clinical isolate, if available. The approach to patients with sulfonamide allergies is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link\">",
"     \"Sulfonamide allergy in non HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamides have been considered the standard of therapy for more than 50 years, despite the lack of controlled comparative data. This consensus is based in part upon the results of a few retrospective reviews in which there was a trend toward increased survival in nocardiosis with the use of sulfonamide-containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/21\">",
"     21",
"    </a>",
"    ]. As noted above, if the patient is allergic to sulfonamides, desensitization should be performed when possible. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Antimicrobial agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although all sulfonamides appear to be equally efficacious,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) is considered by most clinicians to be the drug of choice.&nbsp;Some Nocardia spp are less susceptible or resistant&nbsp;to this regimen by in vitro susceptibility testing. Nevertheless, there have been few reports of patients failing to respond to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Antibiotic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients&nbsp;who develop Nocardia infection while taking low-dose TMP-SMX for Pneumocystis pneumonia prophylaxis,&nbsp;the majority of their isolates remain susceptible to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, in a study of 35 solid organ transplant recipients with Nocardia infection, 24 (69 percent) were receiving prophylactic TMP-SMX (most at a dose of 1 single-strength tablet three times a week), and all breakthrough infections except one involved isolates that were susceptible to TMP-SMX [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/22\">",
"     22",
"    </a>",
"    ]. Furthermore, many of the breakthrough infections were treated successfully with combination regimens that included TMP-SMX. In this setting, it is reasonable to use TMP-SMX as&nbsp;part of empiric&nbsp;combination therapy while awaiting&nbsp;susceptibility results.",
"   </p>",
"   <p>",
"    TMP-SMX has demonstrated synergy against Nocardia in several in vitro studies; the optimal ratio of TMP to SMX in vitro ranges from 1 to &le;5 to a ratio of 1 to 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, controversy exists over the optimal synergistic ratio in vivo and whether this ratio should be achieved in the serum or tissues.",
"   </p>",
"   <p>",
"    Commercial preparations contain a ratio of TMP to SMX of 1:5. Following administration, the ratio achieved is usually 1:20 in the serum and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/23\">",
"     23",
"    </a>",
"    ] and approximately 1:7 in tissues, pus, and cerebral nocardial abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. There is evidence that TMP-SMX is synergistic against Nocardia at a wide range of ratios, including the 1:20 ratio achieved in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. It has not been demonstrated that the TMP component adds clinical benefit over a sulfonamide alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMP-SMX has the additional benefits of excellent penetration into most tissue compartments, including the central nervous system, and high serum concentrations after oral administration. TMP-SMX is the only parenteral sulfonamide currently available in the United States.",
"   </p>",
"   <p>",
"    Sulfonamide levels should be monitored in patients with life-threatening disease and in those failing treatment. A sulfonamide level should be measured two hours after a dose is given. A serum concentration between 100 and 150",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is considered to be an adequate therapeutic concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the success of TMP-SMX in the treatment of nocardiosis, combination therapy with other agents is warranted in patients with severe infections. These drugs are also indicated in patients with sulfonamide intolerance or allergy and documented clinical treatment failures. The choice of agent varies with susceptibility testing and with known patterns of response with different Nocardia spp. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Antibiotic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In vitro susceptibilities and animal models of disease have demonstrated activity against Nocardia with a variety of antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , third-generation cephalosporins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , extended spectrum fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/19,27-29\">",
"     19,27-29",
"    </a>",
"    ]. Several anecdotal reports indicate that these agents are successful in treating patients with nocardiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although limited clinical experience suggests efficacy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , even as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/32\">",
"     32",
"    </a>",
"    ], the use of linezolid for more than two weeks is associated with substantial risk of hematologic toxicity, particularly thrombocytopenia, as well as neurotoxicity (eg, peripheral neuropathy, serotonin syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Given the length of treatment recommended for nocardiosis (usually 6 to 12 months), linezolid seems unlikely to become a widely used in this setting. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Duration of treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Isolated cutaneous infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite reports of spontaneous resolution of some cutaneous lesions, it is judicious to treat all such patients with systemic antibiotics because of the possibility of more widespread disease. Single agent oral therapy is usually sufficient for patients with cutaneous disease from an inoculation injury.",
"   </p>",
"   <p>",
"    Empiric monotherapy regimens include TMP-SMX (2.5 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component orally twice daily) and, less preferably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (100 mg orally twice daily) (",
"    <a class=\"graphic graphic_table graphicRef56194 \" href=\"UTD.htm?5/31/5629\">",
"     table 1",
"    </a>",
"    ). Alternative oral agents may be used if the isolate proves susceptible. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , macrolides, and fluoroquinolones.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    , although active in vitro and in vivo, has significant hematologic toxicity, which requires careful monitoring and may limit its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H683290415\">",
"    <span class=\"h3\">",
"     Mycetoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of nocardial mycetoma usually involves antibiotics alone. Surgical excision may be undertaken before diagnosis, but is usually not warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component orally twice daily) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (100 mg orally once daily) is commonly used for disease of short duration, of limited extent, and with low risk of dissemination (",
"    <a class=\"graphic graphic_table graphicRef56194 \" href=\"UTD.htm?5/31/5629\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/36\">",
"     36",
"    </a>",
"    ]. For patients with more severe disease (eg, with bone or visceral involvement), with longer duration disease, or disease that is refractory to sulfonamides, consideration should be given to IV imipenem alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal duration of therapy for cutaneous disease, including mycetoma, has not been determined, but most recommend a prolonged course because of the relapsing nature of Nocardia infection. Immunocompetent patients with cutaneous disease should be treated with oral therapy for three to six months, although patients with mycetomas require six to twelve months. Immunocompromised patients with cutaneous disease should generally be treated for a minimum of one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Severe infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe nocardiosis includes some cases of pulmonary disease, and all cases of disseminated disease or central nervous system disease, as well as all infections involving more than one site in immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Initial intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of data to support the superiority of combination therapy over single drug regimens, most infectious diseases specialists initially treat severe nocardial infection with two intravenous drugs prior to the availability of susceptibility results (",
"    <a class=\"graphic graphic_table graphicRef56194 \" href=\"UTD.htm?5/31/5629\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, in cases of life-threatening infection, we suggest using three intravenous drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\", section on 'Susceptibility testing'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Antibiotic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with severe infection that does not involve the CNS be treated initially with TMP-SMX (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component per day in two to four divided doses) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours). An alternative approach that some clinicians favor for the initial treatment of severe disease is imipenem (500 mg IV every 6 hours) plus amikacin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2,37\">",
"       2,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We suggest that patients with CNS disease be given TMP-SMX (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component per day in two to four divided doses) plus imipenem (500 mg IV every 6 hours). In patients with CNS disease who have multiorgan involvement, we favor using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      in addition to the above regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antimicrobial susceptibilities should be performed on",
"    <strong>",
"     all",
"    </strong>",
"    Nocardia isolates as a guide to therapy. Susceptibility testing is particularly important in patients infected with Nocardia species known to have high frequencies of antimicrobial resistance, such as N. farcinica or other newly identified species [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/11\">",
"     11",
"    </a>",
"    ]. One caveat is that immunocompromised patients may fail therapy even though susceptibilities indicate that the organism is sensitive. Susceptibility testing is also repeated for patients who fail to respond to initial therapy.",
"   </p>",
"   <p>",
"    Initial treatment (ie, induction therapy) should be administered intravenously for at least three to six weeks",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    until clinical improvement is documented. We favor at least two intravenous agents during this phase of therapy for all patients with severe disease. Patients initially on three intravenous drugs who both improve on initial intravenous combination therapy and are proven to have susceptible isolates may be switched to two intravenous drugs to complete the induction phase of therapy. The results of susceptibility testing should be used to tailor the regimen. As an example, if the isolate is susceptible to the third-generation cephalosporins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ), imipenem can be switched to one of these agents.",
"   </p>",
"   <p>",
"    Some infectious diseases experts recommend exclusive intravenous treatment for patients with central nervous system (CNS) disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Switch to oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected patients who clinically improve with induction intravenous therapy and do not have CNS disease may be switched to oral monotherapy (usually after three to six weeks) based upon susceptibility results.",
"   </p>",
"   <p>",
"    In patients with CNS disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiorgan involvement, particularly if there is also immunocompromise, we suggest switching to combination oral therapy (with two drugs based upon susceptibility studies) after a minimum of six weeks of intravenous therapy",
"    <strong>",
"     and",
"    </strong>",
"    clear evidence of clinical improvement. Patients who are switched to oral therapy should be closely monitored to confirm a continued clinical response.",
"   </p>",
"   <p>",
"    Recommended antibiotics that can be part of an oral regimen following induction intravenous therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A sulfonamide (eg, TMP-SMX 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component per day in two or three divided doses)",
"      <span class=\"nowrap\">",
"       AND/OR",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      (100 mg twice daily)",
"      <span class=\"nowrap\">",
"       AND/OR",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      (875 mg twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Sulfonamide resistance or allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients infected with sulfonamide-resistant organisms or who are allergic to or intolerant of sulfonamides, we suggest a two-drug regimen consisting of imipenem (500 mg IV every six hours)",
"    <strong>",
"     plus",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    (7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antimicrobial treatment for severe disease has not been determined, but most recommend a prolonged course because of the relapsing nature of Nocardia infection. We usually treat for a duration of three to six months for isolated cutaneous infection in immunocompetent patients, but for 6 to 12 months in immunocompromised patients. Serious pulmonary infection is treated for 6 to 12 months or longer. All immunocompromised patients (except those with isolated cutaneous infection) as well as patients with CNS involvement should be treated for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2\">",
"     2",
"    </a>",
"    ], and some suggest indefinite suppressive therapy in immunocompromised patients. Within these ranges, the total duration of therapy (IV followed by oral) is based upon the severity and extent of disease and the clinical and radiographic response to treatment. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Maintenance suppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The duration of intravenous therapy varies with the patient's immune status. In immunocompromised patients, maximal tolerated doses should be given intravenously for at least six weeks",
"    <strong>",
"     and",
"    </strong>",
"    until clinical improvement has occurred; in contrast, immunocompetent patients may be successfully treated with a shorter duration of intravenous therapy. Following the intravenous induction phase, patients may be stepped down to oral antibiotics based upon susceptibility studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Switch to oral therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of disease and underlying conditions may significantly influence the outcome of Nocardia therapy. Poor prognosis is often associated with a delay in diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    premature discontinuation of appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/38\">",
"     38",
"    </a>",
"    ]. However, promptly instituted and effective therapy is usually associated with a good outcome even when the disease has disseminated. In a case-control study that included 35 organ transplant recipients with nocardiosis, 31 (89 percent) were cured, including six of seven patients with disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some patients with localized disease do well with a shorter course, retrospective studies suggest an improved outcome when therapy is given for a prolonged period. In different observational studies, no fatalities occurred among 78 patients treated for more than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/39\">",
"     39",
"    </a>",
"    ] and relapses were rare in 34 patients treated for more than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/25\">",
"     25",
"    </a>",
"    ]. In a small study of HIV-infected patients, relapses were associated with a mean duration of therapy of eight weeks; no relapses were seen in patients treated for a mean of 45 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nocardiosis should be monitored for the response to therapy and possible drug toxicity. Following discharge from the hospital, patients should be seen frequently (eg, at least monthly) to monitor for changes in signs and symptoms, as well as to detect any adverse drug effects.",
"   </p>",
"   <p>",
"    In addition, radiographic studies are useful to evaluate clinical improvement in patients with severe infection. It is our practice to obtain follow-up imaging studies (eg, chest radiographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT scans for pulmonary disease, and brain CT or MRI scans for CNS disease) after 1, 3, 6, and 12 months of treatment. For patients who have completed therapy and for those receiving prophylaxis to prevent relapse of prior nocardiosis, it is our practice to repeat the radiologic studies at 6 and 12 months after clinical cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment failures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical improvement is usually seen within two weeks after initiation of appropriate therapy. Patients who continue to be symptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have progression of their primary lesions after two weeks of therapy should be carefully reevaluated. Poor response may represent primary drug resistance, poor penetration of drug into the infected tissue compartment, or the presence of an abscess requiring surgical drainage. Alternative regimens for treatment of drug-resistant infection are presented above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Severe infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention may be necessary in several settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral and large soft tissue abscesses that do not respond to antibiotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Empyemas and mediastinal fluid collections.",
"     </li>",
"     <li>",
"      Pulmonary nocardiosis complicated by pericarditis, which is almost always fatal unless pericardial drainage is performed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CNS nocardiosis that fails to respond to medical therapy may require craniotomy or aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/40\">",
"     40",
"    </a>",
"    ]. However, in a retrospective series of 11 patients with Nocardia brain abscesses treated at a single institution over a 31 year period, repeated aspiration was as effective as craniotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patients on immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy predisposes patients to Nocardia infection. In patients who are on these drugs because they have undergone transplantation, immunosuppression cannot be stopped, but the dose should be decreased as much as possible. In patients receiving immunosuppressive therapy for other reasons, it is ideal to discontinue the immunosuppressive agent if alternatives are available. Among tumor necrosis factor inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    has been associated with a greater risk of nocardial infection than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link&amp;anchor=H8#H8\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\", section on 'Immunocompromise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Maintenance suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities recommend prolonged oral maintenance therapy to prevent relapse of nocardiosis in patients who continue to be immunosuppressed as a result of their disease or treatment (eg,",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    hematopoietic stem cell or solid organ transplant recipients, and patients receiving high-dose glucocorticoids or cytotoxic therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/21,45\">",
"     21,45",
"    </a>",
"    ]. TMP-SMX is the agent most frequently used, but protection is not complete and the most appropriate regimen has not been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/21,46\">",
"     21,46",
"    </a>",
"    ]. As an example, TMP-SMX given two or three times a week did not prevent nocardiosis in patients at high risk of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29560/abstract/22,47-49\">",
"     22,47-49",
"    </a>",
"    ]. Thus, in patients whose immunosuppression cannot be reversed, we suggest a maintenance regimen of TMP-SMX one single strength tablet daily provided that the Nocardia isolate is susceptible to TMP-SMX. Alternative maintenance regimens for patients unable to tolerate TMP-SMX have not been systematically evaluated. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg daily is a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocardiosis is an uncommon gram-positive bacterial infection that usually causes infection in immunocompromised hosts. Two characteristics that distinguish nocardiosis are the ability to disseminate to virtually any organ, particularly the central nervous system, and the tendency to relapse or progress despite appropriate therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with systemic disease require antibiotic therapy. We also recommend antibiotic therapy even in patients with limited cutaneous disease (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics that are typically effective against Nocardia spp include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , imipenem, and third-generation cephalosporins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ). However, antibiotic susceptibilities vary among isolates. The suggested regimens discussed below are empiric and should be tailored once information on susceptibilities is available. Dosing is presented in the Table (",
"      <a class=\"graphic graphic_table graphicRef56194 \" href=\"UTD.htm?5/31/5629\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antimicrobial agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with isolated cutaneous infection can usually be managed with oral monotherapy. We suggest initial therapy with oral TMP-SMX (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who do not respond require intravenous therapy as discussed below for severe disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Isolated cutaneous infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with non-severe mycetomas, we suggest initial therapy with oral TMP-SMX with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with severe mycetomas, we suggest initial therapy with imipenem with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H683290415\">",
"       'Mycetoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most experts would treat severe infection with two or three intravenous agents while awaiting results of susceptibility testing. In patients without CNS disease, we suggest treating with TMP-SMX plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with CNS disease, we suggest TMP-SMX plus imipenem (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with CNS disease who have multiorgan involvement, we also add amikacin. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Severe infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In selected patients with severe disease who have improved after receiving three to six weeks of intravenous therapy and do not have CNS disease, treatment can be switched to an oral regimen. In these patients, we suggest a monotherapy oral regimen to complete the treatment course (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The oral agent is selected based on susceptibility testing; we use TMP-SMX if the isolate is susceptible. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Switch to oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of antimicrobial treatment for severe disease has not been determined, but most recommend a prolonged course because of the relapsing nature of Nocardia infection. We usually treat for a duration of three to six months for isolated cutaneous infection in immunocompetent patients, but for 6 to 12 months in immunocompromised patients with isolated cutaneous infection. For patients with serious pulmonary infection, we treat for 6 to 12 months or longer. All immunocompromised patients (except those with isolated cutaneous infection) as well as patients with CNS involvement should be treated for at least one year. Within these ranges, the duration of therapy is based upon the severity and extent of disease and the clinical and radiographic response to treatment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nocardiosis should be monitored for the response to therapy and possible drug toxicity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In immunocompromised patients whose immunosuppression cannot be reversed, we suggest indefinite maintenance suppressive therapy with TMP-SMX (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Since breakthroughs have been seen with less frequent dosing regimens (eg, twice or three times per week), we use one single-strength tablet daily.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is a reasonable alternative in patients who cannot tolerate TMP-SMX. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Maintenance suppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/1\">",
"      Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/2\">",
"      Lerner PI. Nocardiosis. Clin Infect Dis 1996; 22:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/3\">",
"      Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore) 2004; 83:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/4\">",
"      Beaman BL, Burnside J, Edwards B, Causey W. Nocardial infections in the United States, 1972-1974. J Infect Dis 1976; 134:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/5\">",
"      Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/6\">",
"      Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis 2010; 51:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/7\">",
"      Brown-Elliott BA, Biehle J, Conville PS, et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol 2012; 50:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/8\">",
"      Conville PS, Brown-Elliott BA, Wallace RJ Jr, et al. Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol 2012; 50:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/9\">",
"      Lai CC, Liu WL, Ko WC, et al. Antimicrobial-resistant nocardia isolates, Taiwan, 1998-2009. Clin Infect Dis 2011; 52:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/10\">",
"      Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010; 38:89.",
"     </a>",
"    </li>",
"    <li>",
"     Sorrell TC, Mitchell DH, Iredell JR. Nocardia species. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier, Philadelphia 2005. p.2916.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/12\">",
"      Wallace RJ Jr, Tsukamura M, Brown BA, et al. Cefotaxime-resistant Nocardia asteroides strains are isolates of the controversial species Nocardia farcinica. J Clin Microbiol 1990; 28:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/13\">",
"      Torres OH, Domingo P, Pericas R, et al. Infection caused by Nocardia farcinica: case report and review. Eur J Clin Microbiol Infect Dis 2000; 19:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/14\">",
"      Wallace RJ Jr, Brown BA, Tsukamura M, et al. Clinical and laboratory features of Nocardia nova. J Clin Microbiol 1991; 29:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/15\">",
"      Khardori N, Shawar R, Gupta R, et al. In vitro antimicrobial susceptibilities of Nocardia species. Antimicrob Agents Chemother 1993; 37:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/16\">",
"      McNeil MM, Brown JM, Georghiou PR, et al. Infections due to Nocardia transvalensis: clinical spectrum and antimicrobial therapy. Clin Infect Dis 1992; 15:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/17\">",
"      Wallace RJ Jr, Steele LC, Sumter G, Smith JM. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother 1988; 32:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/18\">",
"      Wilson RW, Steingrube VA, Brown BA, et al. Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 1997; 35:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/19\">",
"      Cercenado E, Mar&iacute;n M, S&aacute;nchez-Mart&iacute;nez M, et al. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob Agents Chemother 2007; 51:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/20\">",
"      Brown-Elliott BA, Ward SC, Crist CJ, et al. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 2001; 45:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/21\">",
"      Wilson JP, Turner HR, Kirchner KA, Chapman SW. Nocardial infections in renal transplant recipients. Medicine (Baltimore) 1989; 68:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/22\">",
"      Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/23\">",
"      Smego RA Jr, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983; 143:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/24\">",
"      Beaumont RJ. Trimethoprim as a possible therapy for nocardiosis and melioidosis. Med J Aust 1970; 2:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/25\">",
"      Wallace RJ Jr, Septimus EJ, Williams TW Jr, et al. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia. Rev Infect Dis 1982; 4:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/26\">",
"      Smith PW, Steinkraus GE, Henricks BW, Madson EC. CNS nocardiosis: response to sulfamethoxazole-trimethoprim. Arch Neurol 1980; 37:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/27\">",
"      Threlkeld SC, Hooper DC. Update on management of patients with Nocardia infection. Curr Clin Top Infect Dis 1997; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/28\">",
"      McNeil, MM, Brown, JM, Hutwagner, LC, Schiff, TA. Evaluation of therapy for Nocardia asteroides complex infections. Infect Dis Clin Prac 1995; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/29\">",
"      Vera-Cabrera L, Gonzalez E, Choi SH, Welsh O. In vitro activities of new antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004; 48:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/30\">",
"      Beaman BL, Boiron P, Beaman L, et al. Nocardia and nocardiosis. J Med Vet Mycol 1992; 30 Suppl 1:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/31\">",
"      Fihman V, Ber&ccedil;ot B, Mateo J, et al. First successful treatment of Nocardia farcinica brain abscess with moxifloxacin. J Infect 2006; 52:e99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/32\">",
"      Moylett EH, Pacheco SE, Brown-Elliott BA, et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 2003; 36:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/33\">",
"      Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/34\">",
"      Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/35\">",
"      Arenas R, Ameen M. Giant grains of nocardia actinomycetoma. Lancet Infect Dis 2010; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/36\">",
"      Ameen M, Arenas R, V&aacute;squez del Mercado E, et al. Efficacy of imipenem therapy for Nocardia actinomycetomas refractory to sulfonamides. J Am Acad Dermatol 2010; 62:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/37\">",
"      Clark NM, AST Infectious Diseases Community of Practice. Nocardia in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/38\">",
"      Uttamchandani RB, Daikos GL, Reyes RR, et al. Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. Clin Infect Dis 1994; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/39\">",
"      Geiseler PJ, Andersen BR. Results of therapy in systemic nocardiosis. Am J Med Sci 1979; 278:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/40\">",
"      Mamelak AN, Obana WG, Flaherty JF, Rosenblum ML. Nocardial brain abscess: treatment strategies and factors influencing outcome. Neurosurgery 1994; 35:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/41\">",
"      Lee GY, Daniel RT, Brophy BP, Reilly PL. Surgical treatment of nocardial brain abscesses. Neurosurgery 2002; 51:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/42\">",
"      Poland GA, Jorgensen CR, Sarosi GA. Nocardia asteroides pericarditis: report of a case and review of the literature. Mayo Clin Proc 1990; 65:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/43\">",
"      Leang B, Lynen L, Lim K, et al. Disseminated nocardiosis presenting with cardiac tamponade in an HIV patient. Int J STD AIDS 2004; 15:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/44\">",
"      Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/45\">",
"      Simpson GL, Stinson EB, Egger MJ, Remington JS. Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis 1981; 3:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/46\">",
"      King CT, Chapman SW, Butkus DE. Recurrent nocardiosis in a renal transplant recipient. South Med J 1993; 86:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/47\">",
"      van Burik JA, Hackman RC, Nadeem SQ, et al. Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis 1997; 24:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/48\">",
"      Chouci&ntilde;o C, Goodman SA, Greer JP, et al. Nocardial infections in bone marrow transplant recipients. Clin Infect Dis 1996; 23:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29560/abstract/49\">",
"      Walensky, RP, Moore, RD. A case series of 59 patients with nocardiosis. Infect Dis Clin Pract 2001; 10:249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5513 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29560=[""].join("\n");
var outline_f28_55_29560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIBIOTIC SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antimicrobial agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Isolated cutaneous infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H683290415\">",
"      - Mycetoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Severe infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Initial intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Switch to oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Sulfonamide resistance or allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment failures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patients on immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Maintenance suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/31/5629\" title=\"table 1\">",
"      Nocardia treatment regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29561="Osteoporosis after solid organ or stem cell transplantation";
var content_f28_55_29561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteoporosis after solid organ or stem cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Elizabeth Shane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29561/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/55/29561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation has become an established therapy for end-stage kidney, heart, lung, and liver diseases, as well as for several hematologic disorders. Improved survival of transplant recipients has raised awareness of post-transplant complications, such as osteoporosis. Post-transplant osteoporosis and fracture occur in a substantial proportion of patients.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and management of bone loss after solid organ (with the exception of renal transplant) or stem cell transplantation will be reviewed here. Management of bone loss after renal transplantation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplant-related osteoporosis and fracture are due to both pretransplant and post-transplant factors (",
"    <a class=\"graphic graphic_table graphicRef63584 \" href=\"UTD.htm?34/37/35420\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pretransplant bone status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients undergoing transplantation already have low bone mineral density (BMD). The mechanism appears to vary with the underlying disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with severe heart failure (NYHA classes III and IV) who are candidates for cardiac transplantation, chronic kidney disease, vitamin D deficiency, secondary hyperparathyroidism, hypogonadism, chronic use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loop diuretics, and reduced physical activity may contribute to low BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with primary biliary cirrhosis, a toxin or toxins retained because of cholestasis may inhibit normal osteoblast function, causing a low-turnover form of osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"       \"Metabolic bone disease in primary biliary cirrhosis\"",
"      </a>",
"      .) In patients with cirrhosis due to other etiologies, excessive alcohol use, vitamin D deficiency, hypogonadism, and glucocorticoid use increase the risk of osteoporosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with chronic lung disease, preexisting glucocorticoid therapy appears to be the primary risk factor for bone loss [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/3\">",
"       3",
"      </a>",
"      ]. Other risk factors include low body weight, smoking, physical inactivity, and vitamin D deficiency. In patients with cystic fibrosis, additional risk factors are hypogonadism, malnutrition, and malabsorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"       \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H14#H14\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Musculoskeletal disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Post-transplant bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients lose bone rapidly after solid organ [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/4-10\">",
"     4-10",
"    </a>",
"    ] and hematopoietic cell [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] transplantation. The etiology of post-transplant bone loss is multifactorial (",
"    <a class=\"graphic graphic_table graphicRef63584 \" href=\"UTD.htm?34/37/35420\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bone loss is most rapid in the first 6 to 12 months after transplantation with subsequent slowing thereafter, the latter due to a reduction in glucocorticoid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    dose and resolution of pretransplant conditions that were deleterious to skeletal health. Studies of up to three to four years duration show that lumbar spine BMD begins to recover, whereas femoral neck BMD does not. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated BMD in 70 cardiac transplant recipients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/8\">",
"       8",
"      </a>",
"      ]. Despite calcium and vitamin D supplementation, the mean rate of bone loss during the first year was 7.3 percent in the lumbar spine and 10.5 percent in the femoral neck. Bone loss was attenuated during the second year (mean rate of bone loss 0.9 and 0.1 percent, respectively), and during the third year BMD increased in the lumbar spine (mean 2.4 percent) and did not change in the femoral neck.",
"     </li>",
"     <li>",
"      In a prospective study of 280 patients undergoing allogeneic hematopoietic stem cell transplant, lumbar spine and femoral neck BMD decreased by 5.8 and 8.5 percent, respectively, in the first year after transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/11\">",
"       11",
"      </a>",
"      ]. Although spine BMD returned to baseline during the four-year study, femoral neck BMD did not recover.",
"     </li>",
"     <li>",
"      In prospective studies of patients undergoing liver transplantation, bone loss, particularly at the lumbar spine, occurred during the first four to six months after transplant, with gradual improvement thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. By the second post-transplant year, lumbar spine BMD was near or even exceeded baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. After three years, femoral neck BMD improved but was still below baseline levels [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Immunosuppressive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive drugs, particularly glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , contribute to post-transplant bone loss. Glucocorticoids are administered in large doses initially and then tapered over time; however, dose increases for episodes of rejection or graft versus host disease are not uncommon.",
"   </p>",
"   <p>",
"    The predominant effect of glucocorticoids on the skeleton is reduced bone formation. The decline in bone formation may be mediated by direct inhibition of osteoblast proliferation and by increased apoptosis of osteoblasts and mature osteocytes. Glucocorticoids also increase bone resorption by increasing osteoclastogenesis. In addition, glucocorticoids decrease secretion of androgens and estrogens, primarily mediated by inhibition of gonadotropin secretion, and increase secretion of parathyroid hormone (PTH). The etiology of glucocorticoid-induced osteoporosis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (a calcineurin inhibitor) may increase bone turnover in humans. However, the effect of cyclosporine on bone metabolism in humans is less clear, being confounded by the presence of other illnesses or drugs that affect bone, particularly glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H7#H7\">",
"     \"Drugs that affect bone metabolism\", section on 'Cyclosporine'",
"    </a>",
"    .)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    , another calcineurin inhibitor, appears to have less adverse effect on bone than cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/15\">",
"     15",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, rapamycin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    have shown no effects on bone volume in a rat model [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures occur commonly after transplantation. Fracture incidence rates ranging from 10 to 65 percent have been reported (eg, 10 to 36 percent after heart transplantation and 24 to 65 percent after liver transplantation) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/17\">",
"     17",
"    </a>",
"    ]. Several pretransplant and post-transplant risk factors for fracture have been identified (",
"    <a class=\"graphic graphic_table graphicRef63584 \" href=\"UTD.htm?34/37/35420\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a nested case-control study of transplant recipients (kidney, liver, lung, heart), multivariate analysis showed that post-transplant fracture was highest among those with a history of hyperthyroidism, pretransplant diabetes, fracture, or corticosteroid use, and among those currently exposed to antidepressants, narcotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and loop diuretics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/18\">",
"     18",
"    </a>",
"    ]. Use of bisphosphonates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    was also a predictor of fracture, likely indicating the presence of pretransplant osteoporosis.",
"   </p>",
"   <p>",
"    A large proportion of post-transplant fractures occur during the brief phase of rapid bone loss that occurs in the first six months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/5-7,19-22\">",
"     5-7,19-22",
"    </a>",
"    ]. The fracture rate is highest in patients with low pretransplant bone mass who lose bone rapidly; it then falls as bone loss slows 6 to 24 months after transplantation. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective study evaluated patients after cardiac transplantation: 36 percent of all patients and 54 percent of women sustained a fracture after transplantation, 85 percent of which occurred within the first six months (",
"      <a class=\"graphic graphic_figure graphicRef79240 \" href=\"UTD.htm?11/26/11693\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/19\">",
"       19",
"      </a>",
"      ]. Women with the lowest pretransplant hip BMD were at highest risk of fracture. In men, pretransplant BMD did not differ between those who went on to fracture and those who did not. A substantial proportion of men with normal BMD before transplant fractured.",
"     </li>",
"     <li>",
"      In a review of 235 cardiac or liver transplant patients who had annual spinal radiographs, vertebral fracture rates were high in the first two years after transplantation (27 and 21 percent, respectively, in the cardiac and liver groups). Fractures were not prevented by calcium and vitamin D. Predictors included age and pretransplant BMD (cardiac patients) and pretransplant vertebral fractures (liver patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some studies, the rate of post-transplant fracture is decreasing, in part due to increased recognition of the problem, which has resulted in changes in immunosuppressive regimens (reduction in dose and duration of glucocorticoids) and earlier treatment for osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. As an example, in a retrospective review of 531 records from 592 eligible patients undergoing liver transplantation at a single center between 1998 and 2008, following the introduction of a protocol for bone health assessment and management, fractures occurred in 5.6 percent of patients prior to and 3.5 percent after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/25\">",
"     25",
"    </a>",
"    ]. The spine and the wrist were the two most common fracture sites, accounting for 55 and 10 percent of fractures, respectively. Possible reasons for the lower fracture incidence include a reduction in the dose and duration of glucocorticoid therapy, use of bone protective medications (predominantly bisphosphonates), which nearly 30 percent of patients took after transplantation, and improvement in pre- and post-transplantation nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BONE MINERAL DENSITY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bone loss slows or reverses after the first 6 to 12 months, prevention is desirable given the appreciable fracture rate. Because low bone mass is common in adult patients awaiting transplant, and low pretransplant bone density is a risk factor for post-transplant fracture, measurement of bone mineral density (BMD) prior to transplantation is widely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/2,12,16,17,26\">",
"     2,12,16,17,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest measurement of BMD (DXA) of the hip or spine before transplantation in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Method of BMD measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have a history of fracture or have osteoporosis on BMD (T-score &le;-2.5) before transplantation should be evaluated for secondary causes. When a secondary cause (eg, hypogonadism, vitamin D deficiency) is identified, appropriate treatment is recommended prior to transplant. In addition to the treatment (when possible) of secondary causes of osteoporosis, some patients may benefit from additional osteoporosis therapy, such as bisphosphonates, while awaiting transplant. The diagnosis, evaluation, and treatment of osteoporosis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of osteoporosis in men\", section on 'Testosterone therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, patients with normal BMD can defer medical therapy until immediately after transplant. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Candidates for medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same measures used to prevent osteoporosis in the general population apply to transplant recipients. General recommendations that apply to all patients, regardless of the pretransplant BMD measurement, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should receive counseling regarding smoking cessation, early mobilization after transplantation, and fall prevention, which are beneficial for skeletal health.",
"     </li>",
"     <li>",
"      Prior to transplantation, all patients should receive 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of calcium and 800 int.",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      of vitamin D. Higher vitamin D doses should be given if the patient is overtly vitamin D deficient (eg, 25-hydroxyvitamin D level less than 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [50",
"      <span class=\"nowrap\">",
"       nmol/L]).",
"      </span>",
"      Although calcium and vitamin D do not prevent transplantation-related bone loss, randomized trials assessing antiresorptive therapy, such as bisphosphonates, have been carried out in the setting of concomitant calcium and vitamin D repletion. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Medical therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      An effort should be made to find the lowest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose compatible with graft survival. However, bone loss has occurred in patients given prednisone in doses as low as 5 to 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"       \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Regular weight-bearing exercise (30 minutes, three times per week) has proved to be beneficial for the prevention and treatment of osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Exercise'",
"      </a>",
"      .) Trials in cardiac transplant recipients suggest that resistance exercise training may be beneficial after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. In these trials, six months of resistance exercise training, including lumbar extension exercise and variable resistance exercises with a specialized Nautilus machine, restored BMD toward pretransplantation values. However, these studies included a very small number of participants and may not be generalizable to all transplant recipients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates attenuate glucocorticoid-induced bone loss and they are frequently used for the prevention and treatment of osteoporosis in patients taking glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Bisphosphonates'",
"    </a>",
"    .) Because post-transplant bone loss is highly associated with glucocorticoid treatment, bisphosphonates are also frequently used for the prevention of post-transplantation bone loss. Several clinical trials have confirmed their efficacy in reducing bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/24,29-35\">",
"     24,29-35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Bisphosphonates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Calcitriol is also effective in preventing post-transplantation bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/24,32,36\">",
"     24,32,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Calcitriol'",
"    </a>",
"    below.) In addition, both drugs appear to prevent fracture. In a meta-analysis of 11 trials (780 patients) evaluating treatment with bisphosphonates (nine trials) or vitamin D analogs (two trials) versus placebo or no treatment after solid organ (liver, heart, kidney) transplantation, there was a significant reduction in the number of patients with fractures one year post-transplantation (26 versus 51, odds ratio [OR] 0.50, 95% CI 0.29-0.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/37\">",
"     37",
"    </a>",
"    ]. There was also a reduction in the total number of fractures (38 versus 89, OR 0.37, 95% CI 0.22-0.60) and the number of vertebral fractures (29 versus 78, OR 0.24, 95% CI 0.07-0.78). Overall, the number of fracture events was small, limiting the precision of the meta-analysis.",
"   </p>",
"   <p>",
"    Treatment with calcitriol requires monitoring of serum and urinary calcium levels, making it less convenient than bisphosphonates in this setting. Thus, bisphosphonates are considered the medical therapy of choice for the prevention of transplantation-related bone loss. If bisphosphonates are contraindicated or not tolerated, calcitriol or postmenopausal hormone therapy (in women with hypogonadism) are alternative options.",
"   </p>",
"   <p>",
"    Bisphosphonates should be used with caution in premenopausal women because of insufficient information on the potential for harm to the fetus in women who become pregnant while currently or recently receiving bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the trials described below, we suggest bisphosphonates for prevention of transplantation-related bone loss. There are few data to support the use of one bisphosphonate over another. Many of the trials used intravenous bisphosphonates due to ease of administration, especially in post-transplant patients who are required to take many oral medications. In one of the only head-to-head trials comparing an intravenous bisphosphonate (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ) with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , both were similarly effective in preventing bone loss at the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/38\">",
"     38",
"    </a>",
"    ]. Lumbar spine bone density did not change in the alendronate group and increased in the zoledronic acid group. Thus, either oral or intravenous bisphosphonates can be administered. We favor intravenous zoledronic acid for patients at high risk for fracture (eg, osteoporosis at baseline, prior vertebral fragility fracture, T-scores below -1.5 prior to beginning glucocorticoids) and for those who find the weekly dosing schedule of alendronate too burdensome.",
"   </p>",
"   <p>",
"    A number of trials have demonstrated that bisphosphonates are effective for prevention of bone loss after solid organ or stem cell transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/23,24,29-35,39-41\">",
"     23,24,29-35,39-41",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 99 patients receiving stem cell transplantation, subjects were randomly assigned to receive calcium (1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and vitamin D (800 int.",
"      <span class=\"nowrap\">",
"       units/day)",
"      </span>",
"      or the same",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7143?source=see_link\">",
"       calcium-vitamin D",
"      </a>",
"      regimen plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      (60 mg intravenously six times over the first post-transplant year). Treatment with pamidronate prevented spine bone loss (0 percent in the pamidronate group versus -2.9 percent in the calcium group), and attenuated hip bone loss (-5.5 percent and -7.8 percent in the pamidronate and calcium-vitamin D groups, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 62 adults undergoing liver transplantation who were randomly assigned to receive infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (4 mg) or placebo within seven days of transplantation and 3, 6, 9, and 12 months later, the zoledronic acid group lost significantly less bone at the hip at all time points [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/29\">",
"       29",
"      </a>",
"      ]. In the spine, the zoledronic acid group lost less bone at three months, but the difference between the two groups was no longer significant at 12 months because of improvements between 3 and 12 months in the placebo group. Zoledronic acid sometimes caused post-infusion hypocalcemia and temporary secondary hyperparathyroidism.",
"     </li>",
"     <li>",
"      In a trial of 98 patients receiving a liver transplant, subjects randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      (70 mg weekly) versus no alendronate had significant increases in LS (5.1 and 8.9 percent) and FN (4.3 and 8.7 percent) BMD at 12 and 24 months, respectively, compared with the control group [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/34\">",
"       34",
"      </a>",
"      ]. All subjects received calcium (1000 mg daily) and calcitriol (0.5 mcg daily).",
"     </li>",
"     <li>",
"      In one of the only active comparator trials, 84 adults undergoing liver or heart transplant were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (single 5 mg infusion) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      (70 mg weekly) initiated within 30 days of transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/38\">",
"       38",
"      </a>",
"      ]. Both groups were also compared with a reference group of concurrently transplanted patients who had T-scores &ge;-1.5 and who declined participation in the randomized trial. After 12 months, femoral neck and total hip bone mineral density did not change significantly from baseline in the zoledronic acid and alendronate groups. Lumbar spine bone mineral density increased from baseline (2.0 percent) in the zoledronic acid group and did not change in the alendronate group. In the reference group, bone mineral density declined at all sites (-2.2, -3.3, and -2.6 percent at the total hip, femoral neck, and lumbar spine, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to preventing bone loss, bisphosphonates appear to prevent fracture. A meta-analysis of nine trials evaluating treatment with bisphosphonates versus control (placebo or no treatment) on fracture outcomes after solid organ (liver, heart, kidney) transplantation showed a reduction in the proportion of patients with fracture after treatment with bisphosphonates (OR 0.53, 95% CI 0.30-0.91) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/37\">",
"     37",
"    </a>",
"    ]. The reduction in vertebral fractures did not reach statistical significance (OR 0.34, 95% CI 0.09-1.24). Only two of the trials in the meta-analysis were designed to explore fracture as a primary outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of trials, individuals with serum creatinine concentrations above the upper limits of normal were excluded from participation. The safety and efficacy of bisphosphonates for prevention of transplantation-related bone loss in patients with chronic kidney disease has not been carefully evaluated and, in general, there is limited data on the level of renal impairment at which bisphosphonate use should be avoided. This topic is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H7#H7\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Use in chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcitriol also appears to be effective in preventing bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/24,32,36\">",
"     24,32,36",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, placebo-controlled trial of 65 patients undergoing heart and lung transplantation, treatment with calcitriol (0.5 to 0.75 micrograms daily) and calcium prevented bone loss at the hip to a greater extent than did calcium alone [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, 149 heart transplant recipients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      (10 mg orally daily) or calcitriol (0.25 micrograms orally twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/24\">",
"       24",
"      </a>",
"      ]. Treatment was initiated within one month after transplantation; all patients also received calcium (945 mg daily) and vitamin D (1000 int. units daily). Study subjects were compared with a prospectively recruited reference group of 27 patients who declined to participate in the randomized trial.",
"      <br/>",
"      <br/>",
"      At one year, the decrease in BMD was less marked for the alendronate and calcitriol groups than for the reference group in both the lumbar spine (0.7 and 1.6 versus 3.2 percent) and the femoral neck (1.7 and 2.1 versus 6.2 percent). There was a trend toward fewer vertebral fractures with alendronate and calcitriol (6.8 and 3.6 percent versus 13.6 percent in the reference group). Hypercalciuria developed in significantly more patients treated with calcitriol than with alendronate (27 versus 7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although both therapies were equally effective in preventing bone loss, treatment with calcitriol requires monitoring of serum and urinary calcium levels, which may make",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    the more convenient therapy in this setting. However, calcitriol is an alternative for those who are not candidates for or who cannot tolerate bisphosphonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hormone replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many premenopausal women and men undergoing solid organ transplantation have temporary hypogonadism, most often related to the effects of glucocorticoids and chronic illness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In some cases (eg, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for hematopoietic stem cell transplantation), hypogonadism is permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/44\">",
"     44",
"    </a>",
"    ]. In men and women undergoing transplantation, testosterone and estrogen-progestin replacement, respectively, have been shown to slow bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/30,45-47\">",
"     30,45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Estrogen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of osteoporosis in men\", section on 'Testosterone therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of osteoporosis in men\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest gonadal hormone replacement therapy in men and premenopausal women with hypogonadism who do not have contraindications to hormone replacement therapy. The diagnosis of hypogonadism and details of therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of estrogen for osteoporosis in postmenopausal women is also reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .) However, estrogen-progestin therapy is no longer a first-line approach for the treatment of osteoporosis in postmenopausal women because of increased risk of breast cancer, stroke, venous thromboembolism, and perhaps coronary disease (although the risk-benefit profile in the unopposed estrogen trial was different). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    is effective in preventing bone loss in postmenopausal women, it has not been shown to be superior to calcium in transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one trial, the combination of calcitriol and calcitonin was inferior to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in attenuating bone loss three months after cardiac transplant but similar at 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/22/6501?source=see_link\">",
"     recombinant human parathyroid hormone",
"    </a>",
"    (PTH, teriparatide) has been shown to improve BMD in patients with glucocorticoid-induced osteoporosis, there are few studies evaluating PTH for the prevention of post-transplant osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H14#H14\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Parathyroid hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Candidates for medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently little consensus on which patients should receive preventive therapy. In randomized trials of bisphosphonates for the prevention of transplantation-related osteoporosis, patient recruitment was not based upon a particular BMD T-score criterion or clinical risk factor (other than transplantation). Thus, it is difficult to determine the best candidates for preventive therapy.",
"   </p>",
"   <p>",
"    Given the rapid bone loss that ensues immediately after transplant, many experts recommend preventive medical therapy for all transplant recipients, regardless of pretransplant BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. This approach is supported by observational data that show overlap in pretransplant BMD values between those who do and do not fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. In addition, the duration of preventive therapy for transplant recipients may be as short as one year, which reduces concerns about adverse effects and cost. Thus, we suggest preventive medical therapy for all patients undergoing solid organ or stem cell transplantation.",
"   </p>",
"   <p>",
"    Another approach to the management of patients due to receive a transplant is to apply similar guidelines as those used for the prevention of glucocorticoid-induced osteoporosis. As discussed above, early post-transplant bone loss is primarily due to the effects of glucocorticoids. There are several guidelines for the prevention of glucocorticoid-induced osteoporosis. Collectively, they suggest preventive therapy for patients with clinical risk factors for osteoporosis and fracture (age &ge;65 years, previous fragility fracture) or in patients without other risk factors if BMD T-score is below -1.0 or -1.5 (ie, bone mineral density lower than 1.0 or 1.5 SD below the mean for young healthy adults). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Guidelines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H622797#H622797\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Candidates for pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of bone loss after renal transplantation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data to guide duration of therapy in transplant recipients. Given that lumbar spine BMD begins to recover in many patients within 12 months of transplant, long-term treatment may be unnecessary. In some patients, 12 months of therapy may be adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/51\">",
"     51",
"    </a>",
"    ]. Treatment duration should be based upon patient factors, such as ability to withdraw glucocorticoids, presence of other risk factors for low bone mass and fracture, and BMD measurements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the response to therapy is important for identifying patients who may be able to discontinue therapy and for patients who are not responding to therapy. While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach. In the majority of patients, we suggest BMD measurements prior to and one year after transplantation.",
"   </p>",
"   <p>",
"    In patients who require continued glucocorticoid therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at &ge;5 mg daily), BMD measurements every one to two years may be required. In patients who have successfully tapered off glucocorticoid therapy, we suggest annual BMD measurements for two years after transplantation with less frequent monitoring (every two to three years) thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bisphosphonates, calcitriol and, in select patients, hormone replacement therapy are efficacious in preventing bone loss at the time of transplantation, many patients are not evaluated for osteoporosis nor do they receive preventive therapy. Low bone mass is commonly found in patients with a history of transplantation months or years in the past. The treatment of osteoporosis in such patients is similar to the treatment of osteoporosis in patients who have not received a transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For those who remain on glucocorticoids, their treatment is similar to the treatment of osteoporosis in patients on glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Guidelines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link&amp;anchor=H622797#H622797\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\", section on 'Candidates for pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates are efficacious in patients with persistent osteoporosis years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    is less beneficial in the first six months after transplantation, when bone loss is rapid, it has been shown to improve BMD in patients with persistent osteoporosis after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29561/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recombinant parathyroid hormone (PTH) has not been studied in this population. Patients who have received total body irradiation during hematopoietic stem cell transplantation or who have primary or secondary elevations in PTH are not candidates for recombinant PTH therapy. PTH for the treatment of osteoporosis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoporosis and fracture frequently occur after solid organ or hematopoietic transplantation. The etiology is multifactorial (",
"      <a class=\"graphic graphic_table graphicRef63584 \" href=\"UTD.htm?34/37/35420\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General measures to improve skeletal health in transplant recipients include reducing the dose of glucocorticoids as soon as possible, smoking cessation, exercise, and supplementation with calcium and vitamin D. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'General recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients undergoing organ or hematopoietic transplantation, we suggest measurement of pretransplant bone mineral density (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pretransplantation osteoporosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with low pretransplant BMD (T-score &le;-2.5) or a fragility fracture should be evaluated for secondary causes of bone loss. When a secondary cause (eg, hypogonadism, vitamin D deficiency) is identified, it should be treated, if possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients who have pretransplantation osteoporosis (T-score &le;-2.5) or a fragility fracture, we recommend medical therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For men and postmenopausal women, we suggest bisphosphonates as the first-line medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast, medical therapy needs to be individualized in premenopausal women because of insufficient information on the potential for harm to the fetus in women who become pregnant while currently or recently receiving bisphosphonates. However, for premenopausal women with fractures or accelerated bone loss who do not need estrogen replacement therapy because they have normal menstrual function, bisphosphonates are generally the drugs of choice. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Bisphosphonates'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prevention of post-transplantation osteoporosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest preventive medical therapy for all patients undergoing solid organ or stem cell transplantation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An alternative approach is to treat patients with clinical risk factors for fracture (age &ge;65 years, previous fragility fracture) or BMD T-score &le;-1.0. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Candidates for medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the prevention of post-transplant osteoporosis in men and postmenopausal women, we suggest bisphosphonates, rather than calcitriol&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Either oral or intravenous bisphosphonates can be administered as both have been shown to be effective in this setting. We favor intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      for patients at high risk for fracture (eg, osteoporosis at baseline, prior vertebral fragility fracture, T-scores below -1.5 prior to beginning glucocorticoids) and for those who find the weekly dosing schedule of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      too burdensome. Prevention therapy should be initiated immediately after transplant. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Bisphosphonates should be used with caution in premenopausal women because of insufficient information on the potential for harm to the fetus in women who become pregnant while currently or recently receiving bisphosphonates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"      </a>",
"      .)&nbsp;Calcitriol or hormone replacement therapy (in hypogonadal women) are alternative prevention options.",
"     </li>",
"     <li>",
"      Management of bone loss after renal transplantation is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"       \"Parathyroid and mineral metabolism after renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no consensus on the optimal strategy for monitoring patients on therapy. However, we typically measure BMD one year after transplantation and periodically thereafter, depending upon individual patient characteristics. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/1\">",
"      Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997; 103:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/2\">",
"      Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/3\">",
"      Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 1996; 101:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/4\">",
"      Julian, BA, Benfield, M, Quarles, LD. Bone loss after organ transplantation. Transplant Rev 1993; 7:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/5\">",
"      Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/6\">",
"      McDonald JA, Dunstan CR, Dilworth P, et al. Bone loss after liver transplantation. Hepatology 1991; 14:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/7\">",
"      Henderson NK, Sambrook PN, Kelly PJ, et al. Bone mineral loss and recovery after cardiac transplantation. Lancet 1995; 346:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/8\">",
"      Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997; 82:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/9\">",
"      Horber FF, Casez JP, Steiger U, et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/10\">",
"      Spira A, Gutierrez C, Chaparro C, et al. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/11\">",
"      Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 2004; 103:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/12\">",
"      Tauchmanov&agrave; L, Colao A, Lombardi G, et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab 2007; 92:4536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/13\">",
"      Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/14\">",
"      Monegal A, Navasa M, Gua&ntilde;abens N, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001; 12:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/15\">",
"      Monegal A, Navasa M, Gua&ntilde;abens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/16\">",
"      Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/17\">",
"      Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003; 14:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/18\">",
"      Rakel A, Sheehy O, Rahme E, Lelorier J. Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study. J Bone Miner Res 2007; 22:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/19\">",
"      Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 1996; 81:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/20\">",
"      Shane E, Rivas MC, Silverberg SJ, et al. Osteoporosis after cardiac transplantation. Am J Med 1993; 94:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/21\">",
"      Nielsen, HE, Melsen F, Christensen, MS. Spontaneous fractures following renal transplantation: Clinical and biochemical aspects, bone mineral content and bone morphometry. Miner Electrolyte Metab 1979; 2:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/22\">",
"      Ramsey-Goldman R, Dunn JE, Dunlop DD, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999; 14:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/23\">",
"      Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001; 357:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/24\">",
"      Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/25\">",
"      Premaor MO, Das TK, Debiram I, et al. Fracture incidence after liver transplantation: results of a 10-year audit. QJM 2011; 104:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/26\">",
"      Cohen, A, Ebeling, P, Sprague, S, and Shane, E. Transplantation Osteoporosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, sixth edition. American Society of Bone and Mineral Research 2006; 56:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/27\">",
"      Braith RW, Mills RM, Welsch MA, et al. Resistance exercise training restores bone mineral density in heart transplant recipients. J Am Coll Cardiol 1996; 28:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/28\">",
"      Braith RW, Conner JA, Fulton MN, et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant 2007; 26:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/29\">",
"      Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/30\">",
"      Kananen K, Volin L, Laitinen K, et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005; 90:3877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/31\">",
"      Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006; 91:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/32\">",
"      Bianda T, Linka A, Junga G, et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2000; 67:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/33\">",
"      Aris RM, Lester GE, Renner JB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000; 162:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/34\">",
"      Atamaz F, Hepguler S, Akyildiz M, et al. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006; 17:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/35\">",
"      Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009; 24:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/36\">",
"      Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/37\">",
"      Stein EM, Ortiz D, Jin Z, et al. Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab 2011; 96:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/38\">",
"      Shane E, Cohen A, Stein EM, et al. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab 2012; 97:4481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/39\">",
"      Monegal A, Gua&ntilde;abens N, Su&aacute;rez MJ, et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009; 22:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/40\">",
"      Bodingbauer M, Wekerle T, Pakrah B, et al. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 2007; 7:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/41\">",
"      Kaemmerer D, Lehmann G, Wolf G, et al. Treatment of osteoporosis after liver transplantation with ibandronate. Transpl Int 2010; 23:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/42\">",
"      Fleischer J, McMahon DJ, Hembree W, et al. Serum testosterone levels after cardiac transplantation. Transplantation 2008; 85:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/43\">",
"      Tauchmanov&agrave; L, Selleri C, De Rosa G, et al. Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med 2005; 118:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/44\">",
"      Tauchmanov&agrave; L, Selleri C, De Rosa G, et al. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod 2003; 18:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/45\">",
"      Trombetti A, Gerbase MW, Spiliopoulos A, et al. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 2000; 19:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/46\">",
"      Stempfle HU, Werner C, Echtler S, et al. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 1999; 68:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/47\">",
"      Isoniemi H, Appelberg J, Nilsson CG, et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 2001; 34:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/48\">",
"      V&auml;lim&auml;ki MJ, Kinnunen K, T&auml;htel&auml; R, et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos Int 1999; 10:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/49\">",
"      V&auml;lim&auml;ki MJ, Kinnunen K, Volin L, et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/50\">",
"      Cejka D, Benesch T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008; 8:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/51\">",
"      Cohen A, Addesso V, McMahon DJ, et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 2006; 81:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/52\">",
"      Krieg MA, Seydoux C, Sandini L, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 2001; 12:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/53\">",
"      Ippoliti G, Pellegrini C, Campana C, et al. Clodronate treatment of established bone loss in cardiac recipients: a randomized study. Transplantation 2003; 75:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/54\">",
"      Dodidou P, Bruckner T, Hosch S, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003; 14:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29561/abstract/55\">",
"      Valero MA, Loinaz C, Larrodera L, et al. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995; 57:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2043 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29561=[""].join("\n");
var outline_f28_55_29561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pretransplant bone status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Post-transplant bone loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Immunosuppressive regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BONE MINERAL DENSITY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Calcitriol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hormone replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Candidates for medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pretransplantation osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prevention of post-transplantation osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2043|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/26/11693\" title=\"figure 1\">",
"      Bone fractures post heart transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2043|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/37/35420\" title=\"table 1\">",
"      Risk factors fracture after transplant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29562="Initial evaluation and management of shock in adult trauma";
var content_f28_55_29562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of shock in adult trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29562/contributors\">",
"     Christopher Colwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29562/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/55/29562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/55/29562/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/55/29562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock refers to inadequate tissue perfusion, which manifests clinically as hemodynamic disturbances and organ dysfunction. At the cellular level, shock results from insufficient delivery of required metabolic substrates, principally oxygen, to sustain aerobic metabolism.",
"   </p>",
"   <p>",
"    In the setting of trauma, loss of circulating blood volume from hemorrhage is the most common cause of shock. Inadequate oxygenation, mechanical obstruction (eg, cardiac tamponade, tension pneumothorax), neurologic dysfunction (eg, high-spinal cord injury), and cardiac dysfunction represent other potential causes or contributing factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/1\">",
"     1",
"    </a>",
"    ]. Shock is a common and frequently treatable cause of death in injured patients and is second only to traumatic brain injury as the leading cause of death from trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the evaluation and initial management of shock in the trauma patient. The initial management of the trauma patient, a general overview of shock, including pathophysiology and differential diagnosis, and discussions of the management of shock in other clinical circumstances are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of shock primarily relates to an imbalance in oxygen supply and demand. Patients in shock suffer from a critical reduction in the oxygen available to the mitochondria. Adenosine triphosphate (ATP) can still be synthesized by anaerobic glycolysis, but at only 5 to 10 percent of the normal rate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/4\">",
"     4",
"    </a>",
"    ]. Anaerobic glycolysis results in the accumulation of pyruvate, which is converted to lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The compensatory physiologic responses to acute hemorrhage attempt to maintain adequate oxygen delivery to tissues. Stimulation of the sympathetic nervous system results in an increased heart rate, vasoconstriction, and increased ventricular contractility. As the shock state progresses, vital organ (eg, brain and heart) perfusion can only be maintained at the expense of nonvital organs. If the process is not reversed, progressive lactate production leads to worsening systemic metabolic acidosis, which along with hypoxemia ultimately causes the loss of peripheral vasoconstriction and cardiovascular collapse.",
"   </p>",
"   <p>",
"    The Advanced Trauma Life Support&reg; (ATLS&reg;) manual describes four classes of hemorrhage to emphasize the early signs of the shock state [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinicians should note that significant drops in blood pressure are generally not manifested until class III hemorrhage develops, and up to 30 percent of a patient's blood volume can be lost before this occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I hemorrhage involves a blood volume loss of up to 15 percent. The heart rate is minimally elevated or normal, and there is no change in blood pressure, pulse pressure, or respiratory rate.",
"     </li>",
"     <li>",
"      Class II hemorrhage occurs when there is a 15 to 30 percent blood volume loss and is manifested clinically as tachycardia (heart rate of 100 to 120), tachypnea (respiratory rate of 20 to 24), and a decreased pulse pressure, although systolic blood pressure changes minimally if at all. The skin may be cool and clammy, and capillary refill may be delayed.",
"     </li>",
"     <li>",
"      Class III hemorrhage involves a 30 to 40 percent blood volume loss, resulting in a significant drop in blood pressure and changes in mental status. Any hypotension (systolic blood pressure less than 90 mmHg) or drop in blood pressure greater than 20 to 30 percent of the measurement at presentation is cause for concern. While diminished anxiety or pain may contribute to such a drop, the clinician must assume it is due to hemorrhage until proven otherwise. Heart rate (&ge;120 and thready) and respiratory rate are markedly elevated, while urine output is diminished. Capillary refill is delayed.",
"     </li>",
"     <li>",
"      Class IV hemorrhage involves more than 40 percent blood volume loss leading to significant depression in blood pressure and mental status. Most patients in class IV shock are hypotensive (systolic blood pressure less than 90 mmHg). Pulse pressure is narrowed (&le;25 mmHg), and tachycardia is marked (&gt;120). Urine output is minimal or absent. The skin is cold and pale, and capillary refill is delayed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Hemorrhage",
"    </strong>",
"    is the most common cause of shock in the trauma patient. Massive hemorrhage can occur in the chest, abdomen, retroperitoneum, and from major external wounds. The thigh can hold up to approximately 1 to 2 L of blood. Scalp lacerations can bleed profusely and are often overlooked if significant thoracic or abdominal injuries are present.",
"   </p>",
"   <p>",
"    A number of other potential causes of traumatic shock must also be considered, including (",
"    <a class=\"graphic graphic_table graphicRef63698 \" href=\"UTD.htm?4/24/4492\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac tamponade",
"     </li>",
"     <li>",
"      Tension pneumothorax",
"     </li>",
"     <li>",
"      Pulmonary contusion with resulting pulmonary dysfunction",
"     </li>",
"     <li>",
"      Hemothorax with resulting pulmonary dysfunction",
"     </li>",
"     <li>",
"      Myocardial infarction or contusion (ie, cardiogenic shock)",
"     </li>",
"     <li>",
"      Spinal cord injury (ie, neurogenic shock)",
"     </li>",
"     <li>",
"      Effects of pharmacologic or toxicologic agents",
"     </li>",
"     <li>",
"      Fat or air embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In penetrating trauma, diaphragmatic rupture complicated by incarceration of abdominal organs and bowel perforation can lead to septic shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREHOSPITAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prehospital management of patients in traumatic shock is focused on recognition, rapid transport, and stabilization of the airway, breathing, and circulation. Prehospital clinicians must be diligent about looking for signs of hypoperfusion, ideally recognizing traumatic shock before hypotension develops, and providing appropriate management according to their level of skill. Delayed fluid resuscitation for penetrating trauma remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Delayed fluid resuscitation/controlled hypotension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition is the first step in managing traumatic shock. Ideally, shock is recognized before hypotension develops [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/6\">",
"     6",
"    </a>",
"    ]. The clinical presentation of traumatic shock depends on the rate, volume, and duration of bleeding, the patient's baseline physiology, and the presence of other acute pathologic processes (eg, tension pneumothorax, myocardial ischemia).",
"   </p>",
"   <p>",
"    Obvious and immediately detectable manifestations of the shock state include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Cool extremities",
"     </li>",
"     <li>",
"      Weak peripheral pulses",
"     </li>",
"     <li>",
"      Prolonged capillary refill (&gt;2 seconds)",
"     </li>",
"     <li>",
"      Narrowing of the pulse pressure (&lt;25 mmHg)",
"     </li>",
"     <li>",
"      Altered mental status not due to head injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large-scale bleeding occurs at five possible locations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      External hemorrhage",
"     </li>",
"     <li>",
"      Thoracic cavity",
"     </li>",
"     <li>",
"      Peritoneal cavity",
"     </li>",
"     <li>",
"      Retroperitoneal space (often from a pelvic fracture)",
"     </li>",
"     <li>",
"      Muscle or subcutaneous tissue (usually from a long-bone fracture)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the cause of shock is not obvious, evaluation and treatment occur in tandem. A trauma ultrasound examination, or Focused Assessment with Sonography for Trauma (FAST), is performed to look for hemopericardium and intraabdominal bleeding. The three standard initial trauma x-rays include the chest, pelvis, and lateral cervical spine, although depending upon the hospital and the clinical scenario clinicians may forego plain radiographs in favor of computed tomography (CT). Of the standard plain radiographs, the portable chest x-ray is most likely to reveal an injury requiring immediate intervention. Remember that the presence of one injury in no way excludes the possibility of other, more serious injuries. In some centers, clinicians may forego plain x-rays if CT scanners are immediately available and adjacent to the trauma bay.",
"   </p>",
"   <p>",
"    Shock may exist even in the setting of \"normal\" vital signs, making diagnosis difficult. Young patients without underlying comorbidities can maintain a blood pressure within the normal range despite substantial blood loss by compensatory vasoconstriction and increases in heart rate. A bradycardic response to penetrating intraperitoneal injury, which may be vagally mediated, has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, a paradoxical or relative bradycardia has been described in hypoperfusing trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/8\">",
"     8",
"    </a>",
"    ]. A retrospective review of more than 1700 trauma patients that compared presenting heart rate with base deficits and lactate concentrations reported that the absence of tachycardia in the presence of hypoperfusion is associated with a poor prognosis independent of injury severity, systolic blood pressure, and head injury.",
"   </p>",
"   <p>",
"    Recognizing shock in its early stages is more difficult, but provides clinicians the opportunity for early reversal of end-organ hypoperfusion. Serial examinations and serial ultrasound studies can help to identify occult injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alterations in mental status caused by hypoperfusion may be subtle initially and can be difficult to distinguish from drug or alcohol intoxication or associated head injury. Altered mental status on presentation or a subsequent decline in mental status, particularly in patients without obvious evidence of head injury, should raise suspicion for cerebral hypoperfusion. In young, otherwise healthy patients, subtle alterations, such as agitation, confusion, irritability, indifference to surroundings, or inattention to instructions, may be the only sign of early shock. A patient who is aggravating you or your staff may be showing early signs of shock, not intoxication.",
"   </p>",
"   <p>",
"    Subtle examination findings may provide evidence of early shock. Pallor or poor capillary refill may represent peripheral vasoconstriction. Diaphoresis may indicate physiologic stress and appear before vital sign abnormalities. Mild tachypnea may reflect compensation for metabolic acidosis. Low-urine output may indicate inadequate visceral perfusion. Patients who are unable to maintain a urine output greater than 0.5",
"    <span class=\"nowrap\">",
"     mL/kg/hour",
"    </span>",
"    and have a high-urine specific gravity may be compensating for hypovolemia.",
"   </p>",
"   <p>",
"    Elderly patients are more likely to take medications (eg, beta blockers) that affect the hemodynamic response to injury and are more likely to have baseline hypertension. It is important to interpret vital signs with the patient's baseline in mind [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/10\">",
"     10",
"    </a>",
"    ]. The emergency clinician may need to predict this physiologic baseline based on age and other available information (eg, medication list). As an example, a systolic blood pressure of 110 mmHg may be dangerously low in a patient with underlying hypertension.",
"   </p>",
"   <p>",
"    Nonhemorrhagic causes of traumatic shock may demonstrate typical presentations, but often do not. As an example, pericardial tamponade is classically described as exhibiting Beck's triad of hypotension, distended neck veins, and muffled heart sounds, but these are late findings when present. If significant, ongoing hemorrhage exists or the pericardium periodically decompresses by emptying blood into the pleural space, tamponade can occur without distended neck veins. Ultrasound examination (and possibly re-examination) is critical. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management of nonhemorrhagic shock'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A large pneumothorax or hemothorax may be detected clinically by the appearance of respiratory distress, unilateral diminished breath sounds, or air crepitus on palpation. In the stable patient with suspected pneumothorax, confirmation by chest radiograph is prudent; in the unstable patient, immediate treatment with needle decompression or rapid chest tube placement is necessary and must not be delayed for radiography. The classic description of a tension pneumothorax includes ipsilateral absent breath sounds, deviation of the trachea away from the affected side, and hypotension from inadequate preload due to compression of the inferior vena cava. Tracheal deviation and hypotension occur late. Animal studies suggest hypoxemia may be an earlier sign of tension pneumothorax than hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurogenic shock may develop in the patient with a high-spinal cord injury. Neurologic deficits may not be apparent in the unresponsive patient, but are usually obvious otherwise. Hypotension, which may be mild in these patients, results from the loss of peripheral vascular resistance. Tachycardia is absent because of the loss of sympathetic tone. Hypotension associated with neurologic deficits and the absence of peripheral vasoconstriction (these patients often have warm extremities and good urine output) raises suspicion for neurogenic shock. Volume status must be closely monitored because excess fluid administration may be detrimental. Hypotension should not be attributed solely to neurologic injury until hemorrhagic shock has been ruled out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the patient in traumatic shock is focused on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restoring intravascular volume",
"     </li>",
"     <li>",
"      Maintaining adequate oxygen delivery",
"     </li>",
"     <li>",
"      Limiting ongoing blood loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessment and treatment are performed simultaneously in the seriously injured patient (",
"    <a class=\"graphic graphic_algorithm graphicRef76631 \" href=\"UTD.htm?23/30/24046\">",
"     algorithm 1",
"    </a>",
"    ). The emergency clinician evaluates the airway and hemodynamic status and looks for hemorrhage while performing the following immediate interventions listed in order of priority:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Establishing a patent and protected airway while protecting the cervical spine",
"     </li>",
"     <li>",
"      Maximizing oxygenation",
"     </li>",
"     <li>",
"      Gaining intravenous access and initiating fluid resuscitation",
"     </li>",
"     <li>",
"      Controlling hemorrhage",
"     </li>",
"     <li>",
"      Obtaining blood for laboratory and blood bank testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Direct pressure is the primary and preferred means for controlling external hemorrhage. While clamping bleeding vessels under direct visualization is acceptable when necessary, blind clamping should",
"    <strong>",
"     NOT",
"    </strong>",
"    be performed. Scalp lacerations can bleed profusely and are often overlooked if significant thoracic or abdominal injuries are present. Scalp lacerations can be managed with clips (eg, Raney&reg; clips) (",
"    <a class=\"graphic graphic_picture graphicRef52581 \" href=\"UTD.htm?11/10/11426\">",
"     picture 1",
"    </a>",
"    ) or by closing the wound with running (ie, noninterrupted) stitches (ie, whip-stitch) using heavy suture. A whip-stitch may also be used to control severe bleeding from extremity wounds when direct pressure is inadequate and the few available clinicians must perform other important interventions for an unstable trauma patient.",
"   </p>",
"   <p>",
"    Use of a tourniquet is acceptable to stop hemorrhage in cases of amputation when other measures have not successfully controlled bleeding. Tourniquets must be released periodically (eg, every 45 minutes) to avoid prolonged ischemia and possible tissue loss.",
"   </p>",
"   <p>",
"    Vascular access is obtained as rapidly as possible. Two large-bore (16 gauge or larger) intravenous (IV) lines placed in the antecubital region are ideal, but not always possible. Intraosseous devices can be placed rapidly and offer an effective alternative when there is difficulty placing an IV catheter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=see_link\">",
"     \"Peripheral venous access in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link\">",
"     \"Intraosseous infusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placement of a central venous catheter (size 8 French) can be performed when adequate peripheral access cannot be obtained, and allows measurement of central venous pressure. Central line placement under ultrasound (US) guidance offers high success rates with fewer complications than procedures performed without US [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Some experts advocate use of distal saphenous vein cutdowns due to ease of access and consistency of anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traumatic shock occurs most often from hemorrhage, generally from an intraabdominal injury in blunt trauma. Ultrasound (US) is an integral part of the initial evaluation of the trauma patient, and reliably identifies free intraabdominal fluid in the hands of proficient ultrasonographers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/15\">",
"     15",
"    </a>",
"    ]. During the initial resuscitation, the Focused Assessment with Sonography for Trauma (FAST) exam, is performed to assess first for pericardial effusion and then for intraperitoneal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=see_link\">",
"     \"Emergency ultrasound in adults with abdominal and thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound has largely replaced diagnostic peritoneal lavage (DPL) in the initial assessment of the trauma patient, although DPL retains an important role in specific circumstances. If ultrasound is unavailable or its findings are equivocal or inconsistent with the clinical picture, a DPL or diagnostic peritoneal tap (DPT) can provide important information. An example of such a scenario would be an unstable patient with major pelvic trauma in whom the ultrasound cannot determine whether intraabdominal free fluid is blood or urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Diagnostic peritoneal lavage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H18#H18\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unstable pelvic fractures and associated vascular injuries can cause hemorrhagic shock. Preliminary stabilization of the pelvis by applying a circumferential pelvic binder or tying a sheet firmly around the pelvis can reduce bleeding. Such interventions are most important with \"open-book\" pelvic fractures (in which the symphysis pubis is disrupted (&ge;2.5 cm), the pelvis opened, and the retroperitoneal space enlarged) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73047 \" href=\"UTD.htm?13/32/13824\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H24#H24\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intravenous fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid resuscitation in trauma, including the optimal type and volume, is the subject of considerable debate. We suggest that initial fluid resuscitation for trauma patients in hemorrhagic shock consist of 2 L of isotonic saline (ie, normal saline, abbreviated as NS) given as rapidly as possible through short, large gauge (16 or larger) peripheral IVs. Central venous catheters are used when peripheral IVs are not available.",
"   </p>",
"   <p>",
"    Many hospitals have blood products immediately available in the emergency department. In such hospitals, immediate transfusion of blood products, rather than fluid resuscitation, can be performed for patients with severe hemorrhage in obvious need of transfusion. (See",
"    <a class=\"local\" href=\"#H3986774\">",
"     'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infusions of large volumes of NS can lead to the development of a nonanion gap hyperchloremic metabolic acidosis. On the other hand, large volume resuscitation using lactated ringers (LR) can cause a metabolic alkalosis, as lactate metabolism generates bicarbonate. The typical volumes of either NS or LR used during a trauma resuscitation do not appear to have significant clinical consequences. However, harm can ensue in cases when excessive amounts (eg, 10 L) of either fluid are given to a patient at increased risk (eg, patient with acute renal injury caused by hypoperfusion during a period of hemorrhagic shock). LR and blood must be infused through separate IV tubing because of the risk of clotting, which may be problematic in the setting of trauma.",
"   </p>",
"   <p>",
"    Debate over the best approach to fluid resuscitation in traumatic shock is likely to continue. A systematic review of prehospital fluid resuscitation in trauma found insufficient evidence for the superiority of any particular fluid type [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/16\">",
"     16",
"    </a>",
"    ]. Some researchers claim LR is superior to NS in the resuscitation of uncontrolled hemorrhagic shock, stating that patients who receive large volumes of NS experience increased blood loss and greater hypercoagulability; other researchers argue just the opposite [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. We prefer NS for the initial resuscitation fluid, but feel it is reasonable to change to LR (L-isomer if available) after the initial resuscitation (ie, once 50",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of NS has been infused) in patients requiring additional IV fluid.",
"   </p>",
"   <p>",
"    Clear end-points for fluid therapy remain undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/19\">",
"     19",
"    </a>",
"    ]. Further resuscitation is based on the patient's response to initial IV fluids and overall condition. A mean arterial pressure (MAP) around 65 mmHg or a systolic blood pressure (SBP) around 90 mmHg is a reasonable goal in penetrating trauma. The reasons for this are described separately. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Delayed fluid resuscitation/controlled hypotension'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In blunt trauma patients, particularly those with possible traumatic brain injury (TBI), a mean arterial pressure above 105 mmHg or a systolic blood pressure above 120 mmHg is reasonable. These goals may need to be adjusted upward in patients with a known history of uncontrolled hypertension.",
"   </p>",
"   <p>",
"    The ideal MAP or SBP for the multiple trauma patient remains unclear. Some authors advocate strictly limiting the amount of IV fluid used for trauma resuscitation in the absence of hypotension or obvious injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/20\">",
"     20",
"    </a>",
"    ]. Packed red blood cells are given if the goal blood pressure is not maintained following initial IV fluid resuscitation. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Transfusion of red blood cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypertonic saline has been evaluated extensively, and may provide benefit through osmotic movement of interstitial fluid into the vascular compartment and modulation of the inflammatory response to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/21\">",
"     21",
"    </a>",
"    ]. While some clinical trials have shown improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/22\">",
"     22",
"    </a>",
"    ], others have failed to do so, even in patients who would seem most likely to benefit (eg, patients with hypotension and severe TBI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Further study is needed to clarify the role of hypertonic saline.",
"   </p>",
"   <p>",
"    The value of colloids (albumin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    ) for resuscitation of traumatic shock is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Colloids effectively increase intravascular volume and may maintain plasma oncotic pressure at more normal levels compared with crystalloids. However, a systematic review of trials comparing resuscitation fluids found that use of colloids did not improve mortality or morbidity among trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Research continues into oxygen-carrying resuscitation fluids that can serve as alternatives to PRBCs. The ideal replacement fluid would transport oxygen effectively, expand intravascular volume, exhibit few or no side effects, and demonstrate great durability. Potential replacement fluids are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Delayed fluid resuscitation/controlled hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions remain whether reversal of hypovolemia or control of hemorrhage should take priority in trauma resuscitation. Some researchers describe aggressive fluid administration as ineffective and potentially harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/27-30\">",
"     27-30",
"    </a>",
"    ], and suggest that limited volume replacement that maintains minimally adequate organ perfusion may improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/31\">",
"     31",
"    </a>",
"    ]. This strategy is often referred to as delayed fluid resuscitation or controlled hypotension, an approach which targets early fluid resuscitation only to a systolic blood pressure of 70 mmHg.",
"   </p>",
"   <p>",
"    Controlled hypotension may be beneficial in patients with hemorrhagic shock due to torso injuries from gunshot or stab wounds. However, it may be detrimental to blunt trauma patients with brain injury, as hypotension reduces cerebral perfusion and increases mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/32\">",
"     32",
"    </a>",
"    ]. The rationale for improved outcomes with delayed fluid resuscitation is that aggressive fluid administration might, via augmentation of blood pressure, dilution of clotting factors, and production of hypothermia, disrupt thrombus formation and enhance bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one widely cited prospective study of 598 patients with penetrating chest injuries treated at a major trauma center, delayed fluid resuscitation until operative intervention to control bleeding was associated with a statistically significant improvement in patient survival (70 percent versus 62 percent in those given immediate fluid repletion) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/35\">",
"     35",
"    </a>",
"    ]. Care must be taken when extrapolating the results of this trial. Stratification was not performed to identify which patients might benefit from delayed therapy, subjects were primarily young and healthy, and the mean time from injury to operation was two hours, results that are not attainable in most circumstances.",
"   </p>",
"   <p>",
"    In a preliminary analysis of a trial conducted at another major trauma center, 90 young adults with penetrating (n = 84) or blunt (n = 6) trauma resulting in at least one systolic blood pressure reading below 90 mmHg, and hemorrhage requiring immediate laparotomy or thoracotomy, were randomly assigned upon arrival to the operating theater to resuscitation using a low-goal mean arterial pressure of 50 mmHg (LMAP group) or a high-goal mean arterial pressure of 65 mmHg (HMAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/36\">",
"     36",
"    </a>",
"    ]. Among the patients excluded were those with traumatic brain injury. Anesthesiologists did not intervene to lower the blood pressure of patients in the LMAP group whose MAP exceeded 50 mmHg. Patients in the LMAP group had lower postoperative mortality (6 versus 10 deaths), received fewer blood products (1594 mL versus 2898 mL), and did not develop coagulopathy or multiple organ failure (MOF), compared to seven cases of coagulopathy and two cases of MOF in the HMAP group. However, there was no significant difference between the groups in overall mortality at 30 days.",
"   </p>",
"   <p>",
"    Other results favoring delayed fluid resuscitation or controlled hypotension have been reported in small clinical trials and a variety of animal models of hemorrhagic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/33,37-44\">",
"     33,37-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of these studies notwithstanding, adoption of the strategy of delayed fluid resuscitation or controlled hypotension into clinical practice must be undertaken cautiously [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/45\">",
"     45",
"    </a>",
"    ]. Factors that should be considered when determining whether this strategy is appropriate include the patient&rsquo;s mental status and likelihood of intracranial injury, type of injury (penetrating versus blunt), severity of injury (eg, ongoing hemorrhage), and proximity to a trauma center. Delayed fluid administration and controlled hypotension should probably not be implemented unless emergent surgical exploration with rapid control of the bleeding source can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/39\">",
"     39",
"    </a>",
"    ]. Further research is needed in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3250855\">",
"    <span class=\"h2\">",
"     Transfusion of blood products",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3986774\">",
"    <span class=\"h3\">",
"     Transfusion for severe ongoing hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For trauma patients with severe, ongoing hemorrhage that is unlikely to be controlled quickly or adequately, we suggest immediate transfusion of blood products in a 1:1:1 ratio of packed red blood cells (PRBC), fresh frozen plasma (FFP), and random donor platelets. In other words, as soon as the treating clinician recognizes that the patient will require 4 or more units of PRBCs over one hour (or 10 or more units over 12 to 24 hours),",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    should begin transfusing 6 units of PRBCs, 6 units of FFP, and 6 units of random donor platelets (or 1 unit of apheresis platelets). Note that 1 unit of apheresis platelets is equivalent to 6 units of nonapheresis (ie, random donor or whole-blood derived) platelets. Hypothermia must be controlled during transfusions.",
"   </p>",
"   <p>",
"    A massive transfusion protocol should be in place for any hospital that manages trauma. This protocol should be activated in anticipation of the need for large-scale transfusion as soon as the clinician treating the patient recognizes the presence or likelihood of severe, ongoing hemorrhage.",
"   </p>",
"   <p>",
"    Prospective randomized trials to support the approach described here are lacking, and some researchers have questioned the benefit of high (ie, 1:1:1) transfusion ratios in trauma, raising the possibility that survival bias and other factors may account for the improved outcomes published to date in largely retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/47\">",
"     47",
"    </a>",
"    ]. Nevertheless, a number of large observational studies (discussed in the following sections) report an association between a more aggressive approach to transfusion using high ratios of clotting factors and platelets to red blood cells and reduced mortality and morbidity in severely injured patients. In addition, a study using a Cox proportional hazards model of 604 blunt trauma patients requiring massive transfusion found an association between increased survival and high transfusion ratios at all time intervals studied (6, 12, and 24 hours), suggesting that the benefit from high transfusion ratios is unlikely to be due to survival bias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excessive infusion of crystalloid (ie, ratio of crystalloid to PRBCs &gt;1.5:1) has been associated with worse outcomes in patients with severe hemorrhage, according to observational data, and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Intravenous fluid resuscitation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Transfusion of red blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;When to begin blood transfusion remains an important, unanswered question in trauma research, and often depends on clinical circumstances. As an example, immediate transfusion of packed red blood cells (PRBC) is needed when exsanguination is imminent, such as a patient with a thoracic injury whose chest tube releases over 2 L of blood upon placement. Another patient with a self-inflicted wrist laceration may not require any blood, despite being hypotensive, because hemorrhage is promptly controlled, the wound is easily repaired, and comorbidities are absent.",
"   </p>",
"   <p>",
"    In most trauma patients with hemorrhagic shock, we suggest 2 units of packed red blood cells (PRBC) be transfused if hemodynamics fail to improve after the administration of 2 to 3 L (or greater than 50",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    of crystalloid. Further transfusions are given based upon the patient's injuries and response to the initial transfusion. Transfusion in patients with massive hemorrhage is discussed above. (See",
"    <a class=\"local\" href=\"#H3986774\">",
"     'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Typed and cross-matched PRBCs are best, but can require considerable time to prepare. If the patient's condition warrants, clinicians can transfuse immediately using type O Rh-positive or type O RH-negative for males and type O Rh-negative for girls and women of child-bearing age, until type-specific or typed and cross-matched blood is available.",
"   </p>",
"   <p>",
"    In most instances, preparation of fully typed and cross-matched blood requires at least 20 minutes, and more likely 30 to 45 minutes. Type-specific blood can usually be obtained within 15 to 20 minutes. In general, type O blood is available immediately, depending on transport time from the blood bank to the emergency department (ED). Trauma centers often store type O blood in refrigerators in the ED.",
"   </p>",
"   <p>",
"    The safety of the blood supply continues to improve, and although some risk of transmitting infectious agents persists, such events are rare. Transfusion-associated infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Research continues into oxygen-carrying resuscitation fluids that can serve as alternatives to PRBCs. The ideal replacement fluid would transport oxygen effectively, expand intravascular volume, exhibit few or no side effects, and demonstrate great durability. Potential replacement fluids are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Transfusion of clotting factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hemorrhage with IV crystalloid and packed red blood cells (PRBCs) increases the risk of coagulopathy from dilution of clotting factors and platelets, and possibly hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/49\">",
"     49",
"    </a>",
"    ]. Prevention of coagulopathy with early transfusion of plasma and platelets is critical in the patient with severe hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link\">",
"     \"Coagulopathy associated with trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There remain no clear answers to the questions when and how much to transfuse clotting factors in trauma patients requiring massive transfusion. If bleeding is severe, clinicians cannot wait for laboratory values to guide transfusion, and such measurements may be inaccurate in the setting of massive hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/50\">",
"     50",
"    </a>",
"    ]. Our approach to the transfusion of clotting factors for patients with severe, ongoing bleeding is described above. Hypothermia must be controlled during transfusions. (See",
"    <a class=\"local\" href=\"#H3986774\">",
"     'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with bleeding that is not massive but is ongoing and significant (eg, more than 4 units of PRBCs transfused in the first few hours or chest tube continues to drain &gt;200 mL of blood per hour), we suggest using the same transfusion ratios used for patients with severe hemorrhage: a 1:1:1 ratio of packed red blood cells (PRBC), fresh frozen plasma (FFP), and random donor platelets. If apheresis platelets are used, this becomes a 6:6:1 ratio of PRBCs, FFP, and apheresis platelets respectively.",
"   </p>",
"   <p>",
"    Although no prospective, randomized outcome trials exist to determine the best approach to transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/51\">",
"     51",
"    </a>",
"    ], several retrospective studies have reported higher survival rates among patients with severe bleeding who are treated with higher plasma to PRBC transfusion ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/52-62\">",
"     52-62",
"    </a>",
"    ]. As an example, a retrospective study using data from a US combat support hospital during the second Iraq war assessed the mortality of 246 severely wounded soldiers that required massive blood transfusion and found that patients given a higher ratio of plasma to PRBCs had significantly lower mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients were divided into three groups based on the plasma to RBC ratio: high ratio (1 to 1.14), medium ratio (1 to 2.5), and low ratio (1 to 8). Injury severity scores were identical in all groups, although the low-ratio group had more thoracic wounds and a lower average initial hemoglobin and blood pressure. Group survival was 65 percent, 34 percent, and 19 percent respectively. Logistic regression analysis found that the plasma to RBC ratio was independently associated with survival (OR 8.6; 95% CI 2.1-35.2). Improved survival with more aggressive plasma transfusion is consistent with the results of other studies in both military and civilian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/54-62\">",
"     54-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fewer studies of have assessed the effect of higher plasma to PRBC transfusion ratios in patients with significant, but not massive bleeding. Authors of one retrospective study reported lower mortality and decreased use of blood products among patients treated with higher ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The determination of the optimal plasma to PRBC transfusion ratio awaits prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Nevertheless, in the civilian setting, individual trauma centers have developed effective transfusion protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/66\">",
"     66",
"    </a>",
"    ]. Some advocate 2 units of FFP for every 6 units of PRBCs transfused. Other centers advocate more aggressive approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/67\">",
"     67",
"    </a>",
"    ]. At one of the largest United States trauma centers, 6 units of FFP are given once 6 units of PRBCs are transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/20\">",
"     20",
"    </a>",
"    ]. Another major urban trauma center transfuses 1 unit of FFP for each unit of PRBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors advocate using fibrinogen levels to determine when to transfuse cryoprecipitate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/68\">",
"     68",
"    </a>",
"    ]. A fibrinogen concentration below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is generally treated with 10 units of cryoprecipitate (each unit of cryoprecipitate comes from 1 unit of whole blood, and raises the fibrinogen level by about 5",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    Provided massive, ongoing hemorrhage is not present, using laboratory measurements to guide transfusion is a reasonable approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3250847\">",
"    <span class=\"h3\">",
"     Transfusion of platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hemorrhage with IV crystalloid and PRBCs increases the risk of coagulopathy from dilution of platelets and clotting factors, and possibly hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/49\">",
"     49",
"    </a>",
"    ]. Prevention of coagulopathy with early transfusion of plasma and platelets is critical in the patient with severe hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link\">",
"     \"Coagulopathy associated with trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There remain no clear answers to the questions when and how much to transfuse platelets in trauma patients requiring massive transfusion. If bleeding is severe, clinicians cannot wait for laboratory values to guide transfusion, and such measurements may be inaccurate in the setting of massive hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/50\">",
"     50",
"    </a>",
"    ]. Our approach to the transfusion of platelets for patients with severe, ongoing bleeding is described above. (See",
"    <a class=\"local\" href=\"#H3986774\">",
"     'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Note that 1 unit of apheresis platelets is equivalent to 6 units of nonapheresis (ie, random donor or whole-blood derived) platelets. Hypothermia must be controlled during transfusions. &nbsp;",
"   </p>",
"   <p>",
"    For patients with bleeding that is not massive but is ongoing and significant (eg, more than 4 units of PRBCs transfused in the first few hours or chest tube continues to drain &gt; 200 mL of blood per hour), we suggest using the same transfusion ratios used for patients with severe hemorrhage: a 1:1:1 ratio of packed red blood cells (PRBC), fresh frozen plasma (FFP), and random donor platelets. If apheresis platelets are used, this becomes a 6:6:1 ratio of PRBCs, FFP, and apheresis platelets respectively.",
"   </p>",
"   <p>",
"    Although no prospective, randomized outcome trials exist to determine the best approach to transfusion, a retrospective study, using data from a large trauma database of 657 patients requiring massive blood transfusion, reported a stepwise improvement in survival with higher platelet to PRBC transfusion ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/69\">",
"     69",
"    </a>",
"    ]. After controlling for such factors as injury severity, initial blood pressure, and transfusion of other blood products, the researchers found that patients receiving the highest apheresis platelet to PRBC ratio (&ge;1:6) had a 14.5 percent mortality rate while those with the lowest ratio (&lt;1:18) had a 48.2 percent mortality rate. Other retrospective studies have reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/53,58,62\">",
"     53,58,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors advocate using platelet counts to determine when to transfuse platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/68\">",
"     68",
"    </a>",
"    ]. A platelet count of less than",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    is treated with 6 units of random donor platelets or 1 unit of apheresis platelets. Provided massive, ongoing hemorrhage is not present, using laboratory measurements to guide transfusion is a reasonable approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;No human studies exist to support the use of vasopressors in the resuscitation of the adult with multiple trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/70\">",
"     70",
"    </a>",
"    ]. Their use early in the management of hemorrhagic shock may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematology and chemistry laboratory tests are of limited use in the acute management of the trauma patient. Clinicians should consider them adjuncts to diagnosis and not substitutes for clinical assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following laboratory studies are obtained in all patients with traumatic shock:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type and cross-match several units of packed red blood cells",
"     </li>",
"     <li>",
"      Baseline hemoglobin or hematocrit",
"     </li>",
"     <li>",
"      Serum bicarbonate (base deficit) and serum lactate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The emergency clinician should order a blood type and cross-match for any victim of significant trauma in anticipation of the need for transfusion. The blood bank should be notified directly (ie, by telephone or in person) of the need for packed red blood cells, and other blood products, should a trauma victim present with life-threatening hemorrhage.",
"   </p>",
"   <p>",
"    The hematocrit can be useful as a baseline value, but must be interpreted in light of the clinical context, including the extent of hemorrhage, time since the injury, premorbid hematocrit, and the amount of exogenous fluid administration. As an example, the clinician should not be reassured by a normal hematocrit in the acute trauma victim with hypotension. The hematocrit is most helpful when measured serially to assess ongoing hemorrhage.",
"   </p>",
"   <p>",
"    Hemorrhagic shock may create a metabolic acidosis with a base deficit (ie, decreased serum bicarbonate) or increased serum lactate. While such findings suggest shock, clinicians must interpret them in the context of the patient's clinical appearance. Typically, laboratory values lag behind clinical improvement after aggressive resuscitation.",
"   </p>",
"   <p>",
"    Coagulation studies, a platelet count, and serum electrolytes are helpful to determine the need for blood products and electrolyte replacement, if hemorrhage is ongoing. Additional testing may be needed depending on clinical circumstance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management of nonhemorrhagic shock",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6093434\">",
"    <span class=\"h3\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax occurs often in both blunt and penetrating trauma, and may be delayed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53428 \" href=\"UTD.htm?3/4/3139\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56589 \" href=\"UTD.htm?40/52/41797\">",
"     image 3",
"    </a>",
"    ). Traumatic pneumothorax or hemothorax is managed by the placement of a large thoracostomy tube (36 French or larger) in the lateral chest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    If the clinician suspects a tension pneumothorax and the patient is hypotensive, a needle thoracostomy can be performed, as a temporizing measure, using a long, large (eg, 12 or 14 gauge) angiocatheter or needle inserted above the rib at the second intercostal space in the mid-clavicular line or the fifth intercostal space in the mid-axillary line. The ideal length is unclear, but a 4.5 cm (2 inch) needle is a reasonable first choice. Studies of chest wall thickness using CT scan suggest this length may be inadequate in some patients, but longer needles increase the risk of injuring the subclavian vessels or other structures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Should a 4.5 cm needle fail to decompress a tension pneumothorax and a tube thoracostomy be delayed, clinicians should use a longer needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6093451\">",
"    <span class=\"h3\">",
"     Pericardial tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial tamponade can occur with penetrating or major blunt chest trauma. Immediate ultrasonography (US) or echocardiography offers the best opportunity for rapid, early, and accurate diagnosis. Pericardiocentesis is performed if pericardial tamponade is suspected and the patient is hypotensive and worsening despite volume resuscitation. If pericardiocentesis recovers blood and improves the patient's clinical status, emergent thoracotomy is indicated. If thoracotomy cannot be performed, pericardiocentesis can be repeated as necessary or a J-shaped catheter can be inserted into the pericardial space to allow continual drainage of the hemopericardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Pericardiocentesis is \"classically\" performed using the subxiphoid approach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/74\">",
"     74",
"    </a>",
"    ]. However, some researchers and a large observational study support the use of the paraapical or parasternal approach under ultrasound guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/75\">",
"     75",
"    </a>",
"    ]. Use of the parasternal approach allows the needle entry site to be closer to the pericardium and eliminates the risk of liver injury. No controlled trials have compared these approaches in trauma patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6093466\">",
"    <span class=\"h3\">",
"     Emergency thoracotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In trauma patients who are profoundly hypotensive despite aggressive fluid resuscitation, or have lost discernible blood pressure for only a few minutes, an emergency left lateral thoracotomy to enable decompression of pericardial tamponade, vascular or pulmonary clamping, and direct suture repair, may be life-saving. The indications, contraindications, and performance of emergency thoracotomy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H4933905#H4933905\">",
"     \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Emergency department thoracotomy (EDT)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31801?source=see_link&amp;anchor=H1247118578#H1247118578\">",
"     \"Resuscitative thoracotomy: technique\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6093484\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotensive pregnant trauma patients are placed in the left lateral decubitus position or the right side of their backboard is tilted up about 15 degrees in order to move the gravid uterus off of the inferior vena cava. These maneuvers improve venous return and may increase the blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22569?source=see_link\">",
"     \"Trauma in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monitoring and endpoints for prolonged resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clear end-points for initial fluid therapy remain undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/19\">",
"     19",
"    </a>",
"    ]. A mean arterial pressure (MAP) around 65 mmHg or a systolic blood pressure around 90 mmHg is a reasonable goal in penetrating trauma. In blunt trauma patients, particularly those with possible traumatic brain injury (TBI), a mean arterial pressure above 105 mmHg or a systolic blood pressure above 120 mmHg is reasonable. Some authors advocate strictly limiting the amount of IV fluid used for trauma resuscitation in the absence of hypotension or obvious injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/20\">",
"     20",
"    </a>",
"    ]. Packed red blood cells are transfused, along with appropriate replacement of coagulation products, if the goal blood pressure is not maintained following the initial IV fluid resuscitation. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Transfusion of red blood cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some trauma patients, particularly in community hospitals, must be managed in the emergency department for prolonged periods when surgical resources or transport is unavailable. It remains unclear which endpoints are most useful for guiding such prolonged resuscitations. Those emergency clinicians without access to sophisticated noninvasive technologies rely on standard physiologic and laboratory measurements to determine whether resuscitation is adequate. An approach modeled on goal-directed therapy for septic shock, with the important caveat that greater emphasis be placed on blood transfusion and coagulation factor replacement, may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Transfusion of red blood cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following parameters may be used to guide prolonged resuscitation of traumatic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure: maintain MAP above 65 mmHg for penetrating trauma, and above 105 mmHg for blunt trauma",
"     </li>",
"     <li>",
"      Heart rate: maintain between 60 and 100 beats per minute",
"     </li>",
"     <li>",
"      Oxygen saturation: maintain above 94 percent",
"     </li>",
"     <li>",
"      Urine output: maintain above 0.5",
"      <span class=\"nowrap\">",
"       mL/kg/hour",
"      </span>",
"     </li>",
"     <li>",
"      Central venous pressure: maintain between 8 and 12 mmHg",
"     </li>",
"     <li>",
"      Lactate and base deficit: monitor serum lactate and serum bicarbonate every four hours to ensure end-organ perfusion is adequate or improving with resuscitation",
"     </li>",
"     <li>",
"      Mixed central venous oxygen saturation: monitor every four hours to ensure end-organ perfusion is adequate or improving with resuscitation; goal is to maintain above 70 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion of blood products in patients without massive bleeding undergoing prolonged resuscitation of trauma-related shock may be performed using the following guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin: transfuse 2 units PRBCs if hemoglobin falls below 8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for patients without risk for acute coronary syndrome (ACS), or below 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for patients at risk for ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Platelets: transfuse 1 unit of apheresis platelets, or 6 units of random donor platelets, if the serum concentration falls below",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      International normalized ratio (INR): transfuse 2 units of FFP if INR rises above 2",
"     </li>",
"     <li>",
"      Fibrinogen: transfuse 10 units of cryoprecipitate if the fibrinogen concentration falls below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If bleeding is massive and ongoing, laboratory measurements can be inaccurate. Empiric guidelines for transfusion of blood products in this setting are provided above. (See",
"    <a class=\"local\" href=\"#H3986774\">",
"     'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some researchers advocate using the lactate concentration to assess the adequacy of resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Lactate levels may lag behind clinical improvement following aggressive resuscitation if rapid analyzers are unavailable. Other authors suggest that the magnitude of metabolic acidosis has prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/82\">",
"     82",
"    </a>",
"    ] and that the admission base deficit (ie, serum bicarbonate) may be superior to plasma lactate in predicting injury severity and death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/83\">",
"     83",
"    </a>",
"    ]. Both endpoints may provide useful feedback about tissue oxygen debt and the adequacy of resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have compared noninvasive and invasive (eg, pulmonary artery catheter) monitoring started in the emergency department for resuscitation of critical trauma patients. Enhanced noninvasive monitoring appears to be feasible, safe, inexpensive, and equivalent to invasive monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/76,86\">",
"     76,86",
"    </a>",
"    ]. Noninvasive monitoring in these studies included such technologies as thoracic electrical bioimpedance, esophageal Doppler monitoring, and orthogonal spectral imaging, in addition to standard measures, such as MAP, heart rate, pulse oximetry, and carbon dioxide tension. Many emergency clinicians do not have access to these technologies, and their role in ED management of trauma awaits further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive management of the patient with traumatic shock often requires emergency surgery. Emergency clinicians should consult a trauma surgeon as soon as possible for all victims of significant trauma who may require operative or critical care interventions. If the patient must be transferred for definitive care, early communication with a trauma center and preparation for transfer is performed concurrently with assessment and stabilization. The lack of adequate resources to manage a patient's injuries, including specialty and subspecialty care, is an indication for transfer to a trauma center. In cases involving a hypotensive patient with an identified injury (eg, high-grade splenic laceration), but no trauma surgeon is available, emergent consultation with a general surgeon may be necessary for possible laparotomy prior to a time-consuming transfer that would put the patient at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DEVELOPING TREATMENTS FOR HEMORRHAGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hemostatic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some circumstances, external hemorrhage cannot be controlled using direct pressure and standard dressings. A number of hemostatic products are being developed to control such bleeding, including chitosan dressing, QuickClot&reg; powder, and fibrin sealant dressing. Although some of these products have been used by military personnel in combat, few controlled studies with civilians have been performed and it remains unclear how these products should be used by civilian emergency clinicians. These agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20853214\">",
"    <span class=\"h2\">",
"     Antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antifibrinolytic agents have been shown to be safe and effective at reducing bleeding during elective surgery; these agents may also be of benefit in controlling bleeding following trauma. Antifibrinolytic agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H12#H12\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In CRASH-2, a trial spanning 274 hospitals in 40 countries, over 20,000 trauma patients with or at risk of significant hemorrhage were randomly assigned within eight hours of injury to treatment with the antifibrinolytic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (n = 10,096) or placebo (n = 10,115) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/87\">",
"     87",
"    </a>",
"    ]. Overall mortality was lower in the tranexamic acid group (14.5 versus 16 percent; RR 0.91, 95% CI 0.85-0.97), as was death from hemorrhage (4.9 versus 5.7 percent; RR 0.85, 95% CI 0.76-0.96). No differences in complications from vascular occlusion (eg, pulmonary embolism, myocardial infarction) were noted between the two groups.",
"   </p>",
"   <p>",
"    A follow-up analysis of the CRASH-2 trial confirmed the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    in reducing mortality from bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/88\">",
"     88",
"    </a>",
"    ]. The relative risk of bleeding to death was 0.68 (95% CI 0.57-0.82), a 32 percent reduction in mortality, when the drug was given within one hour of injury and 0.79 (95% CI 0.64-0.97) when given between one and three hours. However, tranexamic acid appeared to increase the risk of fatal hemorrhage when it was administered after three hours.",
"   </p>",
"   <p>",
"    In the United States, experience using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    in trauma patients is growing but remains limited. Based upon the results of the CRASH-2 trial and a subsequent systematic review, we believe tranexamic acid is a reasonable early intervention (within three hours of injury) in patients with signs of significant hemorrhage following trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/55/29562/abstract/89\">",
"     89",
"    </a>",
"    ]. The best place to administer tranexamic acid may be the prehospital environment because early administration is important and storage and administration are simple. However, no published studies have examined prehospital use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recombinant factor VIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Off-label use of recombinant factor VIIa (Factor VIIa) is widespread, including use by the military for injured soldiers with severe hemorrhage. The use of Factor VIIa in this and other clinical scenarios is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H21#H21\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Managing post-traumatic hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Red blood cell substitutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell substitutes (eg, hemoglobin-based oxygen carriers, perfluorocarbons) continue to be studied in both animal and human trials. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link&amp;anchor=H8#H8\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/24/24961?source=see_link\">",
"       \"Patient information: Shock (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhagic shock comprises the majority of cases of traumatic shock and is commonly divided into four classes based on clinical presentation (described in detail above). Significant drops in blood pressure are generally not manifested until class III hemorrhage develops, and up to 30 percent of a patient's blood volume can be lost before this occurs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Massive hemorrhage can occur in the chest, abdomen, retroperitoneum, and from major external wounds. The thigh can hold up to approximately 1 L of blood. Scalp lacerations can bleed profusely and are often overlooked. Other potential causes of traumatic shock may include cardiac tamponade and tension pneumothorax. A detailed list of potential causes of traumatic shock is provided (",
"      <a class=\"graphic graphic_table graphicRef63698 \" href=\"UTD.htm?4/24/4492\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obvious and immediately detectable manifestations of the shock state include: tachycardia, hypotension, cool extremities, weak peripheral pulses, prolonged capillary refill (&gt;2 seconds), narrowing of the pulse pressure (&lt;25 mmHg), and altered mental status. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recognition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shock may exist even in the setting of \"normal\" vital signs. Young otherwise healthy patients can maintain a blood pressure within the normal range despite substantial blood loss; subtle alterations, such as agitation, confusion, irritability, or inattention, may be their only signs of early shock. Altered mental status from inadequate cerebral perfusion can be difficult to distinguish from drug or alcohol intoxication or associated head injury. Altered mental status on presentation or a subsequent decline in mental status, particularly in patients without obvious evidence of head injury, should raise suspicion for cerebral hypoperfusion. Other subtle presentations of traumatic shock are described above. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recognition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management of the patient in traumatic shock is focused on restoring intravascular volume, maintaining adequate oxygen delivery, and limiting ongoing blood loss. The essential tasks include establishing a patent and protected airway (while protecting the cervical spine), maximizing oxygenation, gaining intravenous access and initiating fluid resuscitation, controlling hemorrhage, and obtaining blood for laboratory and blood bank testing (ie, blood typing and cross-matching). Ultrasound (US) reliably identifies free intraabdominal fluid in the hands of proficient ultrasonographers. Management is discussed in detail above and an algorithm is provided (",
"      <a class=\"graphic graphic_algorithm graphicRef76631 \" href=\"UTD.htm?23/30/24046\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best approach to fluid resuscitation remains controversial. We suggest that initial fluid resuscitation for trauma patients in hemorrhagic shock consist of two liters of normal saline (NS) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The infusion is given as rapidly as possible through short, large gauge (16 or larger) peripheral IVs. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intravenous fluid resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best approach to blood transfusion in trauma is unknown. For patients with signs of ongoing bleeding, but",
"      <strong>",
"       without",
"      </strong>",
"      massive hemorrhage, we suggest 2 units of packed red blood cells (PRBC) be transfused if hemodynamics fail to improve after the administration of 2 to 3 L (or greater than 50",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      of crystalloid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Further transfusions are given based upon the patient's injuries and response to the initial transfusion. Treatment of hemorrhage with IV crystalloid and PRBCs increases the risk of coagulopathy from dilution of platelets and clotting factors, and possibly hypothermia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Transfusion of red blood cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Transfusion of clotting factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3250847\">",
"       'Transfusion of platelets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For trauma patients with severe, ongoing hemorrhage that is unlikely to be controlled quickly or adequately, we suggest immediate transfusion of blood products in a 1:1:1 ratio of packed red blood cells (PRBC), fresh frozen plasma (FFP), and random donor platelets (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3986774\">",
"       'Transfusion for severe ongoing hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During resuscitation, do not allow an initial favorable response to volume replacement to distract from possible severe, occult injury. Effective early resuscitation may mask ongoing significant hemorrhage. Remember that the presence of one injury in no way excludes the possibility of other, more serious injuries.",
"     </li>",
"     <li>",
"      The key to management of nonhemorrhagic causes of shock, primarily tension pneumothorax and pericardial tamponade, is early recognition based on clinical, x-ray, and US findings. Emergent thoracotomy may be indicated for pericardial tamponade, particularly in the setting of penetrating thoracic trauma. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management of nonhemorrhagic shock'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2424645\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/1\">",
"      Britt LD, Weireter LJ Jr, Riblet JL, et al. Priorities in the management of profound shock. Surg Clin North Am 1996; 76:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/2\">",
"      Siegel JH. The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. J Neurotrauma 1995; 12:579.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons. Advanced Trauma Life Support&reg; (Student Manual). American College of Surgeons 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/4\">",
"      Vukmir RB, Bircher N, Safar P. Sodium bicarbonate in cardiac arrest: a reappraisal. Am J Emerg Med 1996; 14:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/5\">",
"      Hindman BJ. Sodium bicarbonate in the treatment of subtypes of acute lactic acidosis: physiologic considerations. Anesthesiology 1990; 72:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/6\">",
"      Parks JK, Elliott AC, Gentilello LM, Shafi S. Systemic hypotension is a late marker of shock after trauma: a validation study of Advanced Trauma Life Support principles in a large national sample. Am J Surg 2006; 192:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/7\">",
"      Vayer JS, Henderson JV, Bellamy RF, Galper AR. Absence of a tachycardic response to shock in penetrating intraperitoneal injury. Ann Emerg Med 1988; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/8\">",
"      Mizushima Y, Ueno M, Watanabe H, et al. Discrepancy between heart rate and makers of hypoperfusion is a predictor of mortality in trauma patients. J Trauma 2011; 71:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/9\">",
"      Biffl WL, Harrington DT, Cioffi WG. Implementation of a tertiary trauma survey decreases missed injuries. J Trauma 2003; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/10\">",
"      Oyetunji TA, Chang DC, Crompton JG, et al. Redefining hypotension in the elderly: normotension is not reassuring. Arch Surg 2011; 146:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/11\">",
"      Barton ED, Rhee P, Hutton KC, Rosen P. The pathophysiology of tension pneumothorax in ventilated swine. J Emerg Med 1997; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/12\">",
"      Dunning J, Williamson J. Ultrasonic guidance and the complications of central line placement in the emergency department. Emerg Med J 2003; 20:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/13\">",
"      Milling TJ Jr, Rose J, Briggs WM, et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: the Third Sonography Outcomes Assessment Program (SOAP-3) Trial. Crit Care Med 2005; 33:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/14\">",
"      Posner MC, Moore EE. Distal greater saphenous vein cutdown--technique of choice for rapid volume resuscitation. J Emerg Med 1985; 3:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/15\">",
"      Ma OJ, Mateer JR, Ogata M, et al. Prospective analysis of a rapid trauma ultrasound examination performed by emergency physicians. J Trauma 1995; 38:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/16\">",
"      Cotton BA, Jerome R, Collier BR, et al. Guidelines for prehospital fluid resuscitation in the injured patient. J Trauma 2009; 67:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/17\">",
"      Kiraly LN, Differding JA, Enomoto TM, et al. Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in an uncontrolled hemorrhagic shock swine model. J Trauma 2006; 61:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/18\">",
"      Todd SR, Malinoski D, Muller PJ, Schreiber MA. Lactated Ringer's is superior to normal saline in the resuscitation of uncontrolled hemorrhagic shock. J Trauma 2007; 62:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/19\">",
"      Tisherman SA. Trauma fluid resuscitation in 2010. J Trauma 2003; 54:S231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/20\">",
"      Alam HB, Rhee P. New developments in fluid resuscitation. Surg Clin North Am 2007; 87:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/21\">",
"      Rizoli SB, Rhind SG, Shek PN, et al. The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial. Ann Surg 2006; 243:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/22\">",
"      Wade CE, Grady JJ, Kramer GC. Efficacy of hypertonic saline dextran fluid resuscitation for patients with hypotension from penetrating trauma. J Trauma 2003; 54:S144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/23\">",
"      Cooper DJ, Myles PS, McDermott FT, et al. Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA 2004; 291:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/24\">",
"      Bulger EM, Jurkovich GJ, Nathens AB, et al. Hypertonic resuscitation of hypovolemic shock after blunt trauma: a randomized controlled trial. Arch Surg 2008; 143:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/25\">",
"      Liberati A, Moja L, Moschetti I, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Intern Emerg Med 2006; 1:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/26\">",
"      Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2012; 6:CD000567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/27\">",
"      Veech RL. Immediate versus delayed fluid resuscitation in patients with trauma. N Engl J Med 1995; 332:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/28\">",
"      Roberts I, Evans P, Bunn F, et al. Is the normalisation of blood pressure in bleeding trauma patients harmful? Lancet 2001; 357:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/29\">",
"      Ley EJ, Clond MA, Srour MK, et al. Emergency department crystalloid resuscitation of 1.5 L or more is associated with increased mortality in elderly and nonelderly trauma patients. J Trauma 2011; 70:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/30\">",
"      Neal MD, Hoffman MK, Cuschieri J, et al. Crystalloid to packed red blood cell transfusion ratio in the massively transfused patient: when a little goes a long way. J Trauma Acute Care Surg 2012; 72:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/31\">",
"      Stern SA, Dronen SC, Birrer P, Wang X. Effect of blood pressure on hemorrhage volume and survival in a near-fatal hemorrhage model incorporating a vascular injury. Ann Emerg Med 1993; 22:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/32\">",
"      Winchell RJ, Simons RK, Hoyt DB. Transient systolic hypotension. A serious problem in the management of head injury. Arch Surg 1996; 131:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/33\">",
"      Solomonov E, Hirsh M, Yahiya A, Krausz MM. The effect of vigorous fluid resuscitation in uncontrolled hemorrhagic shock after massive splenic injury. Crit Care Med 2000; 28:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/34\">",
"      Shoemaker WC, Peitzman AB, Bellamy R, et al. Resuscitation from severe hemorrhage. Crit Care Med 1996; 24:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/35\">",
"      Bickell WH, Wall MJ Jr, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994; 331:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/36\">",
"      Morrison CA, Carrick MM, Norman MA, et al. Hypotensive resuscitation strategy reduces transfusion requirements and severe postoperative coagulopathy in trauma patients with hemorrhagic shock: preliminary results of a randomized controlled trial. J Trauma 2011; 70:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/37\">",
"      Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma 2002; 52:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/38\">",
"      Mapstone J, Roberts I, Evans P. Fluid resuscitation strategies: a systematic review of animal trials. J Trauma 2003; 55:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/39\">",
"      Banerjee A, Jones R. Whither immediate fluid resuscitation? Lancet 1994; 344:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/40\">",
"      Capone AC, Safar P, Stezoski W, et al. Improved outcome with fluid restriction in treatment of uncontrolled hemorrhagic shock. J Am Coll Surg 1995; 180:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/41\">",
"      Kim SH, Stezoski SW, Safar P, et al. Hypothermia and minimal fluid resuscitation increase survival after uncontrolled hemorrhagic shock in rats. J Trauma 1997; 42:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/42\">",
"      Owens TM, Watson WC, Prough DS, et al. Limiting initial resuscitation of uncontrolled hemorrhage reduces internal bleeding and subsequent volume requirements. J Trauma 1995; 39:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/43\">",
"      Silbergleit R, Satz W, McNamara RM, et al. Effect of permissive hypotension in continuous uncontrolled intra-abdominal hemorrhage. Acad Emerg Med 1996; 3:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/44\">",
"      McKinley BA, Valdivia A, Moore FA. Goal-oriented shock resuscitation for major torso trauma: what are we learning? Curr Opin Crit Care 2003; 9:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/45\">",
"      Kwan I, Bunn F, Roberts I, WHO Pre-Hospital Trauma Care Steering Committee. Timing and volume of fluid administration for patients with bleeding. Cochrane Database Syst Rev 2003; :CD002245.",
"     </a>",
"    </li>",
"    <li>",
"     Kwan, I, Bunn, F, Roberts, I, on behalf of the WHO Pre-Hospital Trauma Care Steering Committee. Timing and volume of fluid administration for patients with bleeding following trauma (Cochrane Review). In: The Cochrane Library, Issue 2, 2001. Oxford: Update Software.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/47\">",
"      Rajasekhar A, Gowing R, Zarychanski R, et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med 2011; 39:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/48\">",
"      Brown JB, Cohen MJ, Minei JP, et al. Debunking the survival bias myth: characterization of mortality during the initial 24 hours for patients requiring massive transfusion. J Trauma Acute Care Surg 2012; 73:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/49\">",
"      Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 2006; 19:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/50\">",
"      Ho AM, Karmakar MK, Dion PW. Are we giving enough coagulation factors during major trauma resuscitation? Am J Surg 2005; 190:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/51\">",
"      Zehtabchi S, Nishijima DK. Impact of transfusion of fresh-frozen plasma and packed red blood cells in a 1:1 ratio on survival of emergency department patients with severe trauma. Acad Emerg Med 2009; 16:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/52\">",
"      Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/53\">",
"      Perkins JG, Cap AP, Andrew CP, et al. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. J Trauma 2009; 66:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/54\">",
"      Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/55\">",
"      Cinat ME, Wallace WC, Nastanski F, et al. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg 1999; 134:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/56\">",
"      Gunter OL Jr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma 2008; 65:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/57\">",
"      Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J Trauma 2008; 65:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/58\">",
"      Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/59\">",
"      Moore FA, Nelson T, McKinley BA, et al. Is there a role for aggressive use of fresh frozen plasma in massive transfusion of civilian trauma patients? Am J Surg 2008; 196:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/60\">",
"      Teixeira PG, Inaba K, Shulman I, et al. Impact of plasma transfusion in massively transfused trauma patients. J Trauma 2009; 66:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/61\">",
"      Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009; 66:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/62\">",
"      Shaz BH, Dente CJ, Nicholas J, et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010; 50:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/63\">",
"      Wafaisade A, Maegele M, Lefering R, et al. High plasma to red blood cell ratios are associated with lower mortality rates in patients receiving multiple transfusion (4&le;red blood cell units&lt;10) during acute trauma resuscitation. J Trauma 2011; 70:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/64\">",
"      Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma 2008; 65:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/65\">",
"      Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio &gt;/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/66\">",
"      Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008; 64:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/67\">",
"      Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/68\">",
"      Faringer PD, Mullins RJ, Johnson RL, Trunkey DD. Blood component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma 1993; 34:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/69\">",
"      Inaba K, Lustenberger T, Rhee P, et al. The impact of platelet transfusion in massively transfused trauma patients. J Am Coll Surg 2010; 211:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/70\">",
"      Sperry JL, Minei JP, Frankel HL, et al. Early use of vasopressors after injury: caution before constriction. J Trauma 2008; 64:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/71\">",
"      Plurad DS, Talving P, Lam L, et al. Early vasopressor use in critical injury is associated with mortality independent from volume status. J Trauma 2011; 71:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/72\">",
"      Zengerink I, Brink PR, Laupland KB, et al. Needle thoracostomy in the treatment of a tension pneumothorax in trauma patients: what size needle? J Trauma 2008; 64:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/73\">",
"      Wax DB, Leibowitz AB. Radiologic assessment of potential sites for needle decompression of a tension pneumothorax. Anesth Analg 2007; 105:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/74\">",
"      Vayre F, Lardoux H, Pezzano M, et al. Subxiphoid pericardiocentesis guided by contrast two-dimensional echocardiography in cardiac tamponade: experience of 110 consecutive patients. Eur J Echocardiogr 2000; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/75\">",
"      Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/76\">",
"      Bilkovski RN, Rivers EP, Horst HM. Targeted resuscitation strategies after injury. Curr Opin Crit Care 2004; 10:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/77\">",
"      Garcia A. Critical care issues in the early management of severe trauma. Surg Clin North Am 2006; 86:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/78\">",
"      Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. J Trauma 2009; 67:1439.",
"     </a>",
"    </li>",
"    <li>",
"     Baue AE. Physiology of shock and injury. In: Shock and Resuscitation, Gelder ER (Ed), McGraw-Hill, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/80\">",
"      Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med 1992; 20:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/81\">",
"      Mikulaschek A, Henry SM, Donovan R, Scalea TM. Serum lactate is not predicted by anion gap or base excess after trauma resuscitation. J Trauma 1996; 40:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/82\">",
"      Bannon MP, O'Neill CM, Martin M, et al. Central venous oxygen saturation, arterial base deficit, and lactate concentration in trauma patients. Am Surg 1995; 61:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/83\">",
"      Davis JW, Parks SN, Kaups KL, et al. Admission base deficit predicts transfusion requirements and risk of complications. J Trauma 1996; 41:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/84\">",
"      Wilson M, Davis DP, Coimbra R. Diagnosis and monitoring of hemorrhagic shock during the initial resuscitation of multiple trauma patients: a review. J Emerg Med 2003; 24:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/85\">",
"      Tisherman SA, Barie P, Bokhari F, et al. Clinical practice guideline: endpoints of resuscitation. J Trauma 2004; 57:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/86\">",
"      Shoemaker WC, Wo CC, Chien LC, et al. Evaluation of invasive and noninvasive hemodynamic monitoring in trauma patients. J Trauma 2006; 61:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/87\">",
"      CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/88\">",
"      CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/55/29562/abstract/89\">",
"      Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011; :CD004896.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 351 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29562=[""].join("\n");
var outline_f28_55_29562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREHOSPITAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intravenous fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Delayed fluid resuscitation/controlled hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3250855\">",
"      Transfusion of blood products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3986774\">",
"      - Transfusion for severe ongoing hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Transfusion of clotting factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3250847\">",
"      - Transfusion of platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management of nonhemorrhagic shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6093434\">",
"      - Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6093451\">",
"      - Pericardial tamponade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6093466\">",
"      - Emergency thoracotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6093484\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monitoring and endpoints for prolonged resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DEVELOPING TREATMENTS FOR HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hemostatic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20853214\">",
"      Antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recombinant factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Red blood cell substitutes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2424645\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/351|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/30/24046\" title=\"algorithm 1\">",
"      Traumatic shock initial management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/351|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/32/13824\" title=\"diagnostic image 1\">",
"      Open book fracture pubic symphysis diastasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/4/3139\" title=\"diagnostic image 2\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/52/41797\" title=\"diagnostic image 3\">",
"      Chest Xray of pneumothorax after stab wound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/351|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/10/11426\" title=\"picture 1\">",
"      Raney clip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/24/4492\" title=\"table 1\">",
"      Differential diagnosis of shock in trauma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=related_link\">",
"      Emergency ultrasound in adults with abdominal and thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=related_link\">",
"      Oxygen carriers as alternatives to red cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/24/24961?source=related_link\">",
"      Patient information: Shock (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=related_link\">",
"      Peripheral venous access in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31801?source=related_link\">",
"      Resuscitative thoracotomy: technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22569?source=related_link\">",
"      Trauma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_55_29563="Criteria for panic attack";
var content_f28_55_29563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F79985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F79985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for panic attack",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A discrete period of intense fear or discomfort, in which four (or more) of the following symptoms developed abruptly and reach a peak within 10 minutes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Palpitations, pounding heart, or accelerated heart rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Trembling or shaking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. Sensations of shortness of breath or smothering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Feeling of choking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. Chest pain or discomfort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. Nausea or abdominal distress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8. Feeling dizzy, unsteady, lightheaded, or faint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9. Derealization (feelings of unreality) or depersonalization (being detached from oneself)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10. Fear of losing control or going crazy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11. Fear of dying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12. Paresthesias (numbness or tingling sensations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13. Chills or hot flushes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29563=[""].join("\n");
var outline_f28_55_29563=null;
var title_f28_55_29564="Ambulatory detox protocols";
var content_f28_55_29564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ambulatory detoxification protocols",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduce moderate withdrawal symptoms and risk for serious withdrawal symptoms - fixed dosing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        If withdrawal symptoms are moderate (ie, CIWA score between 8 and 15) then use one of the following protocols:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-acting benzodiazepine protocol - (Chlordiazepoxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 1 - 50 mg every 6 to 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 2 - 25 mg every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 3 - 25 mg twice a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 4 - 25 mg at night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shorter-acting benzodiazepine protocol (Oxazepam)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 1 - 30 mg every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 2 - 30 mg every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 3 - 30 mg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 4 - 30 mg at night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-convulsant Protocol (Carbamazepine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 1 - 200 mg every 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 2 - 200 mg every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 3 - 200 mg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 4 - 200 mg one dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduce or prevent mild withdrawal symptoms - symptom triggered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        If withdrawal symptoms are not present or mild (ie, CIWA score less than 8) then use one of the following protocols:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-acting benzodiazepine protocol - (Chlordiazepoxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 1 - 50 mg every 6 to 12 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Days 2 to 5 - 25 mg every 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shorter-acting benzodiazepine protocol (Oxazepam)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Day 1 - 30 mg every 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Days 2 to 5 - 15 mg every 6 hours as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nutritional support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Thiamine 100 mg for 3 days, multivitamins maintenance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29564=[""].join("\n");
var outline_f28_55_29564=null;
var title_f28_55_29565="Exercise and cardiac events";
var content_f28_55_29565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Beneficial effects of any physical activity on coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronary events are less frequent among those who exercise. In a study of 5159 men, aged 40 to 49 years, followed for an average of almost 19 years, the age-adjusted coronary heart disease event rate per 1000 person-years is lower in those who perform any physical activity compared to inactive subjects.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wannamethee SG, Shaper AG, Alberti KG. Arch Intern Med 2000; 160:2108.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29565=[""].join("\n");
var outline_f28_55_29565=null;
var title_f28_55_29566="PET fluorodeoxyglucose";
var content_f28_55_29566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Positron emission tomography scan with fluorodeoxyglucose from a patient with hurthle cell thyroid cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 174px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACuAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2Mk56mnb3GcMR3PNNPX6UCgBfqTRt+tKORxSjrQADjOMYoZFY5Ybj6ml7YHXpS0ACjAwKaUVvvDrTwOn1xRQAwRR5/wBWtL5MRx+7U/hT6Uc0ARGCIgZjQj0IqpfW0HlHZEin1Aq/VW95jIBpAeM/FQ6lbafI+n3lxAR3ibBrwh/FfiWNyp1/Uxg9PPavqDxVax3FrMsgzkHrXy74ttltdTlRBgbulCCxBJ4m158ltb1Ek9cztVd9b1Zx8+q3x+sxqgetJ9aYWLv9raljA1K8x/11NH9rakMgajec9f3pql0ooAs/b77OTfXWfXzDU0WralE2YtSvUPqJTVD+lKuRQBtxeJdfGNmt6kPpOa9e+Ec+vaifM1DU72eEnIEkma8p8Gaauo6tDE6blyM19ReENJisbaOOJNuAOKEJnZ6RAqQrvG5j3PNaJiiPWND+FV7JQqCrmKBkP2eD/njH+VBgh/54p+VTdTQRjFAEIiiHAiQfhTgtP7UUAMKqQQRk0hjXrtFP7Cg0CGbR2FKOAcZpx6dOKTNAxCcCkySOvSlPNB7+1Ahu5gCATg9RTCg4z1p/Q0h6ZoAiZEPak2R5x5aEY5yKkPp2pMflQMh8qPOQig9aCu4DIzipD06fSm9PpQBC0UZzuQH600wRcYiTP0qY+4NIf8mgCHyIs/6tfrio2toGPzwofqKsN0pj/d4oEY2qwokJ8pQn+7xXhPxT1HXrKQfYNSuoIx18t8V71qgJiIryD4nIiafIzLuPvQB4k/inxBkg61qH/f41XfxBrMmfM1W+bPrMao3JzK3pmoqB2Lx1jU2POo3RPvKaT+1tR731z/38NUaSgC2dRvs83lx/38NSR6tqKnK6hdA+0hqjmjn0oA27XxFryuFg1e+B9BKa9s+HU+tXVjG2p6hcT5/56NmvG/BVqt1q8SMMjIr6U8OWAiijCAAKKCWdNZwIIxuXccdTVkwRHrGpogUqoFSnkmgEV2tbdusKVG1janrAh/CrP4UGge5VSzt0/wBXCqn27U8oOf6Gpe1IetAWITChGdtR+REOdgOanPekNADFjUOvGOe1FPHDDHrRQLU6Xv7Uo+tB6mhfagocOBxRSfjThz16UALQOOtHSl7UAL7UdDR1oA4oAPWl7CjuKB92gANVbwfKRVv+lVpxkUAcdq0XmK6v3zXzt8UNCmtr17hUOwnk4r6a1SAbge1cpr2iWmpW7xXKhgw9OaQHyW3fNJivYdW+EweVnsLoKCfukdKrWHwlcyA3l1lAeQB1ouB5faWkt022JGb6Cn3mnz2p/eoVHY19F6D4M0nTIQiQK5HVm60eIfB1hqlsyeWEPqBTEfNWKVV5Ga9I1D4XXolJtJl2dsjNbXhr4UbJlm1KbzAvRV6UDLfwb8OJ5YvZlOT0JFe6aXGFIGOnesDR9OhsYEht1CovGBXWaZD8mTQKxrwrgVMOvPTpTIsBaf6CgYv+NJRnj9KWgBKQYxS96D6UAJRR15o/l6UAIaQ0vT8KKAG98UGg9TSGgQmOetIaWk6e9AxtIe+KcabQIQ9KY386f1pvagBvYU1ulPppFAxlMb7pFPNNbofWgDM1EHyzXm3jPThf2csfVu1eoXS7lPFclqluBI2e9AmfKGvadJYX0kbqdueD61lEV9HeI/Cen6up86LY395RzmuUHwtsfMBad9g7YpBc8fiiaVwiAsT2ArQuNFu7eDzZYmANe4aP4O0zTcGKBWf+8wya1b3RLe6gMc0YKHsBQCbZ8zlfWnRIXcAdSa9jv/hlZTylomePJzgdqu6H8O7GylWR0MrjkF/WmBW+GnhpIIRdyqTI2MAivZtIjARcCuf0mwELqqDCjsO1dfZRBEWgVrluPgUuefagcD3ooHcaf84pCO3enUmaAGnimdqefpTT0IHSgTEPFNp2KaTwaBiL94D3ooX74opks6U9T6Zp38xzSHrQDzSLHCl5wcU2nYyKBC9T9KX6Ug96UdaBgacKT6daAOaAF47/AEpR/wDrpP6UvrQACoZQcVN2IprjIoAxNTj3A1hSoN2BzXSaiPkNc+wIbOaQFF4BuJFEcQGeOKtMAByKryE/dBoEIEXI4prhCSDjAqMROX4Y+9PWAqvLH60AIsAJHzCrkUOBgfpUcce0DirQ4UelMZJaKWmUe9dRaJiMY/Cuc00bphz3rqbcYQY7UATKBwPWlpO3FKegz+lAAetLSd6OgoAKKPpRQAdqaadxSY496AG8UdM0vbpSE80AJ0NIehx0p3fpTefwoAPTtTT0pT196T1FADTSGnGm9u/pQIRutNNKaQ/kKAGk80h4IpT3prdKBjW7Zpp6U80wjjNAivMMg1g6pEM5xzXQyjisLVVOTigDDeEkHjNV2QLncKvnCrgkZqnOxJPagCq7+wpN46YpHXJGKbt49KARIrAkVZRB1qvGgJUjkVbXHegLlvT0zLyK6CJcKPpWRpkYJz71tr0H0oEBxSdaU9KRuKB2EPvTSfSnHnOelNz3PWgBO3WmngU7tTTQJiN09qaad7U0/SgYifeH1opV+8MdaKAOlPU5oHWg8seetFAxwpaT60vb0oAOnWnCkxzSjrzQAo5oHIoFLQADvS0naigBTSdaX2o75xQBnaiMp16Vz8qjccdK6LUB8hrm7j5Sf5UgK8mB1Oahf7w7j2olfqc1CGyc5yfT0pgWUGMA07joaiicHqaezjB560CJVOeD1FS4yABzVISgsMVbik9+PakMv6Su2YZ4APJrp4B8grm9NO6UHI610kX3Bg9aYElFGcYo9qADv7UUUdcUAHGPeg0UHr09qAD096bSk8Gg/SgBKTvSnr9KTPNABSc5pe3FNIoAQ9MUjd6XPApKAG0lKf5UnQUCE7+9NPelPakOKAGHpR14pab+NADW5pD/APqpT7U0nBoBkcv3axdTIA9PrW2/Q1h6r90880AYczDP1qhNktyRiprh8Z571nSzAE0AWB2yaU42g461VjlDDP8ASpGk4wp5oDRlqFgT7Cp0OT61nxvj6Vchfkc0Abmlk9DWwB8orI00rge9awPA+lACmm+vvTjjFNoAQ9eKSlP1pooC4lIetFI3GPSgQhph6c9elPI4zTetACD7y885ooX7w+tFAWOmPUijPrQRywox046UFDgPyNAHOc9qQGnCgA+tO7Ug/KlFABjmnetN6flS9KAF60ev60g/pTsmgAJwc0nQUhIA5qCecKPegCtqcqqpzXNXMoLH0q7qVxvZgW47VhXU+ARQIiuHO4jPSq6S/nUbSc9fzoRS7Kc9O1AF9SvBzTJJAfu5Gaanyg7jzUUr4JxQCJklww7GrUUpxxwKzCxJyBirEDHaMn8aAZv6bKVmGeh7V1FrMCq4PNcJbTEMDzxXRWF1lBzzQB0QbcKX6VQim96sRy9jQMsGimqwPpS0AL0zikNL70dqAEPeg/8A1qP5UmaAEP69KKXpSelACdDSd/al+tJ2oExD6Un9aU0nbFADfUUh9+aWmnr+lAxDzTTS0g5oEN/hzSHoT0pe3NNJoATP5YphHvSscDkVXmmC8ZoAJ5AoJJrmNTu/MYgHpVvVbokEA4rmru527tp5NAEd2xII9ay5QSx9adJMScsag37mOefSgCyh2pk5z6UkswGAAaIzx0z/AFqG5cZxt59aA8iZXfggceoq5FN8vHWspZDt+Y4qwjHbnHBFAmdFp10UYAnNdBFcgrntXC28xU5Bzz1rdsL1doDHnpigaOlVweM07qazYpcgEGraSkj60ATdzTe59qAQRwaQnH0oEJ+tJS5yKaTzQMCaaSQP0px/WmHpQAD74ooH3hRQGh0pPJHvSg0hPJxS5546UDFzS9KaD3/CnAjFADhSim0o5+tAC/SgmkPams4A9/egCQkck1E0o6DvVWa4P0FVJbxVBG7mgC9NOAuSax76/UEjPNVr69Y8J0PWsaeYnO/71AE1zdbm6Vl3EodjzzUd1cgZ5xVJp9/QUB1HO7FsA9+laNnG2BmsyFHeRcjqa6S0gUQcmgRSunWPqeaij2yDI5pmoZ80qBn3q9YRBYvmXBNIOhRnG0+gpI5AvGasXyoeFqm4GeBye5pgX4Jtp61pWtweqnH9K5sS7PmY8CnR69ZwsI5LhFc9ATSGdza3o4BPNacc4POa462nEwDRnjtzWpBdOo+amI6JZz61cjlDD6Vgw3I4J71dt5x2PFAzV4x14ozUUUgYDnnpUh54oAO49qT6gUvak7c0AApM5+lL0/xpKADNJ2+poPag0AICaaQec96X2pPU0CGk4470h60pOTTSfxoAToKa386U9qilmCAZPSgBWPXkVA86rx1NUri8ySFrMuNQWM/eyaANW4uwM5PvWFqWqKudpyaqXd+XUnPFc9eTMXJcnnt6UAWbzUjKxyfwrNafc2c5qncTgbs4HtUcUhflTxQLcmnkySKS2Xc4wc0nlFyNxHNa+nW0aDkfWgYqIFT5uvrVe5UyE7RzUupSGM4AJ9qLI71DNQIy5Y2Q98+lOjk+Qj5smr18iFmz61SKHacHJpBqmIJCjAE8e1Xopzww5rEvJfLbnJ+lJBqSDALYzximFzsbLUGBw1bVvdhsZNcXbyBwCpNaMFyYyMk0AdWJsHINWIp1fqa52G9BHJ96uQ3I3Ag0AbRPrSH1qCC4Eg61KTz2xQDA009etOzzTe59aABfvjPrRQMbhRQCOmP3vxpaafvGgcUFD6BwaQfXimlwOpoAkzxmkZwuSTVSa7RAeRWJfaow4joA3JrxEBJas6fUlOcmsBrmSRssSM04cnPegRduL5nyBniqRcs3OaeF55prsqnmkA5unPJrI1Jwqt61eeTAPNZVykk0nyjNAGNMzyS4UHFXILRyBjOe9asOnbV3MMGo2DxucDgUwKpUw8EcVp2U5bAY5AFZVxc4fBUk0+CcAjB4pAbUkCyHce3apPlSE5NU4brcmBjdVO7lYt8pNMBJyxlODx2IqaKBcAkjJrMWZxJg9avQEuRyaQWI7623QOF5NeSeIPC+p3WsiWB2CFs8tXuEFuGi571VutMj3bwB60AUfByS2WnxRXJDOOpFdMGWXBHGKwUhdPukg561ahnaNgCc0wNxcqanjuGjyOTiq1tMHUZ9KkmZUXigZeivypwDWpb36uoyefeuWjIZqssdi5U0COqE6njNOEit3rjhfSI2N2a0ba9YpycUDOhHfnpQTWMmpBXAPNasMwkXI70ASduKT0pTTc0ABptKepqN5Aq8nvQApwKillVPwqrPeqinntXO6pqj8rH3H5UCNbUNWjgU5Ix9a52+18vwh4rEuYrm5k3M/wAuegNPjgWIZfGRQJvsW2v5ZeRwPeq0jyEZPegsAcg89qZNMRjGaAWo4MuDv4NZuoSDBVfxpLhpHGAccdqjS1eXGScnuRQMxZIZZ5jgDA71rWVmABvIrSttN2+9MubNg3ysVx0xQJsjeJYx8nXtUlnIwOH7dKpXBltzlmJHei3uyzDdj86Afc0bpBIRkUJtiGCcU1HVxlSDTLl1A5oYXuRXDI7Y3cD1pqmNVxkVnSysz8dAau2yb1HHNAEN5apJGWXqR3rBfT2MpbkYPau1W3GPnGRVS4tB1AAFAzLtrwQoqNj/ABrUtZEnAwwrNvLIGJmUYNZtre/Z5wpJPNFwt1OwaMjoeMUwTSIepwO1Q290JYwQeKW4k4zwaALsF+6tknita11QMMEgVzUE0ZxmrO+MD5G6UCOrS6VlzT/ORiMGuWguwOCefrVz7WijIcZoEzoVIJB7UVkWF7vYBj3opgd6Tyc+poJxznpSN1NVL2fy0JzSLHz3SqDzzWXdXp2nnrWNc6g0l0QppZPNkX3oEPlnJJLPxVb7RFz0J75rL1Fp4QTgsB6VUsHkmPzcc/lSA3HukAKgDPYURTGQ8Glis0Kg9aYyrATjp60AXS2F5PNQFwW681C858s5xmq9u4ZvU5pgaIRX9DUkcAHIAqKLJPt7VoWq5HOaBiG3LLx19apT2hXPGa2lA5xUU44yTxSEcfdW7BjwPrWFfzPbkkdPau9ntlfLAdq5HxNbFImZVoAx7TXyj7SoBrT/ALUWRBJIwUd68zvLqWC5IAJ5rSVrm+sGiiJXIxmmCdzsbbWLK5ufKimVnJ6YrrdOsyyqxA55ryLwV4auLbVRNNIWIPTNe5aaQsaAjpxzQAR2rBeKWaHI5FaAIIpkgGCfXmkBjPAAD2rD1HdBJkNx6108i7s4rG1a33rxzimBHpt6So3Veluiy/LyOlcvbmRJQMGti2PGScmgC+hkcYHDetRXV48CkOenH1p8N0FyB0qOcJcsUHP1oAowX0lzIVjzWxbw3PlghiKk07TY4lUgDPr3raVFC47YoA51pJoGO85HrXQ6FfebxnpWXqsIaM7eDUOjSNFKoxgZoA7sHIGKDUVu25Mn0pzthSelAyG5nEakk1iXOoBiQGxijWrrClQcE81zkRMkjHJOfegTLV5fgZ+bPtWXPqMS9Tz/ADqe4tPMBwCD7VgXumsJurbfTNAt9Sy167n5fwqLM8jkEEDrzV7T7ZF++OO2auXRiii+UjNAIzFIQDc2WFU7q5y2PSo7mQrKSTle1VY2L3AGOM/nQF7GnagOQzcitWGMZAAwOlVrWHIUYxWpBblSMn3oDqPjt+nH5UyeBQMkYFXlBxz1qO4IxyMk0BY5rUrcEeuK5u4RoWJOR+NdxMqvkEdK5vW7YCNmGKBowhqflNjfjBqRtQEqli+TXI6i8iXLDnrV3TonkUFzwe2aANi2vvOudi5IrsdOhGxT3rkdKtI4pwQQSTmu2stu0YI+lAi8kSnr1FRTW6sc4q0v3eOtLjHXNAIxLqABcY4rjtXtjHKXUEY9K7+6jzk4rn9TtxKpwMGgdzJ0q82qVYk+laan7QeCR7Viw2jLMc42+1X0cw4GeaET6ml9lIGV7VVuRMnCZzVuG5PlHPWrECrL97GaB6FOyhmfG/g1ea1MaZNW44xHg44pbiVdhDGgFqUbOYpcp65oqsvFyjKeM0Ug5T2SQ4ye1c9rlwUQgdMVvT8BvQ1yXiIk554oGZNgxkuST610aRjaOOfaub07EbdeevNbcN2oXB70DFu7XeD8oNYkka20nAAzW1LdrgnOK5rVbxHlwMk0Es0obosAFP50yeb1GazbKYj6e9WTKJHA2/rQPoNcl2AH4mrdnbOACBwafFCMfdxjvV+3U5H1oAlggYAetXYRtGD0zSxEYxUvHGQKBguOSPzqpdDB4Jq5woOBxWZdsd3WgCSM5X17VzviNPMQqFOOe1bUU4XjIJ9aztUnUIxJFAuh5vd6VG0+905PqOlSpNBbAIhAf/arQv5lkkIUDPYVz95amSbfmmFjp9HugHB3dTXZ2F15mPmrzPTGdGAx0NdhpBlcgqD7+1A7ndW43KD1FTNECM96o2bFYwGz71eRywGKQELwfLgdfas28gO05rb5xkjmqd2oIpgcjc2uJGwMdxTo9sQw33q150G04GaxL2HMmVJ9qBFwbHHFV1lEMnXFV0klhGc8VmajdMGOKAO5sr6NoxhhUsl0S2VbAxiuG0i7kZlAPFdMu5k/nQwLkshkXBPNNsP9aMetVdzrgnmrGnNumyeOfWgDsbRsooxn1ovXwhFNs/ljHqKiv5AEb6UAchr07FmAzmqmm5HcbjRq8qmVgTVWGcqcJQB0AA28GqV0IgDxnNVxeNtHJz61l6jfs3yg49aAJZpj5nXC+1V5y0p4JI71nfaGzznBq7at5hAyQfT1oB9hotmIPy8nvUlvaAOCBg1qRxYWnxxrkYHOaBE1pbgYP5Gr4TA461HECCOKmGQc/pQAjZ24qtdtjr1FWJGKg+lZd1cJyS3NAApDkjpmsbWIcqQTgYNWGvokOWcCsXU9VikysbZ/GgZyeqQxiQtjLVkfbngcqowK17395IcAj3rLliUNuIz7UxbF6xvZC4OSv49a6zSdRO9Qx5PFcTbgbsr16V1uhac7bXdiB6Uhb6nd2UgkUEelW8jGO9ZtqpjQBTmrsIyMvSBaCTRgg49Kxr6EcnFbrjjg5rNulyTuBwKBo5/7Pgk9PWqNzIiH8eM1tyx7h8o6VkXtqeeMGmNsWKYGPJxUn28W6/e61jO0ifKFO0etVpnbgdTQI62PVBMuFOW96jkmLkdOKzNGjJX1rUljXjB6e1AXYkBHmKfeio0ISdVJ70UAj2W5PDfyrjtcYljjNddfSJDBLLKQsaAszegrynW/iB4ZeQrHqIY9DgZpDNCzWR3OOa0fLPckY7VgeGtd03VpHSwuBIy9c8GujkdVB9B3oAztRnMaEDI9658zCSXlgT2OayPGfii2gujaQyFpO5B4FYVh4htbTbLfSHZn+Hk0xnpFnA02AvI9q2LWz2gbhyO5rn/CPjLQNWuFtbSV0lx1kAAJrt2hIJpCKiqcYFXbeHjnpUtvCrfeFaEMSgAYGaBkMUWB0pSm0HvVkR8j0p00QMZ7UAc/qup29hbvJcSrGijJJNefS/E3QJ7s20d6S2cBiOCa4D43a5Pca++nRuywRfeAOMmvLwcH0oA+ovtbywebbkuh5BHesmfUndyk3yMeME034TXhuPCsaTDLKMZPORWT4r06d77fbuRg54piL5tlcFhJyT0qpcqyEkip9IkeK3CzfM2Opp08qseV3A0AiTQrSS5mXA4z2r0Kws/s8Q7etcloM6wup29a66W5Yw7kwTjpQBpwlcc9auQkHGOlYOnTSSPl1wM9K2klTPBoGWCc8VXuI81PGQ3PFJKvHy0AZUkWDjGaga03qPlFW5gwkz1BqzbsGIBFAGHLp6kEsvBrkvE0Cw5KqQP5V6c8QPT8q5TxXYebA2AKBHGeHbpftAQ4HtXfxDdFn1rzKwtmtrzK8AHmvRrCbzLdcjnFAEko/dmn6OpMx5yaa+au6RF849zQB09qP3Y+lUNVY+W2MjvWlDhUwOoFec/GbXbzQvDsVxpsgjneTbuIzxQBW1c/vuMjnPSpNORWUnGa8fudT8cSW/26ZgLZl3b9oHH5V6D8Ptcm1fSPNmTa8Z2M2fve9AHUzBQh44xXL6jLGsr4/M1F8Q/EMuj6YPs20zyHAHdfeuD8MX1/qche6laUg8k0IDv7KF7pwVB+ldHZWJhClxz9K4DWfGlvpdgbbTYJ/tzHZ5skZCr7g969P0QSyaFYS3DF5niDMSOtAiJkJIq1awAnpzTli3OKvQptIHAoGNCBeo7UrJlCRUrlP4iMimtKm07fzoA828deNF8POyNCznsBXlt98T9RuLjMMCxw9wetdZ8crKWRY5okJAPzYrxRVZmxg59KAPd/D122u6Sbj7pYdDXH6vrCaNqLROGc55ya0fh7LNYaWyTFvm5A9Kq+ItJh1G7MrHJ68UBozodKki1S0EsS4yKgvLAknAGcVT0Jm0+MRo5A/nV+4uC5+9QFxujaYDcAzNxnpXbwKkMY24rlNPJ8xccmukVN8Q5zQLqalrNu4Xn3rVh5QbuuK562hkjG4Erg1pWd2ZH2lcGgDSYHnAqncRkjJ6VcU546moJxkEH60AjMVMtg8U6WyVxnANP4L8HvVuA/JzzxQGxzl9YZRtowfXFcbqjNbS4Y8V6lPGrx4ArgvF+lu4yoNA3sP8PXAkQYI/CtmXrkdq47w5+6lCtwc4xXZBQVDDrQStCoV/0lcAdeTRUiqfPXjjIzRQF0j1LxQ2NB1P2havmTwvY+GLiO6bxFMIZg37vtxX074sQ/8I9qfTJiavn3wP4H0vxDZXNzqaO0iPhdrYFLqV1M/wAIrZRePI00p2NoCdpXPI969M8Va5FpdqVUhrmXhIz39eab4d8J6foTObGMbm6s3JH0rnvibok195MkcyR+WM85yaGF9DzG6gLayRI4YyNuJz0z2rUt9Jjl8VWNlMN8MrKGA/iBqnpWhzXurQ2YnVS7gbzmur8TJ/wjHi+zumVZ47RVYrnlsCmGho+MdA07Q/iHo1rptoltFuQsqcZPrXtc+0vgegrw2TxC/jv4g6bexWyWqxlRsZskgf1r2+RWMnaktgJ4QNtW0Py4HWqcAY+lWDuCgcc0xg07KcY4oaYslMKk+lKEOKQHinxW8A3GsXzX+nY8/HzA9DXmlr8P9Y+0hbtFjUdcV9WXcW8c4Gawp7FXY9PxoSsI4LQojounrbRggKMcVFd3jStz0NdFrNhgkqQPYGuZntX5wy8epp3AqSXDIMLToZGducEUrWj9ylSQwuCQCo+lAnqaFjdCNwpzXZ6XKJ4xjkVx9pZOzLkrXY6Nbsi5YqcelA0bEMRCkKADViG2YMGJ4p1uhIH0q9Gh4Bxg0DI4wc4qVgNtSxw5z04pJYzyKAuZdwQG5pYJFz0pbiM4PqOKZbwlj97GDQBeiDOQRwKrahbK8ZD81eto2x2xVXUy+35SMUCucHqdjFFcEop960dKbbH68U/UIC3JIznmksRgYAGcZ60XQi8BkqPWtjTIApBrKhycMQK6HS03opHpmgaNFR8nSvIP2gyBoFivXM2cV6fqF/LaTiJI0YbQckn3rivHehJ4vtreG6nktFhbcDCAS31zSYzxLPjG609LYQMbN1AUf7Nei+CtJl0PQDFMweVjvOO3HSung0JIreGITyERrtBOOccVZOmApt81sGgLHz74i16W7vrv7VE0kxYqJD/CPTFdR8HIPt19LA0eUjG7fjj6V2ms/Dqx1NizXc0JP/PNF/rW14R8OxeGLM29rM0wJyXkABP5UJ2E1c5v44wJDomlxxIiAy87Vrt9NJTRNPTuIU/lWZ4y8PR+K4LWK6uZbcW7bgYsHd9c1rxQmO1ihBBWJAgJ6nFFwsSQtlgRVxCMe9UkQrjGKkLvjACjFFwsF0hk4BNR28JTILZpxL+2KCW7BRRcLGTrumxXkbJNGrqeMGuBuPCGnwXDPHbrk98dK9OmhaXq+PpVR9LWT7zk0XE0eZXVkLdSIxtHtWZIhA6Zr1S48NwTn5pXH0AqlJ4KtXzm5mH0Ap3Q7HlMjMHJyRVm3ZgPmGRXoUnw+tHbJvbgY9FWnJ4AtF63twR6bVouhtM4u1kfzFyRiuu0xt8a8kiro8EWgIIuZh26Crtp4aS2I2XUpA7ECi4mggjB4OauwQKpyo61MtjtUYc1MkBQjnNK4rESKVzmkmHBq1sPoKa0OfSgdjFmIV+OtTROW+hq41ipbJPNSJaqoIFO4WZANoXk81geItjQuF5rp5LYOMHA+hqlc6LFOCGkcduDSuFjy63xHdE9DnrXTQOWiHetP/hBbIymT7Tc5643DH8q0IfDcESgebK2O5NBLTZiwRZmU45zRXQxaJEkquJHyD60UXHZn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this FDG-PET scan from a patient with hurthle cell thyroid cancer, there is evidence of multiple small foci of increased radiotracer uptake. In the left neck, this focus may represent residual carcinoma in the region of the left thyroid bed or within an adjacent lymph node. In addition, foci are notable in the mediastinum and right lung, likely representing distant metastasis. A prior I-123 whole body scan demonstrated no abnormal uptake.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie Lee.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29566=[""].join("\n");
var outline_f28_55_29566=null;
var title_f28_55_29567="Purpura in pneumococcal sepsis";
var content_f28_55_29567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purpuric rash of pneumococcal sepsis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Purpura with a reticular pattern on the abdomen and flank in an HIV-infected patient with pneumococcal pneumonia. Courtesy of Charles V Sanders, MD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_55_29567=[""].join("\n");
var outline_f28_55_29567=null;
